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ABSTRACT
Stroke related death ranks as the fourth most common cause of mortality in the
United States. However, even with those who survive the initial ischemic insult, profound
neurological disability may remain. Current therapeutic options following stroke are
limited and therefore the development of a treatment that can improve functional
outcome after the acute phase of the stroke has passed would have a great impact on the
level of disability and quality of life of stroke sufferers. One potential therapy involves
the use of anti-Nogo-A immunotherapy post-stroke. Our laboratory has shown that the
administration of this novel treatment results in sensorimotor recovery in adult and aged
rats. This therapy has been shown to be efficacious when applied immediately, 24 hours,
and 1 week post-stroke in rats with mild to moderate sensorimotor deficits. In addition,
recent results suggest that administration of anti-Nogo-A immunotherapy up to 9 weeks
after stroke still induces functional recovery and neuroanatomical plasticity in adult rats
with mild to moderate sensorimotor deficits. However, whether and how long anti-NogoA immunotherapy is efficacious when administered in the chronic stroke phase in rats
with moderate to very severe sensorimotor deficits is unknown. In the present project we
sought to investigate the effectiveness of anti-Nogo-A immunotherapy as a therapeutic
intervention to improve sensorimotor recovery when applied to chronic stroke-impaired
adult rats with moderate to very severe sensorimotor deficits. Prior to testing the efficacy
of anti-Nogo-A immunotherapy we set out to evaluate the spontaneous motor recovery
xii

profiles in adult rats after stroke. We found that animals displayed different recovery
profiles based on initial deficit severity after stroke and overall, all spontaneous recovery
occurred within the first 4 weeks post-stroke. Therefore, the neurological deficit in the
stroke animals had plateaued by the time anti-Nogo-A immunotherapy was given at 9 and
25 weeks post-stroke. We found that animals with moderate to very severe deficits
treated with anti-Nogo-A immunotherapy at 9 or 25 weeks post-stroke showed improved
sensorimotor recovery at both time points. However, the improved sensorimotor function
was not associated with dendritic changes in either the perilesional or contralesional
cortex. Our finding of improved sensorimotor recovery even when treatment was started
25 weeks post-stroke demonstrates the promising therapeutic potential for anti-Nogo-A
immunotherapy to treat stroke sufferers long after the initial ischemic damage has taken
place. Further neuroanatomical correlates of the improved sensorimotor function are
being investigated.
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CHAPTER ONE
OVERVIEW AND HYPOTHESIS
Stroke is a leading cause of long-term disability worldwide and it is estimated
nearly 795,000 people experience a new or recurrent stroke every year (AHA, 2013). The
only clinical treatment for acute stroke is thrombolytic therapy and it must be given in the
first hours after stroke onset, thereby limiting its usefulness. Therefore, it is important to
study possible therapeutic interventions that can help repair the brain after the initial
damage has already occurred. One potential therapy involves the use of anti-Nogo-A
immunotherapy following stroke. Our laboratory has shown that the administration of
this novel treatment results in sensorimotor recovery after stroke in adult and aged rats
and is mediated by dendritic and axonal plasticity (Markus et al., 2005; Papadopoulos et
al., 2006). Administration of anti-Nogo-A immunotherapy has been shown to be
efficacious when applied immediately, 24 hours, and 1 week after ischemic stroke in the
rat (Papadopoulos et al., 2002; Wiessner et al., 2003; Seymour et al., 2005; Markus et al.,
2005;Tsai et al., 2007). However, given the vast number of people living with chronic
stroke deficits, the question of whether anti-Nogo-A immunotherapy can be efficacious
when administered long after the ischemic damage has occurred is of extreme
importance. Recent data from our laboratory suggests that administration of anti-Nogo-A
immunotherapy up to 9 weeks following ischemic stroke in adult rats that have mild to
moderate sensorimotor deficits induces functional recovery and neuroanatomical
1
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plasticity (Tsai et al., 2010). We aimed to extend these exciting results in this dissertation
by investigating the important preclinical question of whether there exists a critical
treatment window for the application of anti-Nogo-A immunotherapy in the chronic stage
following ischemic injury in adult rats with moderate to very severe sensorimotor
deficits.

HYPOTHESIS:
Inhibiting the Nogo-A protein using anti-Nogo-A antibodies at 9 or 25 weeks poststroke in adult rats with moderate to very severe sensorimotor deficits will result in
improved functional recovery and enhanced dendritic plasticity.

Specific Aim 1: Determine the magnitude and time course of spontaneous
sensorimotor recovery in adult rats during the first 8 and 24 weeks post-stroke.
Male adult rats will be tested using the skilled forelimb-reaching task post-stroke for up
to 8 or 24 weeks post-stroke to determine sensorimotor recovery.

Specific Aim 2: Evaluate the critical treatment window for administration of antiNogo-A immunotherapy to induce sensorimotor recovery in the chronic stage after
ischemic stroke in the adult rat. The same animals in Aim 1 will be used in Aims 2 and
3. At either 9 or 25 weeks post-stroke, adult rats with severe sensorimotor deficits will be
treated with intracerebroventircular infusion of anti-Nogo-A immunotherapy, a control
antibody, or will receive no treatment. Sensorimotor recovery will be tested using the
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skilled reaching task, the skilled horizontal ladder walking task, and the bilateral adhesive
removal task over the course of 12 additional weeks.

Specific Aim 3: Determine whether treatment with anti-Nogo-A immunotherapy in
the chronic phase after stroke in adult rats will result in enhanced dendritic
plasticity in the perilesional and contralesional cortex. The brains from Aim 2 will be
processed for Golgi-Cox staining and neurons in the perilesional and contralesional
caudal forelimb motor cortex will be evaluated for dendritic complexity. Specifically,
layer V pyramidal neurons will be evaluated in the perilesional cortex and layer II/III and
V pyramidal neurons will be evaluated in the contralesional cortex.

CHAPTER TWO
LITERATURE REVIEW
CHAPTER OVERVIEW
This chapter outlines the relevant concepts and literature background that is
pertinent to the experiments in this dissertation. Firstly, a general discussion of neuronal
plasticity and the capacity for neuronal regeneration after injury is presented in the
context of the developing, adult, and aged central nervous systems. Additionally,
previous work on factors found within the central nervous system that restrict neuronal
plasticity, especially the protein Nogo-A, is presented. Finally, the therapeutic potential
of blocking Nogo-A after various central nervous system injuries is discussed.
Specifically, the potential of blocking Nogo-A in chronic ischemic stroke, which forms
the basis of this dissertation, is addressed in detail.

NEURONAL PLASTICITY IN THE MAMMALIAN CENTRAL NERVOUS SYSTEM
AFTER INJURY
Definition of Neuronal Plasticity
Neuronal plasticity, as used in this dissertation, refers to any change in the structure
or function of neurons in the central nervous system (CNS) in response to a

4

5

specific internal or external stimulus. Such stimuli can include day-to-day environmental
experiences of an animal, pharmacological interventions, or even brain injury. Previously,
the medical and neuroscience community regarded the mature brain as immutable and
unable to undergo such repair or neural circuit reorganization. It is now known that varying
degrees of neuronal plasticity take place not only in the developing and young CNS but
also, given the appropriate circumstances, in the adult and aged CNS as well.
One important type of neural plasticity seen in response to brain and spinal cord
injury takes the form of neuronal structural reorganization. This reorganization is
characterized by the growth of new axons and dendrites and is ultimately thought to lead
to the recovery of function after injury. There are two main types of axonal structural
rearrangements that take place after injury, namely regeneration and compensatory
plasticity (Kartje et al., 2006). During regeneration, a severed axon is able to reconnect
with its deafferented targets by re-growing from its damaged end. In the case of
compensatory plasticity, deafferented targets are reinnervated by new axonal growth from
undamaged spared neurons that can be located quite far from the original injury site.
Additionally, changes in dendritic complexity may also serve to enhance the functioning
of damaged circuits.

It is thought that these mechanisms play a large role in the

spontaneous albeit limited improvements seen after brain and spinal cord injury. However,
the magnitude of neuronal plasticity that can take place in response to injury is dependent
on the age of the animal as well as whether the injury took place in the CNS or the
peripheral nervous system (PNS). By studying the differences in reorganizational potential
between the developing, adult, and aged CNS as well as in the PNS, important factors
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governing neuronal plasticity have been discovered and are the basis of new therapeutic
investigation.

Reorganizational Potential of the Mammalian Developing CNS
Seminal studies on the recovery of motor function in primates after early brain
injury were performed by Margaret Kennard in the 1900s and led to the general premise
that functional recovery after brain injury is faster and more complete in young animals
than adolescent or adult animals (Kennard et al., 1936, 1938, 1942). This concept became
known as the “Kennard Principle” and postulates that there is a negative linear
correlation between recovery potential and age at brain or spinal cord injury, although
exceptions have been reported (Schneider, 1979). The neuroanatomical corollary of
improved motor function in young animals after brain injury was evaluated in numerous
studies and evidence accumulated indicating that the young central nervous system
remodels after injury by compensatory plasticity. The undamaged cortex opposite to the
injury extends newly formed axons across the midline toward the injured side and
reinnervates denervated targets. Specifically, the opposite undamaged cortex sends
projections to the denervated striatum (Kolb et al., 1992), thalamus (Yu et al., 1995), red
nucleus (Nah & Leong et al., 1976; Naus et al., 1985), basilar pontine nuclei (Castro and
Mihailoff, 1983; Kartje-Tillotson et al., 1986), and spinal cord (Castro, 1975; KartjeTillotson et al., 1985; Rouiller et al., 1991). Since it is thought that neuroanatomical
plasticity is the underlying mechanism of functional recovery after CNS injury in young
animals, strategies that could induce the adult and aged CNS to display similar levels of
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plasticity as seen in the young CNS could make a large difference in the rehabilitation of
humans after brain and spinal cord injury.

Reorganizational Potential of the Mammalian Adult CNS
The reorganizational potential of the mammalian adult CNS is much more limited
than during development or in the PNS. Classic experiments performed by Aguayo et al.
investigated whether cut adult CNS axons were capable of long distance regenerative
growth when exposed to a peripheral sciatic nerve graft (David et al., 1981). An
autologous 35 mm sciatic nerve segment was grafted into the lower portion of the
medulla oblongata and lower cervical or upper thoracic spinal cord of adult rats. After
22-30 weeks post grafting, it was found that axons from spinal and medullary neurons
had elongated more than 30 mm into the sciatic nerve graft. Another experiment by
Aguayo et al. showed that when optic nerves were implanted into sciatic nerves, the
regenerating peripheral axons almost completely avoid the optic nerves (Aguayo et al.,
1978; Weinberg and Spencer, 1979). Results from these experiments suggest that
although CNS neurons are not capable of long distance regeneration within the
environment of the CNS, the neurons were capable of long distance growth within the
environment of the peripheral nerve segment. Seemingly, it was the CNS environment
exerting a non-permissive effect that rendered the CNS neurons incapable of meaningful
re-growth.
Since the molecular basis of the differences within the CNS and PNS environment
were unknown at that time, Schwab and colleagues decided to investigate whether the CNS
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environment lacked a potential trophic factor or whether the CNS environment contained
a non-permissive substrate for neurite growth in the CNS. Neonatal rat sympathetic or
sensory ganglia were grown in the presence of nerve growth factor (NGF) in a chamber
culture system where the neurons could grow into explants of either sciatic nerves or optic
nerves. Schwab et al. found that the neurons very frequently grew into the sciatic nerve
explants, but never into the optic nerve explants (Schwab et al., 1985). Additionally, the
same findings were found with previously frozen optic and sciatic nerves that did not
contain living glial cells. This experiment suggested the existence of a non-permissive
substrate in the optic nerves that could not be overcome by the strong fiber outgrowth
promoting effects of NGF.
The Schwab laboratory continued to investigate the possible source of the nonpermissive substrate in the CNS and therefore studied the interaction of CNS neurons and
CNS glia. Rat sympathetic, sensory ganglion, or fetal retinal cells were plated onto
cultures with dissociated optic nerve glial cells of young rats. They found that while
immature oligodendrocytes and astrocytes were often touched by neurons and neurites,
mature oligodendrocytes acted as a non-permissive substance for neuronal adhesion,
neurite growth, and fibroblast spreading (Schwab et al., 1988). They also showed that
adult rat spinal cord myelin acted to inhibit cell attachment, neurite outgrowth, and
fibroblast spreading (Schwab et al., 1988). Rat CNS myelin was analyzed and size
fractionation of myelin protein by SDS-Page resulted in the identification of two
membrane bound proteins (a 35 and 250-kD fragment) that were highly non-permissive
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for neurite growth and fibroblast spreading (Caroni & Schwab, 1988). To generate a
function-blocking antibody, the Schwab laboratory immunized mice with the rat CNS
myelin 35-kD and 250-kD protein fractions, raised hybridoma cells, and screened all the
supernatants for anti-myelin antibodies. The antibody that had the strongest myelin
neutralizing properties was designated as IN-1 and led to neurite growth and fibroblast
spreading in vitro (Caroni et al., 1988). A myelin protein homologue of NI-250 was then
purified from bovine spinal cord myelin (bNI-220) and was also shown to exert a potent
neurite outgrowth inhibitory effect, including the collapse of growth cones and the
inhibition of fibroblast spreading (Spillman et al., 1988). The monoclonal antibody IN-1
was found to neutralize the inhibitory effects of bNI-220. The purification of the bNI-220
protein led to the identification of six peptide sequences that were used to isolate the gene
encoding NI-220/250, and this gene was named Nogo (Chen et al., 2000; GrandPre et al.,
2000; Prinjha et al., 2000).

The Nogo Gene and its Protein Products
Alternative splicing and alternate promotor usage produces three protein isoforms
from the Nogo gene, Nogo-A, -B, and –C, see Figure 1.1 (Chen et al., 2000; GrandPre et
al., 2000; Prinjha et al., 2000). All three Nogo isoforms are assigned to the Reticulon
protein family due to the presence of a shared COOH-terminus containing a reticulon
homology domain (RHD). Therefore, the Nogo gene has also been named as Reticulon-4
(RTN4/nogo). This shared COOH-terminus is made up of two long hydrophobic domains
that are separated by a hydrophilic short loop of 66 amino acids called Nogo-66. All three
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isoforms of Nogo contain the Nogo-66 domain. The Nogo-66 domain in Nogo-A has
been found to induce growth cone collapse in vitro (Oertle et al., 2003). Among reticulon
proteins, there is no homology at the NH2 –terminal, suggesting biologically diverse
functions for this protein family. Specifically, Nogo-A and Nogo-B isoforms share a
common NH2-terminus, which has been found to inhibit fibroblast spreading (Oertle et
al., 2003). Finally, the Nogo-A isoform contains a unique specific region within the NH2terminus called the Amino-Nogo domain, which inhibits neurite outgrowth, induces
growth cone collapse, and inhibits fibroblast spreading (Oertle et al., 2003). The three
active sites found in Nogo-A are exposed to the extracellular space when Nogo-A is in
the cell membrane (GrandPre et al., 2000; Dodd et al., 2005).
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Nogo Protein Isoforms

Figure 2.1. Nogo protein isoforms. Modified with permission from Kempf et al., 2013.
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Nogo-A Signaling Cascade

Figure 2.2 Nogo-A signaling cascade. Modified with permission from Kempf et al.,
2013.
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Localization of the Nogo Proteins
The protein Nogo-A is highly enriched in the endoplasmic reticulum due to its
endoplasmic reticulum retention signal, however, it is also highly expressed in
mammalian oligodendrocytes, localized in the outer and innermost adaxonal myelin
sheath (Huber et al., 2002). Nogo-A is also highly expressed in subpopulations of
neurons during development, with a relative decrease in expression in adulthood
(Josephson et al., 2001; Huber et al., 2002; Hunt et al., 2003; Meier et al., 2003).
Additionally, beyond the CNS, Nogo-A is expressed in developing skin, skeletal muscle
during differentiation, macrophages, testicular tissue, and in heart tissue (Huber et al.,
2002; O’Neill et al., 2004; Fry et al., 2007; David et al., 2008; Pool et al., 2009; Bullard
et al., 2008).
The protein Nogo-B is expressed in the central and peripheral nervous system as
well as in peripheral tissues (Huber et al., 2002; Bullard et al., 2008). In the CNS, NogoB has been found to be involved in regulating vascular homeostasis and remodeling
(Acevedo et al., 2004). Additionally, Nogo-B may play a role in hepatocyte proliferation,
liver fibrosis, immune function, as well as cervical cancer metastasis (Tashiro et al.,
2013; Gao et al., 2013; Di Lorenzo et al., 2011; Xiao et al., 2013).
Nogo-C is expressed in skeletal muscle and to lower levels in the brain and heart
(Huber et al., 2002). The function of Nogo-C remains to be determined. Unlike Nogo-A,
evidence supports little to no role of Nogo-B and Nogo-C taking part in neurite
outgrowth inhibition (GrandPre et al., 2000).
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Nogo-A Receptors and Intracellular Signaling Cascade
The Nogo-66 domain of all three Nogo isoforms signals through two receptors:
the Nogo-66 receptor (NgR1) and the paired immunoglobulin-like receptor B (PirB), see
Figure 1.2 (Fournier et al., 2001; He et al., 2003). NgR is a GPI-linked cell surface
receptor protein that lacks an intracellular domain and therefore signals through coreceptors including p75 (Wang et al., 2002; Wong et al., 2002) or TROY/Taj (Park et al.,
2005), and Lingo-1 (Mi et al., 2004). Given the growth arresting effect of Nogo-A
signaling, including growth cone collapse and neurite outgrowth inhibition, it was
hypothesized that the signaling cascade most likely acted on cytoskeletal dynamics
(Gozenbach & Schwab, 2008). The signaling cascade of the Nogo-66 domain and the
amino-Nogo domain has been found to involve multiple signaling mechanisms. The
major pathway of signaling involves activation of the small GTPase RhoA and
concomitant suppression of Rac1, which leads to growth inhibition via a ROCK pathway
(Fournier et al., 2003; Niederost et al., 2002; Lehmann et al., 1999). Activation of RhoA
is accomplished by its release from the inhibitory regulator Rho-guanine dissociation
inhibitor (Yamashita et al., 2003). Next RhoA activates Rho Kinase (ROCK), with its
ability to activate multiple effectors including Lin-11, Isl-1, and Mec 3 Kinase 1
(LIMK1) (Hsieh et al., 2006). Once activated, LIMK1 inactivates cofilin through
phosphorylation, leading to F-actin polymerization, and causing growth cone
stabalization and the inhibition of neurite outgrowth (Hsieh et al., 2006). The activation
of the RhoA/ROCK pathway also leads to growth inhibition through microtubule
disassembly mediated by CRMP2 and actomyosin contraction mediated by MLCII.
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Additionally, the Nogo-66 domain has been found to signal via the paired
immunoglobulin-like receptor B (PirB) which also signals through p75 (Atwal et al.,
2008). Although much more is known about Nogo-66 signaling, the amino portion of
Nogo-A is considered more important for neurite outgrowth inhibition and the putative
Amino-Nogo receptor has yet to be discovered. Amino-Nogo is thought to also signal by
activating the RhoA/ROCK pathway as well as activation of CREB and down-regulating
the neuronal growth program.
Additionally, Nogo-A signaling has been found to increase intracellular levels of
calcium (Bandtlow et al., 1993; Wong et al., 2002; Hasegawa et al., 2004), activate
Protein Kinase C (PKC, Hasegawa et al., 2004; Sivasankaran et al., 2004), and activate
Epidermal Growth Factor Receptor (EGFR, Koprivica et al., 2005). Interestingly, many
downstream effectors activated by Nogo-A signaling are also activated by other myelin
associated neurite growth inhibitors as well as chondroitin sulfate proteoglycans.
Additionally, various changes in gene and protein expression have been found
after Nogo-A neutralization. Neutralization of Nogo-A by anti-Nogo-A antibodies (11C7
and 7B12) in rat hippocampal slice cultures led to changes in RNA transcripts in genes
related to growth, extracellular matrix, cell adhesion, neurogenesis, GTPase signal
transduction, and growth factors (Craveiro et al., 2008). Furthermore, unlesioned spinal
cord samples from genetically modified mice lacking Nogo-A, exhibited changes in
protein expression in proteins related to cytoskeleton, signaling, neuroprotection,
metabolism, and transport (Montani et al., 2009). These gene and protein changes after
Nogo-A neutralization provide insight into additional signaling cascades that may be
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involved in Nogo-A signaling.
In summary, the protein Nogo-A has emerged as an important inhibitory molecule
located in the CNS environment that acts to restrict the regenerative potential of neurons
and stabilize existing neuronal circuits. With the discovery of Nogo-A, additional factors
have been found that also restrict neuronal reorganization in the CNS and are detailed in
the following section.

Additional Molecules Contributing to the CNS Inhibitory Environment
Although the protein Nogo-A is considered to be one of the most potent neurite
outgrowth inhibitors, there are various molecules that inhibit neurite outgrowth after
injury in the CNS. Additional inhibitory proteins found in myelin that contribute to the
growth restrictive environment seen after injury are myelin associated glycoprotein
(MAG, McKerracher et al., 1994; Mukhopadhyay et al., 1994), oligodendrocyte and
myelin glycoprotein (OMgp, Wang et al., 2002), and the repulsive axon guidance
molecules Ephrin B3 (Benson et al., 2005), and Semaphorin 4D (Moreau-Fauvarque et
al., 2003). Interestingly, MAG and OMgp also interact with NgR1 as well as PirB and it
is thought that myelin inhibitors may signal through multiunit receptor systems and the
contribution of receptor subunits may depend on the type of neuron (Giger et al., 2008).
In addition to myelin proteins, chondroitin sulfate proteoglycans, extracellular matrix
molecules, also contribute to the growth inhibitory environment of the adult CNS
(Niederost et al., 1999; Schmalfeldt et al., 2000). With the discovery of CNS inhibitory
molecules, the possibility of developing strategies to inhibit these molecules and improve
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functional recovery in the human after brain and spinal cord injury is at last a possibility.
If these strategies prove successful in clinical trials, the field of rehabilitative medicine
will be revolutionized and brain and spinal cord injured patients will for the first time
have hope for significant recovery.

Reorganizational Potential of the Aged CNS
As previously described, the adult CNS is much more limited in its capacity to
repair itself after brain or spinal cord injury than the developing CNS or the adult PNS.
However, some limited reorganization can occur and is the basis of some spontaneous
recovery seen in patients. However, with age, the adult CNS becomes even less able to
repair itself. For example, after brain damage due to stroke, functional recovery is
diminished in the aged (Nakayama et al., 1994; Johnston et al., 2000) and it is possible that
aging may reduce the ability of the lesioned brain to reorganize after brain and spinal cord
injury. Animal studies have shown that after focal ischemic stroke in adult and aged rats,
neurons in the peri-infarct cortex in the aged brain showed a greater degree of oxidative
DNA and protein damage as well as a reduced induction of the heat shock protein (HSP)
70, a cell stress protective protein, as compared to the adult brain (Li et al., 2005).
Additionally, another study showed that aged rats versus adult rats after focal ischemic
stroke displayed an abnormal profile of growth promoting and inhibiting proteins. For
example, protein levels of MAG and Ephrin A5 were increased at post-stroke weeks 1 and
2 in aged rats as compared to young adult rats (Li et al., 2006). These results indicate that
the aged CNS may be more limited in its ability to repair itself than the adult CNS and
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therefore therapeutic strategies may need to involve combinatorial therapies that can
simultaneously stimulate a neuronal growth state and block multiple axonal growth
inhibitors to induce functional recovery.

NOGO-A BLOCKADE AFTER CNS INJURY
Following the discovery of Nogo-A’s role in restricting neuronal plasticity in the
adult and aged CNS, a flurry of investigation has been conducted over the last two
decades to determine the therapeutic potential of inhibiting the protein Nogo-A in order
to induce neuronal plasticity and thereby functional recovery after CNS injury. A variety
of approaches have been used to block the function of Nogo-A including specific
monoclonal antibodies directed against Nogo-A, Nogo-66 receptor blockers, and
downstream signaling molecule inhibitors. The following three sections will outline the
effectiveness of Nogo-A blockade to improve function in various CNS injury paradigms
with a focus on using monoclonal antibodies to inhibit Nogo-A in a rat model of focal
ischemic stroke.

Functional Recovery and Neuroanatomical Plasticity after Nogo-A Neutralization after
Spinal Cord Injury
Following the discovery of Nogo-A as a myelin associated inhibitor, experiments
were undertaken to determine whether blockade of Nogo-A function in vivo after spinal
cord injury would lead to axonal regeneration and functional recovery. In the 1990s Schnell
and Schwab used the monoclonal antibody IN-1 and delivered it to spinal cord-injured rats.
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The antibody was delivered to the spinal cord-injured rats by implanting hybridoma cells
that secreted IN-1 or a non-specific antibody into the brain. Rats treated with IN-1
displayed functional recovery and correlated with regeneration considerably past the lesion
site. These exciting results have now been replicated in rats and primates by using local
intrathecal pump infusions of recombinant IN-1 Fab fragments or highly purified Nogo-A
specific monoclonal antibodies that recognize various domains in the Amino-Nogo
segment of the Nogo-A protein.
Furthermore, these antibody treatment results have been extended by using other
approaches to block the function of the protein Nogo-A in spinal cord injury, such as
blocking the Nogo receptor (NgR). A competitive antagonist for the NgR receptor called
NEP1-40 has been used to treat spinal cord-injured rats and resulted in axonal regeneration
and improved recovery (GrandPre et al., 2002). Another NgR antagonist, called
NgR(310)ecto-Fc, also produced improved axonal growth and recovery of function when
administered to spinal cord-injured rats. Given the promising results shown after Nogo-A
inhibition after spinal cord injury in rat and primate studies (Freund et al., 2006; Freund et
al., 2009), a phase I clinical trial was recently completed evaluating the feasibility and
safety of administering anti-Nogo-A antibodies intrathecally to acutely spinal cord injured
patients. The trial reported no safety concerns and a phase II clinical trial is currently in
preparation (Abel et al., 2011).

Functional Recovery and Neuroanatomical Plasticity after Nogo-A Neutralization after
Traumatic Brain Injury
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Based on the in vivo success of treating rats with spinal cord injury with various
approaches that block the function of Nogo-A, the effectiveness of blocking Nogo-A after
traumatic brain injury (TBI) was investigated. Using a lateral fluid percussion brain injury
model, rats were treated with anti-Nogo-A immunotherapy or a control antibody 24 hours
after injury. Using a test of motor function called the composite neuroscore, it was shown
that there was no difference between the anti-Nogo-A antibody treated rats and the control
antibody treated rats when tested 4 weeks post-treatment (Lenzlinger et al., 2005;
Marklund et al., 2007). However, in these same experiments, rats that were treated with
anti-Nogo-A antibody performed better than the control antibody treated rats on the Morris
wate maze task for spatial memory (Lenzlinger et al., 2005; Marklund et al., 2007).
Additionally, rats that were treated with anti-Nogo-A antibody following TBI had a higher
growth-associated protein-43 expression, an axonal growth marker, in the CA1 of the
hippocampus than control antibody treated rats (Marklund et al., 2007). More studies are
needed to address the effectiveness of anti-Nogo-A immunotherapy after TBI for
improving sensorimotor deficits.

Functional Recovery and Neuroanatomical Plasticity after Nogo-A Neutralization after
Ischemic Stroke
Many studies have also been performed evaluating the therapeutic potential of
blocking Nogo-A in rodent models of ischemic stroke. The rodent model of middle
cerebral artery occlusion (MCAO) typically damages the ipsilateral sensorimotor cortical
area and rats are rendered incapable of accurately performing a skilled motor task that
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involves reaching for, grasping, and bringing a pellet to their mouth with the impaired
forelimb (Castro et al., 1972; Whishaw et al., 2000). These types of movements have
been found to be dependent on intact cortico-spinal and cortico-rubral-spinal pathways
(Castro et al., 1972; Whishaw et al., 2000). Using this model, the motor deficits seen after
rodent ischemic stroke, like in humans, are generally permanent and limited spontaneous
recovery occurs over time (Papadopoulos et al., 2002; Weissner et al., 2003; Seymour et
al., 2005; Markus et al., 2005; Tsai et al., 2007; Tsai et al., 2011).
Studies mainly from our laboratory have evaluated the therapeutic potential of
blocking the protein Nogo-A using function blocking antibodies (anti-Nogo-A
immunotherapy) after ischemic injury in the rat. Adult rats underwent a middle cerebral
artery occlusion and were immediately treated with the monoclonal antibody IN-1 that
recognizes the Amino-Nogo domain. These rats were then tested on a skilled reaching
task and it was shown that treatment with IN-1 led to recovery of 80% of pre-stroke
skilled reaching ability while control antibody and stroke only rats recovered only 40% of
their pre-stroke reaching ability (Papadopoulos et al., 2002). Evaluation of the stroke
lesion in these animals showed that the lesions were confined to the cortical tissue with
no subcortical involvement and the average hemispheric stroke size was between 8% and
12%, with no significant difference between groups. Therefore, no neuroprotective effect
was seen with anti-Nogo-A immunotherapy. This study also displayed for the first time
the successful application of anti-Nogo-A immunotherapy in rats with small to medium
sized strokes. This profound functional recovery was also found to be associated with
new axonal growth from the undamaged hemisphere. The unlesioned hemisphere was
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found to form new cortico-efferent projections to the contralateral red nucleus
(Papadopoulos et al., 2002).
Since immediate treatment following stroke is often not possible in the hospital,
subsequent studies went on to evaluate the treatment time window that exists for the
successful administration of anti-Nogo-A immunotherapy after ischemic stroke in adult
rats. The efficacy of anti-Nogo-A immunotherapy administered 24 hours, 1 week, and 9
weeks post-stroke was evaluated in three different studies, using three different antiNogo-A antibodies: 7B12, IN-1, and 11C7 respectively (Weisser et al., 2003; Seymour et
al., 2005; Tsai et al., 2011). All three antibodies recognize the Amino-Nogo domain,
however 7B12 and 11C7 are more specific and recognize short amino acid sequences
within the Amino-Nogo domain. Adult rats treated with these function blocking Nogo-A
antibodies at each of the three time points recovered up to 70 to 78% of their pre-stroke
skilled reaching ability while control antibody and stroke only animals recovered only 30
to 50% of their pre-stroke skilled reaching ability (Weisser et al., 2003; Seymour et al.,
2005; Tsai et al., 2011). Functional recovery in these studies was also associated with
neuroanatomical plasticity, and increases in cortico-efferent projections from the
undamaged hemisphere were found crossing the midline to reinnervate the contralateral
deafferented red nucleus (Seymour et al., 2005) and the contralateral cervical spinal cord
(Weisser et al., 2003). Additionally, increased dendritic complexity was found in layer V
pyramidal neurons within the undamaged homotopic sensorimotor cortex in adult rats
treated with IN-1 at the time of stroke (Papadopoulos et al., 2006). Together, these
studies support the use of anti-Nogo-A immunotherapy in adult rats with small to
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medium sized strokes in the acute (immediate to 24 hours post-stroke), subacute (1 week
post-stroke), and early chronic (9 weeks post-stroke) phases after ischemic stroke.
Given that stroke is more prevalent in human aged populations (Lloyd-Jones et
al., 2009), it is important to test preclinical therapies in aged rodents. Therefore, antiNogo-A antibodies (7B12) were administered to aged rats 1 week post-stroke. AntiNogo-A immunotherapy improved functional recovery on the skilled reaching task in
aged rats to the same magnitude as seen in previous studies, although the rate of recovery
was slower and a longer time period for recovery was necessary as compared to adult rats
(Markus et al., 2005). Anti-Nogo-A immunotherapy administered 1 week post-stroke has
also been shown to improve cognitive impairment in aged rats as measured by the Morris
Water Maze spatial memory task (Gillani et al., 2011). Anti-Nogo-A immunotherapy
administered 1 week post-stroke has also been found to improve cognitive recovery from
neglect after cortical aspiration lesion in adult rats (Brenneman et al., 2008).
Other experimental methods have been used to interfere in the Nogo-A-NgR
signaling pathway after stroke in rodents. Various mechanisms can be used to inhibit the
Nogo-66 receptor (NgR) including the NEP1-40 antagonist peptide, the NgR(310)EctoFc IgG fusion protein that binds to Nogo-A, genetic knockout of the NgR gene, and
RNAi mediated NgR knockdown. NEP1-40 is a Nogo-66 receptor antagonist peptide that
competes for the NgR receptor with the Nogo-66 domain (GrandPre et al., 2002).
Treatment with the NEP1-40 antagonist peptide improved skilled reaching after cortical
stroke in rodents (Fang et al., 2010; Zai et al., 2011). Another mechanism for blocking
NgR signaling is the use of a truncated soluble Nogo receptor fragment that binds the
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Nogo-66 domain (Fournier et al., 2002). Rats treated with this IgG fusion protein after
stroke displayed improved motor recovery in skilled reaching (Lee et al., 2004). Other
ways of inhibiting the signaling mediated by NgR include adenovirus-mediated RNA
interference knockdown of NgR and NgR genetic knockout mice. Knockdown of the
NgR receptor by RNAi in rats after stroke at 24 hours or two weeks post-stroke lead to
motor recovery on the Montoya’s Staircase skilled reaching task (Wang et al., 2010).
NgR -/- mice also showed improved motor recovery after ischemic focal stroke as
compared to NgR +/+ mice (Lee et al., 2004).
Although methods of interfering with NgR signaling have been shown to be
effective in improving recovery after stroke in rodents, antibody based approaches for
inhibiting the protein Nogo-A directly are thought to be more effective in inducing
neuronal plasticity. This is due to several reasons. Firstly, the Nogo-A protein is thought
to signal through three different receptors at minimum, which include NgR, PirB, and the
proposed Amino-Nogo receptor. Antibody binding to Nogo-A may lead to direct and
indirect inability (steric inhibition) of the protein to bind all three receptors at once.
Secondly, antibody binding of Nogo-A leads to endocytosis and a decreased level of
Nogo-A levels at the cell membrane (Joset et al., 2010). Finally, signaling through the
Amino-Nogo domain and the unknown Amino-Nogo receptor is thought to lead to gene
changes in the neuron that render it more responsive to growth promoting signals (Joset
et al., 2010).
The following section will describe the pathophysiology, epidemiology, and
recovery potential of human ischemic stroke. Afterwards, the unanswered questions
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regarding the use of anti-Nogo-A immunotherapy to improve recovery of function in
chronic large sized strokes will be discussed.

STROKE
Introduction
Cerebrovascular disease encompasses conditions that arise as a result of
pathology affecting cerebral blood vessels. Stroke is defined as the sudden focal loss of
brain function due to an interruption of cerebral blood flow. Following decreased blood
flow, neurons begin to dysfunction due to the lack of oxygen and nutrients. Neurological
functioning is compromised and the brain will become permanently damaged if blood
flow is not reestablished as soon as possible. Strokes are either ischemic or hemorrhagic,
depending on whether the compromised cerebral blood flow is caused by a blockage in a
cerebral blood vessel or by rupture of a cerebral blood vessel respectively. Ischemic
strokes caused by an occluded blood vessel are the most common type of stroke seen
(87%), while the remainder of strokes are hemorrhagic (AHA, 2013). Most commonly,
ischemic strokes occur due to thrombosis or emboli from a large vessel or the heart while
hemorrhagic strokes often occur due to rupture of blood vessels due to hypertension or
rupture of intracranial aneurysms (Biller, 2012).
Prevalence and Incidence
Over 6 million American adults living in the United States have suffered a stroke
and it is estimated that an additional 795,000 people will experience a new or recurrent
stroke each year (AHA, 2013). Globally, it is estimated that upwards of 60 million people
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have suffered a stroke and yearly more than 16 million new stroke events will occur
(Truelsen & Bontina, 2009). While the overall incidence of stroke is declining in many
developed countries, the overall burden of stroke is increasing due to the aging
population globally (WHO, Global Burden of Stroke, 2013).

Constellation of Symptoms Seen Post-Stroke
Symptoms of a stroke start suddenly and are dependent on the area of brain tissue
that is affected. Commonly, stroke causes deficits across many modalities including
motor, sensory, language, and cognitive domains, with the severity related to how
extensive the stroke damage was (Kelly-Hayes et al., 2003). Due to the extensive deficits
caused by stroke, it is considered to be the leading cause of serious long-term disability in
the United States (Survey of Income and Program Participation, a survey of the US
Bureau of the Census). Among ischemic stroke survivors over the age of 65, a large
proportion still suffers from significant disabilities after 6 months post-stroke (KellyHayes, 2003). Specifically, up to 80% experience motor dysfunction, including 50% who
are suffering from hemiparesis and 30% who are unable to walk without assistance
(Kelly-Hayes, 2003). Almost half of stroke survivors suffer from cognitive symptoms
and 35% had depressive symptoms (Kelly-Hayes, 2003). Language troubles also plague
stroke sufferers, with approximately 19% having aphasia (Kelly-Hayes, 2003). The most
severely affected stroke survivors are dependent in activities of daily living (~26%) and
are institutionalized in nursing homes (~26%) (Kelly-Hayes, 2003).
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Treatment Strategies
Currently, the only approved treatment strategy for acute ischemic stroke is the
use of recombinant tissue plasminogen activator (tPA) within the first 4.5 hours after
stroke onset (Hacke et al., 2008). Unfortunately, multiple barriers exist for the
widespread utilization of tPA in most stroke cases. Firstly, a large percent of stroke
patients do not recognize the symptoms of stroke and therefore delay seeking treatment.
According to one study, only 23.5% of stroke patients arrive at the emergency room
within 3 hours of symptom onset, and only 4.3% end up receiving thrombolytic therapy
(CASPR Investigators, 2005). Additionally, it is estimated that only 21% of U.S. counties
have a hospital and this may also lead to delays in seeking treatment (CDC, 2008). Other
factors limiting the use of tPA include delays in diagnosis, misdiagnoses, and adverse
side effects. Once the short time window for tPA administration has passed, rehabilitative
strategies are the only viable approaches in the subacute and chronic stages after stroke.
Such therapy may include physical therapy, speech therapy, occupational therapy, and
neuropsychological and cognitive therapy. Although real improvements in function are
seen after rehabilitation, the magnitude of recovery is limited (Duncan et al., 2000).
Additionally, neuroprotective therapies once held great promise in preclinical trials,
however this class of drugs mainly failed in clinical trials (Cheng et al., 2004; Savitz et
al., 2007; Ginsberg et al., 2007; Faden et al., 2007; Young et al., 2007). Therefore, it is
important to investigate treatment strategies that can be used successfully after a stroke
has already taken place to enhance recovery. The population of chronic stroke sufferers is
large and optimism exists among neuroscientists for the development of neurorestorative
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therapies, such as anti-Nogo-A immunotherapy, that can improve functional recovery
after stroke by enhancing brain plasticity even in the chronic phases after stroke.

Prognosis for Functional Recovery in Stroke
For most patients, the majority of significant recovery occurs during the first 3-6
months after stroke (Skilbeck et al., 1983). Although limited in magnitude, further
improvements may occur beyond 6 months and for many years if the stroke patient
engages in stimulating and rehabilitative activities. Many factors play a role in the time
course and magnitude of functional recovery after stroke. In general, the strongest
prognostic factor for the magnitude of stroke recovery is the severity of the initial deficit.
In addition, stroke severity affects the time course of recovery as well. Data from the
Copenhagen Study of stroke survivors showed that 95% of mild stroke survivors reached
their best recovery within 6 weeks post-stroke while moderate, severe, and very severe
stroke patients reached their best recovery at 10, 15, and 13 weeks post-stroke
respectively (Jorgensen et al., 1995a, 1995b).

Enhanced Potential for Neuronal Plasticity Early After Stroke Injury
Immediately after stroke, it is recognized that a critical time window opens that
reinstates a molecular environment in the adult CNS that is more conducive to neuronal
plasticity. The peri-infarct tissue that lies beyond the glial scar turns into a growth
permissive zone where levels of growth inhibitory molecules are reduced and growthpromoting molecules are increased during the first month after stroke in adult rats

29

(Carmichael, 2006; Carmichael et al., 2005; Carmichael et al., 2001). Additionally, a
transient increase in neurotrophic factors such as basic fibroblast growth factor (bFGF)
and nerve growth factor (NGF) are seen after focal ischemia in ipsilateral non-ischemic
areas (Speliotes et al., 1996). Furthermore, hyperexcitability exists in the tissues
ipsilateral and contralateral to the infarct, though dissipating over several weeks
(Buckkremer-Ratzmann et al., 1996). Finally, recovery after brain injury can be delayed
by pharmacological prevention of hyperexcitability during the first 3 weeks after
ischemia, but not during later time points (Schaller et al., 1986). Therefore, treatments
that enhance neuronal plasticity such as rehabilitation and restorative therapies may be
more efficacious when applied early after stroke (within the first four weeks in adult rats)
than when applied later. Research in rats exposed to rehabilitation support this
hypothesis. Biernaske et al. exposed adult rats after stroke to enriched environments and
rehabilitative reach training starting at 5 days, 14 days, or 30 days after focal ischemia.
The effect of enriched rehabilitation was found to be time dependent. Animals that were
exposed to enriched rehabilitation beginning at 5 days post-stroke showed a statistically
greater improvement in skilled reaching than rats that began the enriched rehabilitation at
14 days post-stroke. Furthermore, rats that began the rehabilitation scheme at 30 days
post-stroke did not display any improved motor performance as compared to control
animals. Changes in dendritic complexity in the homotopic contralesional sensorimotor
cortex were also time dependent and only animals that underwent the enriched
rehabilitation paradigm at 5 days post-stroke displayed increases in dendritic complexity
in layer V pyramidal neurons (Biernaske et al., 2004). These results support the view that
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the remaining ipsilesional and contralesional cortical tissues are more responsive to
rehabilitation early after stroke. Therefore, in humans and rodents, it is likely that
spontaneous neuronal plasticity will be most likely to occur in the early weeks after
stroke.

Mechanisms of Stroke Recovery
Early spontaneous recovery after stroke in humans (within hours to days) is
attributed to the resolution of edema and the reperfusion of the ischemic penumbra
(Dombovy et al., 1991). Recovery seen over the course of weeks, months, and years after
stroke is considered to be the result of spontaneous neural circuit reorganization
(Carmichael et al., 2006; Murphey et al., 2009), with neurogenesis and angiogenesis
(Thored et al., 2007; Hermann et al., 2009) potentially playing a role as well. Through
rehabilitation, the stroke-injured brain is able to relearn tasks, and other undamaged areas
of the brain are thought to take over the lost functions. With the advent of functional
neuro-imaging techniques such as functional Magnetic Resonance Imaging (fMRI),
Positron Emission Tomography (PET), Electroencephalography (EEG), and
Magnetoencephalography (MEG), extensive investigations of the neural correlates of
motor recovery after stroke have been evaluated at the systems level. Various motor areas
in both the damaged (ipsilesional) hemisphere and the undamaged (contralesional)
hemisphere have been implicated (Chollet et al., 1991; Grefkes et al., 2008; Weiller et al.,
1992).
In the damaged hemisphere, increased task related neural activity has been found
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using fMRI in the spared adjacent tissue around the infarct and the primary sensorimotor
cortex, as well as in secondary motor areas such as the premotor cortex and the
supplementary cortex (Chollet et al., 1991; Cramer et al., 2003; Johansen-Berg, et al.,
2002). Increased activation has also been found in the ipsilateral cerebellum (Chollet et
al., 1991).
Cortical reorganization has also been seen in the undamaged hemisphere.
Increased neural activation related to movement of the affected hand has been seen in the
contralesional sensorimotor cortex as well as in secondary motor areas such as the
premotor cortex and the supplementary motor cortex, and the ipsilateral cerebellum
(Chollet et al., 1991; Rehme et al., 2010).
The factors leading to increased activation of ipsilesional versus contralesional
motor areas and which pattern of activation leads to better recovery is controversial.
Feydey et al. showed that the nature of the lesion affects cortical reorganization and may
dictate which hemisphere is recruited in recovery mechanisms. They found that in strokes
that affected most of the primary motor cortex, it was more likely for the contralesional
hemisphere to show increased activation (Feydey et al., 2002). Conversely, strokes that
mostly spared the primary motor cortex were more likely to show increased activation in
the ipsilesional hemisphere (Feydey et al., 2002). Additionally, studies have shown that
activity in bilateral premotor areas and in contralesional primary motor cortex correlate
with more severe motor impairment (Loubinoux et al., 2007; Marshal et al., 2009; Ward
et al., 2003; Ward et al., 2004). A recent meta-analysis evaluated the current literature on
motor related neural activity after stroke and found that better motor performance was
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associated with greater activation in the ipsilesional primary motor cortex (Rehme et al.,
2012). Acutely after stroke, neural activity is enhanced in both hemispheres and is
correlated with stroke recovery, while over the course of 12 months post-stroke, good
recovery is correlated with the return of ipsilesional activation patterns (Ward et al.,
2003; Tombari et al., 2004; Rehme et al., 2010).

Summary
Currently, the only FDA approved treatment for stoke is thrombolysis. However,
most stroke patients do not receive this therapy and are left with permanent and profound
deficits. A treatment that could restore function long after the acute phases after stroke
have passed would greatly decrease disability among stroke survivors. Anti-Nogo-A
immunotherapy has been shown to be successful in restoring lost functions after small
and medium sized strokes in adult and aged rats when applied immediately or up to 9
weeks post-stroke. However, it is not known whether anti-Nogo-a immunotherapy is
effective in adult rats with large strokes. Additionally, it is not known how long the
treatment window exists for the administration of anti-Nogo-A immunotherapy in chronic
stroke-impaired rats. Therefore, this dissertation proposes to examine the treatment time
window and efficacy of anti-Nogo-A immunotherapy in the early and late chronic phases
after ischemia in adult rats with large sized strokes.

CHAPTER THREE
METHODOLOGY AND EXPERIMENTAL DESIGN
INTRODUCTION
The experiments outlined in this dissertation involve testing the hypothesis of
whether blocking the function of Nogo-A after chronic moderate to very severe stroke in
a rodent model of focal ischemic infarction will induce functional sensorimotor recovery.
In the clinic, there is a tendency towards pessimism regarding the expected success of
interventions, whether pharmacological or rehabilitative, to be successful in chronic
stroke. A similar pessimistic outlook exists for the success of interventions for severe
stroke, with many questioning the appropriate use of resources to try to rehabilitate this
low likelihood recovery population. We decided to assess whether treatment with antiNogo-A immunotherapy in the chronic phases after stroke can lead to functional recovery
in adult rats with moderate to very severe chronic sensorimotor deficits. This chapter will
outline the experimental design, rationale, and methods used for this dissertation

Methodological Considerations in Preclinical Stroke Studies
Over the past decade many therapeutic agents and strategies were tested in
preclinical studies and found to be efficacious in small animal models of ischemia.
Billions of dollars later, none of these treatments except tPA, were found to be effective
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in human trials (Turner et al., 2013). In general, it is thought that various experimental
design issues in preclinical studies may have contributed to the translation failure of
neuroprotective strategies. In 1999, Dr. Marc Fisher and Dr. Gary Houser of
Massachusetts University conceived of assembling a select group of the world’s leading
scientists to meet and discuss issues that were critical for the development of drugs and
devices for stroke treatment. The recommendations of this group are known as the Stroke
Therapy Academic Roundtable Preclinical Recommendations (STAIR) and updates to
their statements are issued on a periodic basis (Fisher et al., 1999; Fisher et al., 2009).
Furthermore, recent meta-analyses have shown that when quality scores are calculated for
preclinical studies using the STAIR criteria, there is a troubling negative association
between studies with low methodological quality and large estimates of treatment
efficacy (Horn et al., 2001). Clearly, problems with preclinical study design are
contributing factors in the failure of “bench to bedside translation”. Therefore, the most
recent recommendations of the STAIR committee as well as recommendations from key
reviews on the topic of preclinical design quality will be discussed as applicable
throughout this methodology chapter (Fisher et al., 1999; Dirnagl et al., 2006; Fisher et
al., 2009; Kahle & Bix, 2012). For an overview of specific recommendations for the
design of preclinical studies and how the experiments in this dissertation adhere to those
recommendations, refer to Table 3.1.
Additional factors that complicate the evaluation of treatment effects in both
preclinical and human clinical trials include the suboptimal reporting of a priori
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inclusion/exclusion criteria as well as post-randomization exclusions. The gold standard
for avoiding these types of problems is to design studies with strict a priori
inclusion/exclusion criteria as well as to use an intention-to-treat (ITT) paradigm for the
analysis of the data. Intention-to-treat paradigms involve analyzing all the data from
subjects as they were randomized, regardless of study protocol or treatment delivery
deviations. This approach is considered to provide the highest level of evidence regarding
the treatment efficacy since investigator bias under the disguise of well intentioned postrandomization exclusions is not allowed to influence the data (Fisher et al., 1999). The
use of this type of analysis is highly recommended in human randomized clinical trials
(FDA Guidelines, 1988). Additionally, this type of analysis may give a better estimate of
what the treatment efficacy would be in actual clinical use as deviations from treatment
paradigms are frequent. As of yet however, not many preclinical studies adhere to this
type of analysis. Therefore, in order to adhere to similar levels of stringency seen in
human clinical trials, the data in this dissertation were first analyzed using an intentionto-treat paradigm. Given that the intention-to-treat analysis may provide very
conservative estimates of treatment efficacy, a second analysis was done that excluded
animal subjects that majorly deviated from the experimental protocol. This analysis is
known as a per-protocol analysis (PP), and is often conducted with human clinical trial
data as well. PP paradigms may lead to treatment estimates that are inflated and may be
more reflective of optimal conditions and not typical efficacy. In human clinical trial
literature, the results from these types of analyses are considered to have a higher chance
of specified and unspecified bias due to the loss of pure randomization procedures.
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Therefore, if a study conducts post-randomization exclusions, the potential of this
treatment to improve recovery must be evaluated in light of both an ITT and a PP
analysis. The results from this project will be expressed from both of these types of
analyses to provide an accurate picture of treatment efficacy. Finally, reporting of
dissertation study parameters and results was based on specific guidelines described in
the Consolidated Standards of Reporting Trials (CONSORT) and the Animal Research:
Reporting In Vivo Experiments (ARRIVE) checklists (Schultz, et al., 2010; Kilkenny et
al., 2010). These checklists were used to improve the reporting in this dissertation.
Experimental Design and Timeline
See Figure 3.1 for a description of experimental design and timeline. As described
in CHAPTER ONE, the experimental overview and hypothesis chapter, Specific Aim 1
evaluated the spontaneous sensorimotor recovery profile of all the animal subjects that
underwent a focal ischemic stroke. This aim was designed like a prospective
observational cohort study to determine the relationship between sensorimotor recovery
across three different behavioral tasks during the acute and chronic phases after stroke
induction. Furthermore, retrospective analysis of sensorimotor recovery and its
correlation to stroke size was performed using histological sections. Post-stroke data was
collected from all animal subjects for a total of 8 weeks post-stroke (2 months). A subset
of animals from the original set was examined for a total of 24 weeks post-stroke (6
months), see Figure 3.1.
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Specific Aim 2 evaluated anti-Nogo-A immunotherapy as a treatment to improve
sensorimotor function in adult rats suffering from chronic stroke with moderate to very
severe deficits. This aim was designed as a randomized, single blind, preclinical trial
evaluating treatment efficacy at two different chronic administration time points,
approximately 2 and 6 months post-stroke. This was done to evaluate the treatment
window for anti-Nogo-A immunotherapy in the chronic stage following ischemia in
moderate to very severely impaired rats. All data was evaluated using an intention-totreat paradigm as well as a per-protocol paradigm. The animals used in the ITT and PP
analyses are shown in Table 3.2. The animals excluded from the PP analysis are shown
in Table 3.3 and a description of these exclusions is listed in Table 3.4.
Aim 3 involved post-mortem evaluation of neuroanatomical plasticity following
anti-Nogo-A immunotherapy in the brains of treated rats, specifically evaluating dendritic
complexity of layer V pyramidal neurons located in the perilesional and contralesional
caudal forelimb motor cortex.
All animals (n = 75) underwent focal ischemic stroke. Post-stroke data was
collected for n = 66 animals. After a period of 8 weeks, n = 35 animals (according to
inclusion/exclusion criteria) were randomized into three balanced groups, taking into
account the severity of their stroke deficit. The three experimental groups treated at 9
weeks post-stroke consisted of: (1) middle cerebral artery occlusion (MCAO)/anti-NogoA immunotherapy (n = 14), MCAO/control antibody (n = 12), and MCAO only (n = 9).
A subset of the original n = 66 animals, namely n = 7 animals were used to collect post-
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stroke data for a total of 24 weeks. These animals were then randomized into three
groups. The three experimental groups treated at 25 weeks (6 months) post-stroke
consisted of: (1) middle cerebral artery occlusion (MCAO)/anti-Nogo-A immunotherapy
(n = 4), MCAO/control antibody (n = 2), and MCAO only (n = 2).
Animal Subjects
Animal Subjects Background. The selection of species, strain, and even vendor is an
extremely important parameter in the design of preclinical studies and in the potential
success of translating preclinical treatment results to clinical trials in humans. Studies
have shown that different rat strains and even the same strains from different vendors
display remarkable differences in regards to behavioral performance, evolution of injury
after lesion models, and recovery responses to treatment interventions (O’Bryent et al.,
2011; Oliff et al., 1995; Oliff et al., 1996). Therefore when evaluating a treatment
intervention during the preclinical phase it is important to maintain the same parameters
as closely as possible to previous work in order to properly compare across studies. In
keeping with this premise, the previous work in the Kartje laboratory using anti-Nogo-A
immunotherapy after stroke has mostly focused on using male adult (2-3 month old)
Long Evans black-hooded rats to evaluate recovery potential (Seymour et al, 2005;
Papadopoulos et al., 2006; Tsai et al., 2007; Gillani et al, 2010; Tsai et al., 2011).
Consequently, the experiments in this dissertation were conducted using the Long Evans
black-hooded rat strain (2-3 months of age) to maintain experimental homogeneity. This
outbred strain was initially selected for our laboratory experiments due to the rats’
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temperament being very amenable for behavioral training. Additionally, Long Evans
black-hooded rats have been shown to display superior skilled reaching ability, larger
forelimb movement representations in the motor cortex, and lower cortical stimulation
intensities needed to initiate forelimb movements as compared to other rat strains
(Vandenberg et al., 2002). All these factors have lead to the continued use of this rat
strain in our laboratory as a model species for the evaluation of sensorimotor function
after cerebral injury. Although the use of this strain to evaluate the efficacy of anti-NogoA immunotherapy in chronic severe stroke in this dissertation is considered prudent in
regards to facilitating comparison across similar studies, it is also important to note that
once a particular hypothesis has been tested in this setting of homogenous methodology,
the next step in evaluating a treatment for bench to bedside translation is evaluating its
efficacy across various heterogenic parameters such as rat strain, age, sex, health status,
ischemic lesion model, and ultimately different species such as larger mammals and
nonhuman primates. With this approach, preclinical to clinical trial translation failure can
be minimized and the robustness of a particular treatment strategy can be evaluated.
Animal Subjects Description. All experiments described in this dissertation were
approved by the Institutional Animal Care and Use Committee of Hines Veterans Affairs
Hospital under IACUC protocol # H10-028. IACUC documentation is provided in
Appendix A of this dissertation. A total of 75 adult male Long Evans black-hooded rats
(2 months of age at the start of the study) were used. All animals, strain ID HsdBLU:LE,
were ordered from the Harlan Laboratories animal facility, Barrier 217, in Indianapolis.
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This was done in order to maintain the same genetic background in the animals, as
animals were ordered in overlapping cohorts. Animals were housed in standard cages (2
rats per cage) with a 12-hour light/dark cycle in a fully accredited animal care facility at
Hines Veteran Affairs Hospital. Due to aggressive fighting, some rats had to be separated
and housed individually (n = 10). Rats had access to fresh water ad libitim and were fed
standard laboratory chow (Harlan 2018 Rodent Diet). Rats were food restricted to 95% of
their predicted weight by age at the start of the experiments. Rats were fed approximately
12 grams of standard rat chow each at the beginning of the study (2 month old rats
weighing 250-300 grams each) and increased over time to approximately 16-20 grams
per rat (7-16 month old rats weighing 400-500 grams). All animals were number coded
and investigators conducting behavioral testing and neuroanatomical analyses were
blinded to the treatment condition throughout the experiment.
Behavioral Training and Testing
Skilled Forelimb Reaching Task
Reaching Task Background. Skilled forelimb movements involve the ability to reach for
an object and manipulate it using the digits. These movements are thought to originate
from general food-handling behavior (Ivanco et al., 1996) and are displayed by various
mammals including rats, primates, and humans. The level of homology across skilled
forelimb movements such as reaching for food is quite striking when comparing rodents
and humans as shown in Figure 3.2 (Iwaniuk et al., 2000; Whishaw et al, 1992;Sacrey et
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al., 2009;Klein et al., 2012). These similarities can be explained by the morphological
homology across mammalian species that includes similarities in skeletal and muscular
structure, as well as comparable neural control of motor movement (Iwaniuk et al., 2000).
Due to this fact, this natural behavior has become the focus of a select number of
behavioral tests meant to measure movement deficits after various insults to the central
nervous system in preclinical studies. One such test is the skilled forelimb-reaching task.
This task is a sensitive skilled motor task designed to test voluntary skilled forelimb
function in normal as well as brain damaged rats. It has been shown that the execution
and coordination of skilled forelimb movements in this task are dependent on the
synergism of multiple descending cortico-efferent pathways that primarily include the
corticospinal tract originating from both the rostral and caudal forelimb motor cortex, the
rubrospinal tract, the tectospinal tract, as well as the reticulospinal tract (Kennedy, 1990;
Neafsey et al., 1986; Naus et al., 1985; Akintude and Buxton, 1992). Damage to any of
these tracts will lead to impairment of skilled forelimb reaching performance.
Additionally, damage to the dorsolateral striatum impairs forelimb reaching as well
(Whishaw et al., 2007). Expectantly, various forms of neurological injury, including focal
ischemic stroke in the rat, have produced acute and chronic deficits in skilled forelimb
reaching due to damage to the various motor systems involved in skilled motor control
(Markus et al., 2005; Papadopoulos et al., 2009). Therefore, this task is considered to be a
good model of skilled movement in the rat that can be used to evaluate therapies aimed at
improving manual dexterity in humans.
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Reaching Task Description. Although reach to eat behavior in rats is a natural and
spontaneous behavior, rats must be trained to perform the skilled reaching task. Training
begins with food restricting the rats as stated previously. This is done to motivate the rats
to reach for a food object, a round sucrose pellet (45 mg; Bilaney Consultants,
Frenchtown, NJ). Rats were trained within approximately 2-4 weeks. Rats were placed in
the reaching apparatus in pairs during the first 1-3 days of training to decrease anxiety
during the habituation period. The reaching apparatus is a Plexiglas chamber (30 x 36 x
30 cm) with an oval opening on one wall (1.5 x 3 cm). Underneath the oval opening there
is a shelf where sugar pellets are placed on a grid (see Figure 3.3). Rat pairs were given
two 10-minute trials per day (morning/afternoon). The trials consisted of placing 10-15
pellets near the oval opening in order to entice the rats to reach. Once both rats began
reaching through the oval opening for sugar pellets, they were separated and singly
trained. Training continued daily (Monday through Friday), for two 10-minute trials per
day. At this time sugar pellets were placed near the opening, one at a time, to train rats to
grasp the pellets with precision. Once rats began showing a limb preference and started
grasping the pellets successfully, the pellet was moved slightly farther from the opening
and lateral, since Long Evan black-hooded rats are documented to be able to reach out at
a considerable distance and tend to reach to the side, instead of straight out. Placing the
pellet laterally also dissuades the rat from using their non-preferred forelimb. The rats
were slowly challenged to reach for a pellet that was located at a final distance of 1 cm
away from the opening (see Figure 3.3). Rats were trained daily, until a success score of
15 out of 20 pellets was obtained for three consecutive days. Once the rat successfully
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completed this criterion, it was deemed to be “at baseline”.
Reaching Task Analysis. A successful pellet was defined as a pellet that was grasped by
the rat with the preferred forelimb off the shelf, pulled back inside the reaching apparatus,
and placed in the mouth without being dropped. Rats naturally grasp food with both
forelimbs while eating, however some use only their preferred forelimb during eating.
Therefore, the contribution of the non-preferred forelimb during eating was not
quantified, as long as the pellet was eaten from the preferred forelimb and was not
dropped. Additionally, rats typically eat while sitting on their hindlimbs, with their
forelimbs lifted against gravity. However, some rats at baseline eat with their forelimbs
resting on the ground and move their head down to their paws. Therefore, a successful
reach was defined as grasping a pellet and bringing it to the mouth with the forelimbs
either held up against gravity or with forelimbs resting on the floor. As a caveat, rats did
display increased prevalence of non-preferred forelimb assisted eating, as well as
decreased ability to hold forelimbs against gravity post-stroke. However, due to the
complexity of testing these behaviors, these changes were not quantified, only noted. The
types of errors that led to non-successful pellets were also noted.
During evaluation post-stroke (specific aim 1) and post-treatment (specific aim 2),
rats were tested once a day (20 pellet trial), 1-5 days a week. The exact number of testing
sessions per week during the different parts of the experiment are summarized in Table
3.5.
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Inclusion/Exclusion Criteria:
*Inclusion/exclusion criteria were based on performance in the skilled reaching task
only.
A Prior Inclusion Criteria. Rats that were trained on the skilled reaching task to a
criterion of 15/20 successful pellets, 3 days in a row, were included in the study and
proceeded to undergo ischemic stroke surgery. All animals were trained to this criterion.
A Priori Exclusion Criteria. Following stroke surgery, rats were tested on the skilled
forelimb-reaching task weekly. At either 8 or 24 weeks post-stroke, rats were assessed for
a new post-stroke baseline, through three days of skilled reaching testing. Any rats that
scored more than 10/20 successful pellets were excluded from Aim 2 and Aim 3
experiments, namely treatment with anti-Nogo-A immunotherapy.
Post-Randomization Exclusion Criteria. Additional exclusion criteria were deemed
necessary for the PP analysis. For an in depth description of these exclusions, refer to
Table 3.4. Briefly, animals were excluded from the PP analysis due to antibody pump
technical problems, behavioral abnormalities that interfered with assessment of skilled
forelimb reaching score, animals displaying no functional spontaneous recovery poststroke prior to treatment initiation (success score = 0/20), and severe (> 80%) subcortical
striatal damage.
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Ladder Rung Walking Task
Walking Task Background. The ladder rung-walking task is a test used to assess skilled
walking, limb placement, and limb co-coordination (Metz et al., 2009; Metz and
Whishaw, 2002). This task has been found to be sensitive to acute and chronic deficits
seen after various motor system lesions, including different models of rat stroke including
MCAO (Rieck-Burchardt et al., 2004; Farr et al., 2006; Papadopoulos et al., 2009;
Gemerasca Mestriner et al., 2013). Through the use of qualitative and quantitative
measures, this task is able to determine subtle losses of movement capacity as well as
assess performance during post-lesion recovery periods.
Walking Task Description. The horizontal ladder apparatus consists of two, 1-meter
Plexiglas panels connected with irregularly placed metal rungs (minimum inter rung
distance of one cm, rung diameter of 3 mm, Fig. 3.4). Animal cages were placed
underneath each side of the horizontal ladder, one clean cage at the start and a home cage
at the end. Each rat was placed individually in the clean cage and allowed to climb up
onto the ladder and to cross the ladder. The rat was motivated to cross the ladder in order
to reach their home cage. Rats were habituated to this task over the course of three
consecutive days, with one daily 10 minute session or until each rat crossed the ladder
three times. Once the rats were habituated to the apparatus, they were videotaped while
crossing the horizontal ladder for three trials. The animals were tested using the skilled
horizontal ladder walking task across three time-points during the experiments outlined in
this dissertation: at baseline (prior to stroke), 8 or 24 weeks post-stroke (prior to
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treatment), and at 20 or 32 weeks post-stroke (final testing week post-treatment).
Walking Task Analysis. Qualitative and quantitative performance on the ladder rung
walking task was assessed using the videotaped trials. Although both forelimb and
hindlimb function can be analyzed using this task, only the preferred forelimb
(determined by the skilled reaching task) was evaluated. Qualitative analysis of forelimb
placement involves analysis of videos frame-by-frame and scoring the foot placements
according to a 7-category foot fault scale developed by Metz and Whishaw (2003). The
foot fault scoring scale is described in Table 3.6. Briefly, a foot placement is assigned a
score of 0 when the limb completely misses the rung and a fall occurs (total miss), a score
of 1 when the limb slips off the rung and causes a fall (deep slip), a score of 2 when the
limb slips off the rung but the animal is able to maintain balance and keeps stepping
(slight slip), a score of 3 when the limb was placed on a rung but moved to another rung
before weight bearing (replacement), a score of 4 when the limb was either aimed for one
rung and placed on another or when a limb was repositioned on the same rung
(correction), a score of 5 when the limb was placed on a rung using either the wrist or
digits of the forelimb (partial placement), and a score of 6 when the mid portion of the
palm of the limb was placed on the rung with full weight bearing support (correct
placement). When more than one error occurred, the lowest score was used. The final
score was expressed as the mean foot fault score per step. Quantitative analysis of the
skilled horizontal ladder-walking task involved counting the number of foot fault errors
that occurred while crossing the ladder. The errors were based off the foot fault scoring
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scale and were defined as foot faults with scores 0, 1, and 2, effectively anytime the
forelimb slipped off the rung or missed it completely. Foot faults were expressed as the #
of foot faults per 10 steps (based on three crossings).
Bilateral Tactile Adhesive Removal Task
Adhesive Removal Background. Contralateral tactile sensory neglect commonly occurs
after cortical or striatal injury in humans and over time the complete sensory neglect can
dissipate, leaving a patient with residual tactile extinction deficits (Benton et al., 1952;
Benton et al., 1972). A patient with tactile extinction will be able to perceive unilateral
tactile stimulation however simultaneous bilateral tactile stimulation will mask the ability
of the patient to perceive stimulation on the affected side. However, with time, this tactile
extinction deficit can also improve and patients are often left with “obscuration deficits”,
where the perception of the contralateral stimulus is reduced. This evolution from
complete contralateral tactile sensory neglect to obscuration has also been demonstrated
in rats (Schallert et al., 1984). The bilateral tactile adhesive removal task is a sensitive
test for discriminating these types of sensorimotor dysfunctions in rodents, and was
originally described by Schallert et al. (1982; 1983). This task, as described by Dr.
Schallert was originally based on the human clinical sensory exam used to test sensory
neglect, which is called the Double Simultaneous Stimulation Test (DSS). In the tactile
DSS exam, patients are presented with tactile sensory stimulation unilaterally and then
bilaterally to the same location on each side of the body. This test allows the physician to
determine if sensory loss is located in the primary somatosensory cortex as evidenced by
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the patient denying unilateral sensation or if there is damage in the higher level sensory
association cortex as evidenced by the patient losing the ability to discriminate sensation
during bilateral stimulation. The rodent version of this test is a good translational
functional outcome assessment as it is directly comparable to the human version of the
same test.
Adhesive Removal Description. Sticky paper sheets with adhesive backing (Staples,
product # 490429) were used to manually cut out small 0.5 inch by 0.5 inch square
adhesive stickers (161 mm2). Rats were well handled before attempting this task. Each rat
was taken out of its home cage and was held by one investigator while another
investigator placed two adhesive stickers on the forelimbs, one on the palmar surface of
each forepaw, covering the whole palm and most of the digits, see Figure 3.5. The order
of placement (right versus left) was randomized for every trial. Additionally after sticker
placement, both forelimbs with the stickers were simultaneously pressed firmly before
the trial started. Quickly, before the rat could attempt to remove the stickers, the rat was
placed inside the skilled reaching apparatus for the duration of the trial. Before data
acquisition started, rats were given one training day consisting of four trials to habituate
the rats to the testing procedure. Then the animals were tested using the bilateral tactile
adhesive removal task across three time-points during the experiments outlined in this
dissertation: at baseline (prior to stroke), at 8 or 24 weeks post-stroke (prior to treatment),
and at 20 or 32 weeks post-stroke (final testing week post-treatment).
Adhesive Removal Analysis. Each trial consisted of a maximum of 240 seconds (4
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minutes). Rats typically contact the stickers with their mouths and removed them using
their teeth. During the trial, it was noted which forelimb sticker was touched with the
mouth first and which was removed first. The time it took for each forelimb sticker to be
contacted (contact latency) and removed (removal latency) was also recorded for each
forelimb using four separate stopwatches. Four trials were given per session until a >75%
forelimb bias was found, defined as which forelimb sticker was contacted using the
mouth first. If a greater than 75% bias for either forelimb was not found, an additional
trial was given. The inter-trial rest period lasted 2-3 minutes.
Magnitude of Sensory Asymmetry Testing
Asymmetry Testing Description. Once a forelimb bias has been found in the bilateral
tactile adhesive removal task, the magnitude of sensory asymmetry between the forelimbs
can be quantified. The test is conducted by progressively increasing the size of the sticker
on the impaired forelimb and decreasing the size of the sticker on the non-impaired
forelimb by an equal amount (20.2 mm 2) until the rat reverses its bias from the nonimpaired forelimb to the impaired forelimb. There are seven levels of magnitude ratios
(Schallert et al., 2000; Schallert and Whishaw, 1984). The reversal of this original bias
represents the magnitude of sensory asymmetry score and a higher score indicates a
greater degree of somatosensory impairment. This testing has been shown to be very
sensitive to the extent of brain damage in various lesion models (Schallert et al., 1982;
Schallert et al., 1983; Schallert et al., 1984; Schallert et al., 1986; Barth et al., 1990).
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Asymmetry Testing Analysis. As described above, there are 7 levels of magnitude
differences that each rat is tested with. Testing begins at level 3, and depending on
whether the rat takes off the sticker on the impaired or non-impaired forelimb, testing
will continue with levels higher or lower. For example, at level 3 if the rat has not
reversed its bias for the non-impaired forelimb, the rat will be tested with the level 4
sticker sizes. At this point, if the rat contacts the impaired forelimb first, it will receive a
score of 3.5, signifying that the rat switches bias from the non-impaired forelimb to the
impaired forelimb somewhere between level 3 and level 4. In addition to the seven levels,
if the original bias is towards the impaired forelimb (i.e. at baseline) the scores are given
a positive sign, if however the bias is towards the non-impaired forelimb (i.e. post-stroke)
the scores are given a negative sign.

Stroke Surgery
Stroke Procedure Background. Human clinical stroke is a heterogeneous disorder with
various etiologies, presentations, and recovery profiles. However, 80% of human strokes
are ischemic in nature and typically affect the middle cerebral artery territory (AHA,
2013). Therefore, a majority of preclinical studies model human stroke by occluding the
middle cerebral artery in the rat. The rat, although not perfect, is a good model for human
focal ischemic stroke due to similarities in cerebral vasculature (Macrae et al., 1992),
genomics (Ginsberg et al., 1996), and post-stroke deficits (Whishaw et al., 1992).
However, when evaluating recovery data post-intervention in the rat it is important to
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note that the rodent brain, among other differences, is lissencephalic and has a higher
grey matter to white matter ratio than does the human brain.
Stroke Procedure Description. A focal ischemic stroke was induced by using the middle
cerebral artery occlusion (MCAO) method as described in Chen et al. (Chen et al., 1986),
and as in our previous work (Papadopoulos et al., 2002; Markus et al., 2005, Seymour et
al., 2005; Papadopoulos et al., 2006; Tsai et al., 2007; Gillani et al., 2009; Tsai et al.,
2011). See Figure 3.6 for a surgical view of the MCAO procedure. Rats were
anesthetized with isoflurane inhalant anesthesia (3% in oxygen) and body temperature
was maintained during the entire procedure. Temperature was maintained using a rectal
probe and automatic heating pad during the MCAO procedure and during the transient
CCA occlusion temperature was maintained manually with a heating pad and was
manually checked using a rectal thermometer. Animals’ core body temperature were
maintained at normal physiological ranges, between 99 to 101 degrees F. The bilateral
common carotid arteries (CCA) were isolated from an anterior cervical incision and the
common carotid artery ipsilateral to the intended ischemic stroke hemisphere was
permanently ligated using a 5-0 chromic gut suture. Rats were then placed in a
stereotaxic frame and a 2 cm vertical incision was made between the eye and ear and the
temporalis muscle was retracted. A burr hole was made to expose the middle cerebral
artery (MCA) and it was permanently occluded by cauterization and then transected with
microscissors. Lastly, the contralateral CCA was temporarily occluded for 45 minutes
using an aneurysm clip. After the aneurysm clip was removed, the surgical wound was
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closed and animals were warmed using a heating pad until awake. Animals were
monitored during the post-op period until fully awake, and able to eat and drink. If
animals showed signs of severe lethargy post-stroke, a 1 cc saline injection was given to
protect against dehydration and animals were given standard rat chow dissolved in water
to facilitate feeding. Animals were tested for either 8 or 24 weeks to determine
sensorimotor deficits prior to antibody infusion as described below.
Antibody Intracerebroventricular Infusion
Antibody Infusion Background. An intracerebroventricular antibody infusion approach
was used in these experiments. This approach is considered to be a clinically viable
approach as such delivery systems are already used in humans to administer anti-spastic
agents such as baclofen for dystonia and opiates to treat intractable cancer pain
(Fleischhack et al., 2005). Previous work from our laboratory has shown that intrathecal
injection of anti-Nogo-A antibodies also induces sensorimotor recovery after ischemic
stroke in rodents. Therefore, application of anti-Nogo-A antibody is clinically feasible,
either through intracerebroventricular infusion or intrathecal delivery. In fact, a phase I
clinical trial, testing the safety of intrathecal delivery of anti-Nogo-A immunotherapy in
spinal cord injury patients recently was completed and there have been minimal side
effects to this treatment.
Antibody Infusion Description. After the post-stroke testing period, either 8 or 24 weeks
post-stroke, rats were randomized to either stroke only, anti-Nogo-A antibody, or control
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antibody treatment groups (see experimental timeline Figure 3.1) with careful attention to
balance pre-stroke deficit from post-stroke week 8 on the skilled reaching task. Antibody
infusion was initiated at the beginning of either 9 weeks or 25 weeks post-stroke. Rats
were placed in a stereotaxic frame and a midline incision was made in the scalp. A burr
hole on the same side as the stroke lesion exposed the cortex. A cannula was placed into
the lateral cerebral ventricle at coordinates 1.3 mm lateral, 0.8 mm posterior, and 3.8 mm
ventral (relative to bregma) and secured to the skull with cyanoacrylate gel. Through a
mid-scapular incision an Alzet osmotic mini-pump (model 2ML2; Duract Corporation,
Cupertino, CA, USA) was implanted subcutaneously posterior to the scapulae and
connected to the cannula with polyethylene tubing. Either purified mouse monoclonal
anti-Nogo-A antibody (11C7; IgG1) or control antibody (anti-BRDU, IgG1) was infused
at a rate of 15-micrograms/ hour (2.5 mg/ml) for two weeks, after which the animals are
again anesthetized and the pumps removed.
Perfusion and Golgi-Cox Staining
Golgi-Cox Method Background. In 1873 the Italian physician and scientist, Camillo
Golgi, discovered what was then called the “black reaction” to stain whole neurons and
effectively ushered in a new era of neuroscience discovery. The black reaction became
known as the Golgi stain and was improved and used by Ramon y Cajal to study the
morphology of neurons and to the eventual birth of the neuron doctrine. Since then, this
method has been adapted and used by countless investigators studying neuronal
morphology as well as changes to neuronal morphology following various insults.
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Golgi-Cox Method Description. At either 21 or 33 weeks post-stroke (one week after the
end of sensorimotor testing), rats were overdosed with pentobarbital (100mg/kg, i.p.) and
transcardially perfused with 0.9% saline and10,000 U heparin/liter. The brains were
removed and immersed whole in Golgi-Cox solution (Glaser et al., 1981) for two weeks.
The brains were then coronally sectioned at 200 microns on a vibratome, mounted on 2%
gelatinized slides and reacted as described by Gibb and Kolb (Gibb et al., 1998). Slides
were coded to blind the experimenters to antibody treatment group. Refer to Figure 3.7
for Gogi-Cox method overview.
Stroke Lesion Analysis
Method Description. Golgi-Cox stained coronal brain sections were quantitatively
analyzed (+4.7 to -5.2 mm from bregma according to Paxinos and Watson, 1998) using a
computer-interfaced imaging system (NIH Image) by the method described in Kawamata
et al., 1999) (total area of the intact contralateral hemisphere – total area of the intact
ipsilateral hemisphere, and multiplied by the total distance between sections). Stroke size
was expressed as a percentage of the intact contralateral hemispheric volume, see Figure
3.8.
Neuroanatomical Analysis
Description of Tracing Neurons. Layer V pyramidal neurons were located within the
caudal forelimb area (CFA) region of the unlesioned motor cortex and the perilesional
area of the lesioned motor cortex with the aid of an atlas, see Figure 3.9 (Paxinos &
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Watson, 2005) and according to previous electrophysiological studies (Neafsey et al.,
1986). Criteria for inclusion in the analyses were that the neuron had to be well
impregnated, unobstructed by other dendrites, blood vessels or glia cells, and that the
dendritic aborization were intact and visible in the plane of the section.
Neuronal Morphology Analysis. An average of 6 apical and basilar dendritic trees of
layer V pyramidal neurons were traced using Neurolucida software and Leica DM 4000B
with a 40x objective. Dendritic trees were analyzed for dendritic length and number of
branch segments using the branched structure analysis tool of Neurolucida. Branches
emanating from the apical shaft were considered first order as well as branches
originating from the cell body (basilar) were considered first order, see Figure 3.10.
Statistical Analysis for Behavioral Data
Skilled Forelimb Reaching Task. An alpha value of < 0.05 was considered statistically
significant for all behavioral data. Skilled reaching data, including post-stroke
spontaneous recovery data and anti-Nogo-A immunotherapy data from both ITT and PP
datasets, was analyzed initially using a repeated measures analysis of variance (RM
ANOVA), as has been done in previous work and most recently in Tsai et al, 2010.
However, there are many disadvantages to using the RM ANOVA in the analysis of
longitudinal data, most important of which are its inability to analyze data sets with
missing data points across time, its assumption that measured values across time points
are independent with no correlation, its rigid variance-covariance structure, and its focus
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on estimation of group mean trends without information about how specific individuals
change across time. A more robust way to analyze longitudinal data is to use non-linear
mixed effects modeling to gather information about recovery curves including initial
severity, rate of recovery, and final magnitude of recovery reached at the plateau. The
biological response to a treatment is often nonlinear and therefore the most accurate way
to analyze this type of data is to use a bespoke mathematical equation that will match the
data. Therefore, the statistical software SAS was used to run the “nlmixed proc”
procedure to generate a non-linear model of the reaching data. The equation that was
used for modeling of the reaching data was an exponential function expressed by pi =
theta1 + (theta2 – theta1) * exp (-theta3 * (time-8)), where pi signifies probability of
success (# of successful pellets out of 20), theta 1 signifies the upper asymptote (final
magnitude of success score reached at plateau), theta 2 signifies the y-intercept (initial
pre-treatment stroke severity), and theta 3 signifies the rate (rate of recovery). For a
graphical display of the nlmixed proc equation, refer to Figure 3.11.
Skilled horizontal ladder walking task. Slips per ten steps were analyzed using a RM
ANOVA.
Bilateral adhesive removal task/Magnitude of sensory asymmetry testing. Sensory contact
and removal latencies were analyzed using a RM ANOVA.
Neuroanatomical Data. . An alpha value of < 0.05 was considered statistically
significant for all neuroanatomical data. All statistical analyses were performed with
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SPSS 17.0 (SPSS, Chicago, IL). Total stroke lesion size was evaluated using a one way
ANOVA. Dendritic plasticity measurements were analyzed using a one way ANOVA.
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Experimental Design and Timeline

Figure. 3.1. Experimental Design and Timeline
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Comparison of dissertation experimental design and preclinical design
recommendations.
Recommendation
Randomization

Dissertation Experiments
Yes; Randomization based on stroke
deficit severity pre-treatment.

Blinded Surgery Procedure

Yes; Animals were randomized post
surgery.
Yes

A priori inclusion/exclusion criteria/
report excluded animals
Analyze as randomized (ITT)
Monitor physiological parameters
A priori power analysis
Use CIs, do not use SEMs
Professional advice on statistics
Replicate key findings
Report mortalities
Report exact details on animal (sub)strains
Report sponsorship, conflict of interest
Define SOPs (including quality checks)
Drug (clinically relevant treatment
window
and delivery route)

Yes; ITT and PP analysis performed.
Yes; Temperature controlled during
MCAO
Yes
Yes; Both were used
Yes
Yes
Yes
Yes
Yes; Anti-Nogo-A antibody was
received from Novartis as a gift.
Yes; As defined in ACORP Details.
Yes; Chronic treatment time point (9
weeks or 25 weeks post-stroke in
moderate to severe stroke deficit.
ICV delivery.

Previous Work
-

Blinded drug administration
Blinded outcome evaluation
Use of aged, diabetic, or hypertensive
animals

No
Yes
No

Assessment of both infarct and functional
outcome
Outcome assessment in the chronic phase
(7-30 days)
Dose-response curve performed

Yes

Intrathecal delivery (Tsai et al., 2007);
Established treatment window 24 hours to 9
weeks post-stroke in mild-moderate stroke
deficit (Weissner et al. 2003; Seymour et
al., 2005; Tsai et al., 2010)
Aged rats + stroke, treated at 1 week poststroke (Markus et al., 2005); Adult
Spontaneously Hypertensive Rats (SHR)
treated 24 hours post-stroke (Weissner et
al., 2003)
-

Yes

-

No

Initial rodent studies, then consider
gyrencephalic species

Rat study only

Permanent MCAO then transient MCAO

Permanent MCAO model used only

Using ARRIVE guidelines for reporting in
vivo experiments
Using CONSORT guidelines for reporting
RCTs

Yes

5 mg versus 1.65 mg (total received) antiNogo-A antibody more effective after
MCAO in SHR (Weissner et al., 2003)
Evidence of functional recovery and
sprouting shown in primates treated with
anti-Nogo-A antibodies after spinal cord
injury + cortical lesions using ibotenic acid
(Fouad et al., 2004; Freund et al., 2006,
2007, 2009); Primates + stroke yet to be
tested
Transient MCAO not evaluated yet; Other
stroke models not evaluated yet
-

Yes

-

Table 3.1. Recommendations for improved preclinical trial quality.
Recommendations are summarized from various recommendation statements and reviews
regarding preclinical study quality (Fisher et al., 1991; van der Worp et al., 2005;
Dirnagl, 2006; Kahle & Bix, 2012; Fisher et al., 2009).
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List of Animal Numbers used in ITT and PP Analysis

Analysis
ITT
(treatment at 9
weeks post-stroke)

11C7
09, 14, 32, 34, 47,
48, 51, 56, 64, 67,
72, 76, 84, 89
(n = 14)

Control Antibody
27, 31, 41, 45, 49,
52, 53, 59, 74, 77,
78, 82
( n = 12)

Stroke Only
11, 16, 32, 55, 60,
61, 68, 80, 88

PP
(treatment at 9
weeks post-stroke)

09, 14, 34, 47, 51,
56, 76
(n = 7)

31, 41, 45, 49, 52, 11, 16, 32, 55, 61,
59, 74, 77, 78, 82 68, 80, 88
(n = 10)
(n = 8)

ITT
(treatment at 25
weeks post-stroke)

06, 18, 19, 20
(n = 4)

12, 13
(n = 2)

17, 24
(n = 2)

PP
(treatment at 25
weeks post-stroke)

06, 18, 19
(n = 3)

12, 13
(n = 2)

17, 24
(n = 2)

(n = 9)

Table 3.2. List of animals used in the two different analyses used for evaluation of
anti-Nogo-A immunotherapy in chronic stroke. An ITT and PP data analysis paradigm
was used for evaluating anti-Nogo-A immunotherapy treatment effects in animals treated
at 9 or at 25 weeks post-stroke.
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PP Analysis Exclusions

Rat
ID

Treatment
Timepoint

Treatment
Group

Pump
Disconnect

Absolute
Deficit

KP32
KP48
KP64
KP67
KP72
KP84
KP89
KP20
KP27
KP53
KP54

9 weeks
9 weeks
9 weeks
9 weeks
9 weeks
9 weeks
9 weeks
25 weeks
9 weeks
9 weeks
9 weeks

x
x

x

KP60

9 weeks

11C7
11C7
11C7
11C7
11C7
11C7
11C7
11C7
Control Ab
Control Ab
Stroke
Only
Stroke
Only

Severe FL
Switching

Severe
Striatal
Damage

x
x
x
x
x
x
x
x
x
x

Table 3.3. Exclusion categories for animals excluded in PP analysis.
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Detailed Descriptions of Post-Randomization Exclusions for
Per-Protocol Analysis
Exclusion Type
Pump Disconnect
Absolute Deficit

Severe FL Switching

Severe Striatal
Damage

Description
Tubing connecting cannula to osmotic pump was disconnected at removal
from animal. Final volume of antibody delivered intracerebroventricularly
is unknown. Full treatment regimen not administered.
During the reaching task, the rat was never able to grasp a pellet
successfully during any post-stroke testing time point (post-stroke + posttreatment). This type of rat is unable to perform the reaching task and it is
assumed that no recovery of motor function as tested by the reaching task
is possible (supported by data).
After stroke, rat changes forelimb preference and this extreme reliance on
the non-impaired forelimb leads to inaccuracy in testing the impaired
forelimb (forelimb affected by stroke). Extreme reliance on non-impaired
forelimb leads to maladaptive changes in strategies used in reaching such
as: posture, aiming, two-handed reaching, learned non-use, learned baduse. Performance score is deemed inaccurate with a large signal to noise
ratio.
Rats with ischemic necrosis leading to a complete loss of the dorsolateral
striatum have an inability to initiate forelimb movements and typically
show little improvement (ref). Rats displaying grasps in the air for pellets
instead of on the shelf typically have striatal damage (ref) and therefore
are to be excluded.

Table. 3.4. Detailed Descriptions of Post-Randomization Exclusions for
Per-Protocol Analysis.
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Comparisons in Rat and Human Reaching

Movement Component
Orientation towards food
Advance
Pronation of paw/hand
over food
Grasp
Supination of paw/hand
with retraction, rotation
at wrist, placement of
food in mouth

Rat
Olfaction
Similar
Similar

Human
Vision
Similar
Similar

Whole paw grasp

Pincer grasp (between
thumb and index finger)
Similar

Similar

Figure 3.2. Comparisons between limb movements made by normal rats and
humans during a reach for food task. Information in figure modified from Sacrey et
al., 2009 and Whishaw et al., 1992.
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Diagram of Skilled Reaching Task

Success Score: # Successful

Figure 3.3. Diagram of skilled reaching task. Rats are trained to reach for sugar pellets
placed on a ledge. The number of successful pellet is attained when the rat reaches out
with its preferred forelimb, grasps the pellet, pulls the forelimb back inside and brings the
sugar pellet to the mouth without dropping it.
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Number of Skilled Reaching Testing Sessions per Time Point

Experimental Time Point
Baseline
Post-Stroke Weeks 1-7 or 1-23
Pre-Treatment Baseline
(post-stroke week 8 or 24)
Treatment Weeks
(post-stroke weeks 9-20 or 25-32)

# of Sessions (days per week)
3
1
3
3-5

Table 3.5. Number of Skilled Reaching Testing Sessions per Time Point
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Skilled Horizontal Ladder Walking Task

Figure 3.4. Diagram of Skilled Horizontal Ladder Walking Task. A normal rat can
easily traverse the horizontal ladder with little to no errors (1 slip or less). After brain
injury, the number of slips and errors increases.
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Foot Fault Scoring Scale

Category
Total Miss
Slight Slip
Deep Slip
Replacement
Correction

Points
0
1
2
3
4

Partial
Placement
Correct
Placement

5
6

Description
Forelimb completely misses a rung; a fall occurs
Forelimb slips off rung with weight bearing; a fall occurs
Forelimb slips off with weight bearing; no fall occurs
Forelimb placed on a rung but then replaced on another
Forelimb aimed for one rung but placed on another or
repositioned on the same rung
Forelimb placed on rung with either wrists or digits of
forelimb
Mid portion of palm of forelimb is placed on rung with full
weight bearing

*Table information modified from Metz et al., 2009

Table 3.6. Overview of foot fault scoring system. The table describes the scoring
system based on assigning points (0 to 6) for each foot fault category. Information in the
table is modified from Metz et al., 2009.
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Bilateral Adhesive Removal Task

Figure 3.5. Diagram of bilateral adhesive removal task.
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MCAO Procedure

Dissect contralateral CCA
Untied suture left as marker

Dissect Ipsilateral CCA
Permanent occlusion with
suture ligation

Craniotomy to expose MCA
Permanent occlusion of MCA
using suture ligation

Transient 45-minute occlusion
of contralateral CCA

Figure 3.6. MCAO procedure. Procedure shown involves a Fisher 344 rat, however the
procedural steps are performed identically in either Fisher 344 or Long Evans blackhooded rats. Pictures compliments of Daniel Sheperd.
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Golgi-Cox Method for Staining Neuronal Morphology

Figure 3.7. Golgi-Cox staining procedure.
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Analysis of Stroke Volume and Lesion Location

Figure 3.8. Analysis of Stroke Volume and Lesion Location
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Selection of Neurons

Figure 3.9. Location of selected neurons.
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Analyzing Dendritic Morphology
A

B

Figure 3.10. Dendritic Analysis. (A) Representative neuron morphology. (B) Example
of branching pattern and numbering scheme
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Theta 1 = Asymptote
(Pi)

Probability of Success

Non-Linear Mixed Effects Modeling of Skilled Reaching

Theta 2 =
Y‐Intercept
Weeks Post‐Stroke

Non‐Linear Equation =

Pi = Theta 1 + (Theta 2 – Theta 1) * exp (‐Theta 3 * (time ‐8))

Figure 3.11. Graphical display of equation used for non-linear mixed effects
modeling of skilled reaching data.

CHAPTER FOUR
TIME COURSE OF SPONTANEOUS SKILLED REACHING RECOVERY
POST-STROKE
ABSTRACT
Following human clinical stroke, spontaneous recovery of function is limited but
does occur. The majority of spontaneous recovery of motor function occurs within 3
month post-stroke, with small improvements in function seen up to 6 months post-stroke
and beyond. Severity at initial stroke onset is considered to be the best prognostic factor
in determining recovery after stroke in humans. Patients with mild to moderate stroke
deficits immediately after stroke improve faster and better than patients with severe
stroke deficits. New therapeutic strategies are commonly tested in rat models of ischemic
stroke, including the middle cerebral artery occlusion model. In order to increase the
successful translation of preclinical findings to human trials it is important to model
human stroke appropriately in the rodent models used in preclinical studies. Therefore,
prior to testing the efficacy of anti-Nogo-A immunotherapy in the chronic phase after
stroke in adult male rats, we set out to evaluate and compare the spontaneous motor
recovery profiles in adult rats after stroke to that of humans after stroke. Adult male rats
underwent a middle cerebral artery occlusion and were evaluated for motor recovery in
skilled reaching performance for 8 weeks and 24 weeks post-stroke. On average, rats
showed a profound impairment on the skilled reaching task at post-stroke week 1. Similar
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to humans, animals displayed different recovery profiles based on initial deficit severity
immediately after stroke. Overall, spontaneous recovery was seen in the first few weeks
after stroke, with no improvements seen beyond 4 weeks (one month) post-stroke, even
in animals evaluated out to 24 weeks post-stroke (6 months). Similar to the recovery
profile seen in humans, the majority of spontaneous motor recovery occurs early poststroke with essentially little to no improvements seen beyond 6 months post-stroke.
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INTRODUCTION
Neuronal death and damage following ischemic stroke leads to permanent deficits
in motor, sensory, language, and cognitive function. The potential burden of disability
post-stroke is very large and with the world’s population aging, the magnitude of
disability and loss of function is likely to increase exponentially (WHO, 2011; United
Nation, 2001).
Treatment options post-stroke are fairly limited, and often the patient is faced
with limited options for improving recovery after stroke. One mechanism of improved
function after stroke is due to spontaneous recovery. Although limited, spontaneous
recovery occurs to varying degrees following stroke. Numerous studies have shown that
initial clinical severity after stroke is the strongest prognostic factor for spontaneous
clinical recovery after stroke in humans (Jorgensen et al., 1995; Jorgensen et al., 1996;
Jorgensen et al., 2000). Overall, most spontaneous recovery occurs before 6 months poststroke. In the Copenhagen study (Jorgensen et al., 2000), it was estimated that 80% of
patients reach their best neurological recovery within 4.5 weeks, with varying time
profiles based on initial severity post-stroke. Therefore, clinical stroke recovery profiles
vary from patient to patient based on initial clinical severity, potential for spontaneous
recovery, individual potential for neuroplasticity, and other various factors. Generally, it
is thought that the majority of spontaneous recovery plateaus by 6 months post-stroke
leaving a patient with little options for further improved recovery in the chronic phase.
Hence, there is a need for the development of therapeutics options that can
improve functional recovery post-stroke in the chronic stable phase after spontaneous
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recovery has ended. One such promising therapy is anti-Nogo-A immunotherapy (Tsai et
al., 2010). By inhibiting the protein Nogo-A, the regenerative potential of neurons is
enhanced, and it is possible to induce reorganization of neural circuits, leading to
functional recovery. In order to improve the translatability of preclinical findings using
this therapy to human clinical trials it is important to model human stroke appropriately
in preclinical studies using this therapy. Therefore, before the application of anti-Nogo-A
immunotherapy in the chronic phase after stroke, we set out to evaluate the time course of
spontaneous sensorimotor recovery in the adult rat after stroke up to 24 weeks post-stroke
(6 months) and to compare it to the recovery patterns seen in human stroke recovery. Rats
underwent a stroke procedure by permanent occlusion of the middle cerebral artery and
sensorimotor recovery was assessed weekly for 8 or 24 weeks post-stroke using the
skilled forelimb reaching task.
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RESULTS
Spontaneous recovery of skilled reaching success score over 24 weeks post-stroke
Rats were trained to reach a baseline criterion of 15 successful pellets out of 20 on the
skilled forelimb reaching task. Then skilled forelimb reaching recovery was assessed for
a total of 8 weeks post-stroke in a cohort of 66 rats and was assessed for an additional 24
weeks post-stroke for a subset of the former cohort, in 7 rats (see Figure 4.1A and 4.1B).
Analysis of the first 8 weeks post-stroke showed a significant main effect of time during
the post-stroke recovery phase, Figure 4.1A (p < 0.001, repeated measures ANOVA).
Initially, all animals exhibited a profound decrease in skilled reaching performance at 1
week post-stroke (p < 0.001). On average, rats improved until post-stroke week 2 (0.019)
and then reached a recovery plateau until post-stroke week 7. Reaching success was
significantly different between post-stroke week 7 and week 8.
Analysis of the smaller cohort assessed out to 24 weeks post-stroke (Figure 4.1B)
showed that there was also a significant main effect of time on skilled reaching
performance (p <0.033). Following stroke, there was a profound decrease in skilled
reaching performance at post-stroke week 1 (p < 0.001). There was also a significant
difference between skilled reaching performance between post-stroke week 1 and poststroke week 4 (p = 0.022). Further statistically significant improvements in skilled
reaching performance were not seen beyond post-stroke week 4.
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Recovery profiles based on initial skilled reaching severity at post-stroke week 1
Animals were categorized into four stroke severity deficit groups based on the skilled
reaching score at post-stroke week 1, Figure 4.2A. Figure 4.2B shows the scoring criteria
used to categorize animals to mild, moderate, severe, and very severe stroke deficit
groups.
Repeated measures ANOVA showed that there was a significant interaction
between stroke severity category and skilled reaching recovery over time (p = 0.001). On
average across all deficit categories, post-stroke recovery plateaued by post-stroke week
4. Bonferroni post-hoc testing showed that recovery profiles between the mild and
moderate categories was not significantly different across time (p = 0.203). However, the
recovery profiles of the severe and very severe deficit groups were different from the
either the mild or moderate recovery group and different from each other (all p values <
0.01) (see Figure 4.2A).
Recovery profiles for animals in each stroke severity category were analyzed
separately to determine the time course of recovery. Since the recovery profiles of mild
and moderate stroke severity animals was found to be non-significant, these two
categories were combined to evaluate the time course of recovery. Post-stroke, animals in
the combined mild and moderate deficit category did not exhibit a significant change
over time in their skilled reaching performance after stroke (p = 0.085, repeated measures
ANOVA).
Animals in the severe stroke category displayed a change in skilled reaching
recovery over time (p < 0.001, repeated measures ANOVA). Skilled reaching

81

performance improved from post-stroke day 3 over time up to post-stroke week 3 (p <
0.001). No significant improvements were seen beyond post-stroke week 3 (p > 0.05).
Animals in the very severe category showed no improvements across time and
were never able to grasp and bring any pellets to the mouth on any attempt out of 20
during the skilled reaching task.

Body weight of rats post-stroke
The body weights of rats post-stroke across the 4 stroke severity deficit categories was
compared. There was no different between the weight of rats in any stroke deficit severity
group across time (p = 0.577, Repeated Measures ANOVA), see Figure 4.3.

No correlation between skilled reaching performance and post-stroke body weight
Rats were food restricted in order to provide motivation for performing the skilled
reaching task. Therefore it was evaluated whether there was a correlation between weight
and success score at baseline or post-stroke week 8 across all rats post-stroke. There was
no significant correlation between either baseline weight (p = 0.091, Pearson’s
Correlation) or post-stroke weight (p = 0.901, Pearson’s Correlation) with performance
on skilled reaching.

Positive correlation between initial skilled reaching impairment and final reaching
recovery
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The correlation between skilled reaching success score at early time points post-stroke
was correlated with final reaching recovery at post-stroke week 8 (see Table 4.1). Poststroke severity at post-stroke week 1 (p < 0.01, Pearson’s Correlation) and post-stroke
week 4 (p < 0.01, Pearson’s Correlation) was strongly correlated with post-stroke week 8
recovery.

No difference in skilled reaching performance at baseline based on skilled reaching
forelimb preference
Rats were trained to perform the skilled reaching task to a criterion of 15 successful
pellets out of 20. Most rats were trained to this criterion within 2-4 weeks. Rats exhibit a
forelimb preference when trained on the skilled reaching task. The majority of rats
displayed a purely single forelimb preference (right or left) on the skilled reaching task
(78%) while a minority displayed ambidextrous reaching patterns (22%), Figure 4.4A.
Based on these categories, 49% of rats had a right forelimb preference, 29% had a left
forelimb preference and 22% were ambidextrous. A chi squared test of the distribution
forelimb preferences among the rats indicated that the distribution was significantly
different (p = 0.019). A larger proportion of rats displayed a single right forelimb
preference than a left preference or ambidexterity. Ambidextrous rats were not excluded
from the study since it was possible to elicit a largely single forelimb reach by placing the
sugar pellet very far lateral. Including ambidextrous rats, a significantly larger proportion
of the total, 66% of rats displayed primarily a right forelimb preference, while 34% of
rats displayed a largely left forelimb preference (p = 0.009). Neither primary forelimb
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preference nor ambidexterity influenced performance on the skilled reaching task at
baseline, Figure 4.4.B. There were no differences in mean skilled reaching performance
across animals with different forelimb preferences (p = 0.731, one-way ANOVA).
No difference in skilled reaching performance at post-stroke week 8 based on
baseline forelimb preference
The final skilled reaching recovery score at post-stroke week 8 was evaluated by original
forelimb preference (right, left, ambidextrous right, and ambidextrous left) at baseline.
There was no difference between the scores at post-stroke week 8 on the skilled reaching
task based on original forelimb preference determined at training, Figure 4.5 (p = 0.510,
one-way ANOVA).

Increased prevalence of forelimb preference change post-stroke and a correlated
decrease in skilled reaching performance
Following stroke, there was an increase in the reliance of animals using the unimpaired
forelimb to reach for pellets in the skilled reaching task, Figure 4.6A. The percent of
animals with solely a right forelimb preference dropped to 28% after stroke versus a
baseline value of 49%. Likewise, the percent of animals with solely a left forelimb
preference decreased to 18% after stroke compared with a baseline value of 29%. The
percentage of animals displaying ambidextrous reaching patterns increased to 53% after
stroke compared with a baseline value of 22%.
Due to the increased prevalence of animals using the unimpaired forelimb after
stroke, we evaluated whether animals with a change in forelimb preference had an effect
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on recovery of skilled reaching ability at post-stroke week 8. First we evaluated whether
there was a difference between animals with a right or left preference within switching
categories, i.e. animals that never relied on the unimpaired forelimb, animals that were
ambidextrous from baseline, and animals that began to rely on the unimpaired forelimb
after stroke. There was no difference in post stroke week 8 success scores among animals
with right or left forelimb preferences that never used the unimpaired forelimb (p =
0.323), were ambidextrous from baseline (p = 0.348), or that developed a stroke
preference for the unimpaired forelimb (p = 0.473). Since there was no effect of original
right or left forelimb preference and switching status, it was evaluated whether overall
there was a difference in skilled reaching success score at post-stroke week 8 across
animals that never switched (right and left preferences combined), animals that were
ambidextrous from baseline (right and left preferences combined) or animals that
developed a new preference for the unimpaired forelimb (right and left preferences
combined). Switching status had a significant effect on post-stroke week 8 success score
(p = 0.004). There was no difference between animals that never switched and those that
were ambidextrous from baseline (p = 0.066). The skilled reaching scores at post-stroke
week 8 were also not significantly different between the ambidextrous group and the
group that developed a new forelimb preference (p = 1.0). However, there was a
significant difference in the skilled reaching success score at post-stroke week 8 between
animals that never switched and animals that developed a new forelimb preference after
stroke (p = 0.006), Figure 4.6B.
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Figure 4.1. Spontaneous recovery of skilled reaching success score over 24 weeks
post-stroke. (A) shows how skilled reaching performance changed over the course of 8
weeks post-stroke. Initially, there was a significant decrease in the skilled reaching
success score at 1 week post-stroke (p < 0.001). The success score improved until poststroke week 2 (p = 0.019) with no further improvements until post-stroke week 8 (p =
0.001). (B) shows how skilled reaching performance changed over the course of 24
weeks post-stroke in a subset of animals. Similarly to the larger cohort, there was a
significant decrease in the skilled reaching success score at 1 week post-stroke (p <
0.001). Furthermore, there was an improvement in success score from week 1 to week 4
post-stroke (p = 0.022), with no further improvements seen at post-stroke week 8 or 24.
*p < 0.05, **p < 0.01, ***p < 0.001 comparing the current week to the previous week,
repeated measures ANOVA. Error bars denote ± standard error of the mean.
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A

Mild Stroke
Moderate Stroke
Severe Stroke
Very Severe Stroke
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14
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Day 3

Deficit Category
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Moderate
Severe
Very Severe

1

2

3
4
5
Weeks Post-Stroke

Success Score Criterion at
Post-Stroke Week 1
greater than 10

6

7

% of total stroke population
7. 6 (n= 5)

5 to 10

9.1 (n = 6)

less than 5/greater than 0

65.2 (n = 43)

0

8

18.2 (n = 12)

Figure 4.2. Spontaneous skilled reaching recovery based on initial severity at poststroke week 1. Animals were categorized into four stroke severity groups based on the
skilled reaching score attained at post-stroke week 1. (A) shows the recovery profiles of
animals based on mild, moderate, severe, and very severe deficit categories. The recovery
profiles of the mild and moderate stroke groups were statistically insignificant (p = 0.203,
repeated measures ANOVA). However, recovery profiles for the severe and very severe
stroke groups were significantly different from that of the mild and moderate stroke
groups (p < 0.01) and different from each other (p <0.01). Animals within the mild and
moderate stroke deficit categories displayed no significant improvement of reaching
success score over time (p = 0.085). Animals with a severe stroke deficit improved until
post-stroke week 3 (p < 0.001). No improvements were seen in the very severe deficit
animals. (B) shows the criteria used to categorize animals into mild, moderate, severe,
and very severe stroke deficit groups. Error bars denote ± standard error of the mean.
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Body Weight of Rats Post-Stroke
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Figure 4.3. Body weight of rats post-stroke. Rats that underwent stroke were weighed
once a week starting at week 0 (pre-stroke) and lasting through week 8 post-stroke.
Weight was considered as a measure of health and simultaneously as an indirect measure
of motivation to perform the food restriction based skilled reaching task. There was no
difference in the body weight of rats across any stroke deficit category (mild, moderate,
severe, very severe) across time (p = 0.577). Error bars denote ± standard error of the
mean.
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Correlation between Weeks Post-Stroke and Success Score

Time Point
PSWk1
PSWk4
PSWk8

PSWk1
-0.649**
0.753**

PSWk4
0.649**
-0.798**

PSWk8
0.753**
0.798**
--

* p < 0.05, ** p < 0.01

Table 4.1. Pearson’s correlations between skilled reaching success scores across
different post-stroke weeks.
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A

B

Figure 4.4. The effect of forelimb preference on skilled reaching success score at
baseline. At the start of training, all rats use both forelimbs to make largely
unsuccessful attempts for pellets. With training, most rats begin to show a forelimb
preference and pellet retrieval improves. (A) Once baseline criteria are attained, the
majority of rats (78%) show a single forelimb preference on the skilled reaching
task, with a minority displaying ambidextrous reaching patterns (22%). (B) There
were no differences in mean skilled reaching performance across animals with
different forelimb preferences (p = 0.731). Error bars denote ± standard error of the
mean. FL = forelimb, Ambi = ambidextrous
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Skilled Reaching Performance at Post-Stroke Week 8 based on Baseline Forelimb
Preference
20
18
Success Score
(# of pellets out of 20)

16
14

Right FL
Left FL
Ambi Right FL
Ambi Left FL

12
10
8
6
4
2
0
Post-Stroke Week 8

Figure 4.5. Relationship between baseline forelimb preference and post-stroke week
8 reaching score. Forelimb preference determined at baseline (right, left, ambidextrous
right, ambidextrous left) had no effect on the final skilled reaching success score at poststroke week 8 (p = 0.510). Error bars denote ± standard error of the mean. FL = forelimb,
Ambi = ambidextrous

Success Score
(# pellets out of 20)
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Post-Stroke Week 8

Figure 4.6. Increased reliance on unimpaired forelimb and correlated decrease in
skilled reaching performance. (A) Following stroke, the number of animals using
unimpaired forelimb to reach for sugar pellets during the skilled forelimb reaching task
increased by 31%. (B) There was a significant difference in the skilled reaching success
score at post-stroke week 8 in animals that never changed forelimb preference and
animals that changed forelimb preference after stroke (p = 0.006). Animals that changed
preference after stroke and used their unimpaired forelimb as well as their original
reaching forelimb had a lower average skilled reaching score at post-stroke week 8 than
animals that did not use their unimpaired forelimb during reaching. Note: attempts with
the unimpaired forelimb were not counted in the success score. Only attempts with the
training defined ‘preferred limb’ were counted towards the success score. Error bars
denote ± standard error of the mean. **p < 0.01
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DISCUSSION

In this study we have demonstrated that spontaneous sensorimotor recovery takes place in
adult rats post-stroke as measured by the skilled forelimb reaching task. The time course
and magnitude of recovery is related to initial stroke deficit severity at post-stroke week
1. Overall, animals displayed spontaneous sensorimotor recovery on the skilled reaching
task within one month (4 weeks) post-stroke with no further improvements in skilled
reaching performance out to 6 months (24 weeks) post stroke. Interestingly, the time
course of recovery of adult animals post-stroke is similar to reports of human post-stroke
recovery. Therefore, the rat model of ischemic stroke (MCAO) is a valid model that can
be used to study treatment effects in the acute and chronic phases after stroke.
Overall, in rats that were evaluated for 8 weeks post-stroke, the rats displayed a
large decrease in skilled reaching ability post-stroke at week 1. Spontaneous recovery of
function was seen up to week 2 post-stroke. Beyond the second week post-stroke, no
further statistically significant improvements in reaching ability were seen up to poststroke week 7. However, a statistically significant increase in skilled reaching
performance was also seen from post-stroke week 7 to post-stroke week 8. It is likely that
this improvement in function, after a total of 5 weeks of plateau in skilled reaching
success score is related to a change in the frequency in testing. Animals were tested once
a week during post-stroke weeks 1-7 and were tested three times during post-stroke week
8. Therefore, the increase in the pellet score likely represents a practice effect and not
true recovery. A similar recovery pattern was found in the smaller subset of animals that
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were evaluated for a total of 24 weeks. Rats displayed a large decrease in skilled reaching
performance at post-stroke week 1, with improvement in skilled reaching score occurring
between post-stroke week 1 and post-stroke week 4. Statistically significant
improvements were not seen beyond post-stroke week 4 until the end of the assessment
of spontaneous recovery at post-stroke week 24. Overall, the majority of improvements
seen post-stroke take place within two weeks post-stroke with an unequivocally stable
deficit seen at 6 months post-stroke. The time course for spontaneous recovery of skilled
forelimb reaching in these experiments is supported by previous studies in our lab that
used a stroke only group as a control group during other anti-Nogo-A immunotherapy
experiments. On average, spontaneous skilled reaching improvements were seen in stroke
only animals up to 2-4 weeks post-stroke, mirroring the results in the present experiments
(Papadopoulos et al., 2002; Seymour et al., 2005; Tsai et al., 2007).
In humans, the most valid predicting factor for stroke recovery is the magnitude
of initial stroke severity. Therefore, we evaluated if initial stroke deficit as measured by
the skilled reaching task affected the recovery profile of adult rats post-stroke. A strong
correlation between success score at early post-stroke weeks (week 1 and 4) was found
with the recovery success score at post-stroke week 8. Therefore, it is likely that initial
stroke deficit is a factor in the prognosis of stroke recovery in rats. To further assess the
relationship between recovery and initial deficit in rats we categorized the rats into 4
stroke deficit categories based on post-stroke week 1 (mild, moderate, severe, and very
severe) and analyzed the corresponding recovery profiles.
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Animals in the mild deficit category (n = 5) displayed a small statistically
insignificant improvement from day 3 post-stroke to post-stroke week 1. No further
improvements over time were seen up to post-stroke week 8. Since the deficits in this
group were so mild, improvements post-stroke were not detectible possibly due to a
ceiling effect. This has also been demonstrated in human stroke recovery as well (Duncan
et al., 1992). Patients with very mild post-stroke deficits display very little to no
measureable improvements over time, and any improvements that do occur do so within
the first month post-stroke. Since this population has near normal use of the forelimb (rat)
or upper extremity (human) post-stroke it is less likely to show significant improvements
in function. Due to the low level of deficits and no recovery seen in the mild deficit
category, animals in this deficit category would be unlikely to show improvements in
recovery due to treatment interventions or rehabilitation.
The recovery profile of animals in the moderate deficit category was statistically
indistinguishable from the recovery profile seen in animals with mild initial deficits.
However, it is possible that due to the low number of animals in this group (n = 6) there
was not enough statistical power to distinguish between the recovery profiles of mild and
moderate deficit animals. Animals in the moderate deficit category displayed lower
reaching success scores at post-stroke week 1 than the mild deficit category, but over
time, their success scores improved and at post-stroke week 7 and 8 became
indistinguishable from that of the mild deficit category. Animals in the moderate deficit
category start from a greater post-stroke deficit and although statistically insignificant,
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display an increased rate of recovery over the first weeks post-stroke, eventually reaching
the same overall recovery plateau as the mild deficit animals.
Animals in the severe deficit category (n = 43) show a slow and steady rate of
improvement from post-stroke day 3 to post-stroke week 3. From post-stroke week 3 to
post-stroke week 7 no statistically significant improvements area seen. A statistically
significant increase in skilled reaching success score is seen from post-stroke week 7 to
post-stroke week 8. As discussed previously, this is likely due to the change in testing
frequency from week 7 to week 8. The severe deficit animals were shown to be the most
sensitive to this increase in testing frequency among the deficit categories. Additionally,
primarily among the severe and very severe deficit category animals, we observed an
increase in animals switching their forelimb preference post-stroke and relying on the
unimpaired forelimb during skilled reaching. Although, attempts with the unimpaired
forelimb were not counted as an attempt, the use of the unimpaired forelimb may have
affected the ability of the rat to successfully grasp the pellet with its impaired forelimb.
Comparison of post-stroke week 8 success scores in animals that had no change in their
forelimb preference post-stroke to animals that changed their forelimb preference to the
unimpaired forelimb post-stroke showed that there was a statistically significant decrease
in the mean success score at post-stroke week 8. There have been reports in the literature
that large cortical lesions are more likely to cause a change in forelimb preference
(Castro-Alamancos et al., 1991) and therefore would support our finding of increased
forelimb preference change among animals in the severe and very severe deficit
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categories. The decrease in the mean recovery success score in the animals with forelimb
preference change may have be due to the switching behavior interfering in obtaining
successful pellets with the impaired forelimb, or it may have been simply a symptom of
the greater stroke severity in these animals that leads to the lower success score and
higher prevalence of switching behavior.
Animals in the very severe deficit category (n = 12) immediately after stroke were
not able to successfully grasp and place a pellet in the mouth during the skilled reaching
task. However, the rats did attempt to obtain pellets, and sometimes would drag the pellet
into the cage and drop it or would knock it away. This group of animals showed
absolutely no change in reaching performance over the course of 8 weeks. This group
may be the hardest to rehabilitate and may not show improvements in skilled reaching
even with rehabilitation or restorative treatments. Patients with very little to no recovery
post-stroke have also been reported in stroke literature (Prabhakaran et al., 2007; Stinear
et al., 2012). This absolute deficit population may not show traditional improvements in
sensorimotor function but may instead show improvements in ancillary measures such as
spasticity or shoulder pain (Stinear et al., 2012).
Given that animals in the mild and moderate deficit categories showed recovery
up to 65% of baseline performance it is likely that treating this group of animals with
anti-Nogo-A immunotherapy may not show statistically detectible improvements due to a
ceiling effect. Since the severe stroke category only showed recovery up to 25% of
baseline performance, it may be more likely that treating these animals with anti-Nogo-A
immunotherapy would show an effective improvement in function because there would

97

be more room for anti-Nogo-A immunotherapy effects to be seen. Finally, the very
severe stroke category could be treated with anti-Nogo-A immunotherapy, however this
group may be too severely damaged to show improvement.
One of the potential limitations to the interpretation of recovery profiles based on
initial severity is the unequal distribution of rat numbers within the different deficit
categories. The mild and moderate deficit categories each had approximately 5 rats while
the severe category had 43 rats and the very severe category had 12 rats. The low number
of animals in the mild and moderate deficit categories may have led to the inability to
detect statistical differences between these two recovery groups. Additionally, since the
distribution of deficits post-stroke was so heavily localized in the ‘severe’ deficit
category, it is possible that there are additional clusters of recovery trajectories within this
category. Further analysis of this data could use initial severity post-stroke as well as
stroke size and location in order to predict recovery clusters. Additionally, since poststroke recovery in rats and humans has been shown to progress non-linearly (Jorgensen et
al., 1995), the data could be analyzed using a non-linear model with initial severity and
stroke lesion characteristics as covariates in order to further characterize spontaneous
recovery post-stroke in adult rats.
In conclusion, animals undergoing ischemic focal stroke undergo a short
spontaneous recovery time course, up to 4 weeks depending on severity of initial deficit,
and do not show further improvements over time up to post-stroke week 24 (6 months)
on the skilled forelimb reaching task. Therefore, when treatments or rehabilitative
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strategies are initiated after 1 month post-stroke in adult rats, regardless of initial severity,
any improvements seen are likely to be due to the therapy and not spontaneous recovery.

CHAPTER FIVE
SENSORIMOTOR RECOVERY AND DENDRITIC PLASTICITY AFTER
CHRONIC TREATMENT DELAY USING ANTI-NOGO-A IMMUNOTHERAPY
IN THE ADULT RAT WITH MODERATE TO VERY SEVERE STROKE
DEFICITS.
ABSTRACT
Yearly, more than 700,000 people in the United States suffer from a new or
recurrent stroke and the majority are left with permanent life changing impairments.
Therefore, the development of strategies to enhance neural repair following stroke is of
utmost clinical importance. One promising new approach is to inhibit the Nogo-A
protein, a myelin associated protein that acts to restrict neuronal plasticity in the adult
central nervous system. A previous study from our laboratory showed that inhibition of
protein Nogo-A at 9 weeks post-stroke in rats with mild to moderate deficits resulted in
sensorimotor recovery and was associated with axonal plasticity (Tsai et al., 2010). The
current study was designed to further evaluate the treatment time window for the
administration of anti-Nogo-A immunotherapy in the chronic period following stroke.
We aimed to examine the extent functional recovery in rats with moderate to very severe
chronic sensorimotor deficits. Adult rats were trained on the skilled forelimb reaching
task and subsequently underwent a unilateral permanent middle cerebral artery occlusion.
Rats received anti-Nogo-A antibody, control antibody, or no treatment at one of two
delayed treatment time points: 9 weeks post-stroke (subchronic) or 25 weeks post-stroke
99
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(chronic), approximately corresponding to 2 and 6 months post-stroke. Sensorimotor
performance was assessed up to12 weeks following treatment initiation and was
evaluated using an intention-to-treat and per-protocol analysis. Following testing, rats
were sacrificed and brain tissue was processed and stained to evaluate dendritic
morphology using the Golgi-Cox method. Layer V pyramidal neurons in the perilesional
caudal forelimb motor cortex and layer II/III and layer V pyramidal neurons in the
contralesional caudal forelimb motor cortex were evaluated for dendritic tree complexity.
Both intention-to-treat and per-protocol analysis showed that anti-Nogo-A
immunotherapy administered at either 9 or 25 weeks post-stroke resulted in improved
sensorimotor recovery on the skilled forelimb reaching task but no significant recovery
was seen in sensory function or skilled walking. The improved performance on the
skilled reaching task was not associated with dendritic changes in layer V pyramidal
neurons in the perilesional caudal forelimb motor cortex or layer II/III or layer V
pyramidal neurons in the contralesional caudal forelimb motor cortex. Our finding of
improved sensorimotor recovery even when treatment was started 25 weeks post-stroke
demonstrates the promising therapeutic potential for anti-Nogo-A immunotherapy to treat
stroke sufferers long after the initial ischemic damage has taken place.
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INTRODUCTION
Stroke is a leading cause of death and the primary cause of serious long-term
disability in the United States (AHA, 2013; CDC, 2005). Neuronal damage subsequent to
the interruption of blood supply in the brain leads to the profound sensorimotor,
linguistic, and cognitive deficits seen following stroke. Stroke is classified into two main
categories, ischemic or hemorrhagic. The majority of strokes are ischemic in nature
(87%), while the rest are either intracerebral hemorrhages (10%) or subarachnoid
hemorrhages (3%) (Woo et al., 1999). It is estimated that there are over 6 million stroke
survivors living in the United States at the present time and over 700,000 new or
recurrent strokes take place each year (AHA, 2013). Given these statistics, it is clear that
the potential burden of disability seen after stroke is profound. In fact, 80% of ischemic
stroke survivors over the age of 65 have hemiparesis or cannot walk without assistance.
Additionally troubling is the fact that up to 26% of these ischemic stroke survivors are
institutionalized in a nursing home and lose all ability for independent living (KellyHayes et al., 2003).
Unfortunately, treatment options following ischemic stroke are limited, and
therefore exacerbate the magnitude of disability seen after stroke. Acutely after ischemic
stroke, the only therapeutic option is to use thrombolytic therapy to lyse the blood clot
causing the ischemia. However, the use of tissue plasminogen activator (tPA) is only
effective when used within 4.5 hours of stroke onset, and its efficacy at promoting
improvement of function is greatest when applied early in the 4.5-hour time window
(Hacke et al., 2008). Given the short treatment time window of tPA therapy, only a small
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percentage of patients (4.3%) receive the drug (CASPR Investigators, 2005). With the
majority of ischemic stroke patients not receiving thrombolytic therapy, patients can only
hope for recovery of function through spontaneous recovery mechanisms and their
potential augmentation through stroke rehabilitation.
Given the fact that spontaneous recovery is the main mechanism available for
recovery after stroke, it is important to take a pragmatic view of its efficacy. Although
real gains in function can occur through spontaneous recovery, in general, the recovery
potential after moderate to very severe strokes is generally limited even with the addition
of rehabilitative approaches. This is due to the limited ability of the adult mammalian
central nervous system (CNS) to engage in restorative regeneration and neuroplasticity
after injury. The lack of widespread regeneration and neuroplasticity in the CNS after
injury is in part related to the inhibitory environment that surrounds neurons. The main
components of this growth restrictive environment include inhibitory proteins that are
associated with myelin. The most potent of these myelin inhibitory proteins is Protein
Nogo-A (Gozenbach and Schwab, 2008). Protein Nogo-A is expressed on the membrane
of oligodendrocytes and restricts the outgrowth of neurites after CNS injury (Caroni et
al., 1988; Caroni Schwab, 1988; Chen et al., 2000; GrandPre et al., 2000; Prinjha et al.,
2000). Therefore, the neutralization of Nogo-A has become a fascinating and active
avenue for preclinical and clinical investigation as a therapeutic approach to improving
CNS regeneration and neuroplasticity and thereby functional recovery after CNS injury.
Previous studies from our laboratory have shown that inhibition of the protein
Nogo-A after focal ischemic stroke in the adult rat immediately and one week post-stroke
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results in significant recovery of skilled reaching ability. This improved recovery was
associated with axonal and dendritic plasticity in the contralesional sensorimotor cortex
(Papadopoulos et al, 2002; Seymour et al., 2005; Papadopoulos et al., 2006). In order to
properly model human stroke, anti-Nogo-A immunotherapy was also tested in aged rats
one week post-stroke. The skilled reaching recovery results mirrored the effects seen in
adult rats, albeit with a slower rate of improvement (Markus et al 2005). Most recently,
our lab began investigating the use of anti-Nogo-A immunotherapy in chronic stroke. A
small set of animals with mild to moderate stroke deficits were treated with anti-Nogo-A
immunotherapy 9 weeks post-stroke and evaluated for skilled reaching recovery. Tsai et
al (2010) showed that adult rats treated at 9 weeks post-stroke had a similar rate and
magnitude recovery profile as those treated at one week post stroke. The reaching
recovery seen in these animals was also associated with enhanced corticorubral axonal
sprouting from the contralesional forelimb motor cortex to the deafferented red nucleus.
These results opened up the possibility of anti-Nogo-A immunotherapy being a powerful
treatment even in the chronic phases after ischemic injury and set the stage for further
investigation of recovery of function after chronic stroke following anti-Nogo-A
immunotherapy.
The following experiments described in this chapter set out to further evaluate the
effective treatment time window for anti-Nogo-A immunotherapy chronically after stroke
in adult rats. Additionally, the efficacy of anti-Nogo-A immunotherapy has been
evaluated in rats with mild to moderate stroke deficits and small to medium stroke sizes
primarily involving the cortex. Therefore, we also set out to evaluate the efficacy of anti-
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Nogo-A immunotherapy in adult rats with moderate to very severe chronic sensorimotor
deficits and medium to large stroke sizes that include cortical and subcortical damage.
Rats were treated with anti-Nogo-A immunotherapy at either 9 weeks (subchronic time
point) or 25 weeks (chronic time point) post-stroke. Treatment efficacy was evaluated
using an intention-to-treat and a per-protocol analysis.
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METHODS
General methods common to both aims 1 and 2 are described in chapter 3.
Methods specific to the experiments outlined in this chapter (Aim 2 experiments) are
described here.

A priori inclusion criteria
All rats (n = 75) were trained to successfully reach 15 out of 20 pellets, for three
consecutive days and then all rats underwent a MCAO procedure. After stroke, all
surviving rats (n =66) were tested on the skilled reaching task once a week to assess for
spontaneous recovery for a total of 8 weeks or 24 weeks prior to treatment group
randomization (see chapter 4 on spontaneous recovery (Aim 1)). All remaining rats were
included in the study if they were able to reach with their impaired forelimb through the
opening aperture in the skilled reaching apparatus, and at least touch the pellets on some
attempts out of 20 total.

A priori exclusion criteria
Rats were excluded if a score of > 10/20 pellets was attained during any testing
session post-stroke, weeks 1-8 for the subchronic delay treatment cohort and weeks 1-24
for the chronic treatment delay cohort. A total of 23 out of 66 rats (35%) rats were
excluded from the study with a score > 10/20 pellets.
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Randomization
Based on the skilled reaching deficit at post-stroke week 8 (subchronic treatment cohort)
or post-stroke week 24 (chronic treatment cohort), animals were randomized across three
stroke groups: Stroke/Anti-Nogo-A Ab, Stroke/Control Ab or Stroke Only. Treatment
was initiated at the beginning of week 9 for the subchronic treatment delay cohort and at
the beginning of week 25 for the chronic treatment delay cohort.

Description of the intention-to-treat (ITT) dataset for the subchronic treatment
delay cohort (treatment at 9 weeks post-stroke)
In the intention-to-treat (ITT) dataset, all animals regardless of experimental
protocol deviation were included in the final skilled reaching analysis as randomized. The
subchronic treatment cohort was analyzed as both an ITT and a PP dataset. The ITT
dataset for the subchronic treatment delay cohort is composed of the following treatment
groups: Stroke/Anti-Nogo-A Ab (n = 14); Stroke/Control Ab (n = 12); Stroke Only (n =
10).

Description of the Per-Protocol (PP) dataset for the subchronic treatment delay
cohort (treatment at 9 weeks post-stroke)
The per-protocol (PP) dataset includes all animals from the subchronic treatment
delay ITT dataset that adhered to the experimental protocol without major deviations.
Experimental protocol deviations that led to post-randomization exclusions included
treatment pump disconnection upon removal (2 rats), absolute deficit animals that never
grasped a pellet and scored a 0 out of 20 throughout the experiments (6 rats), severe
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behavioral compensation using the unimpaired forelimb to reach for pellets and the
resultant inability to obtain an accurate score for the impaired forelimb (2 rats), and
severe striatal damage (1 rat). The PP dataset for the subchronic treatment delay cohort is
composed of the following treatment groups: Stroke/Anti-Nogo-A Ab (n = 7),
Stroke/Control Ab (n = 10), Stroke Only (n = 8).

Description of the dataset for the chronic treatment delay cohort (treatment at 25
weeks post-stroke)
The chronic delay treatment cohort (treatment initiated at 25 weeks post-stroke)
had a minimal number of animals, thereby making an ITT vs. PP distinction obsolete.
However, there were no animals with pump disconnections, no absolute deficit animals
included, no severe behavioral abnormalities, or severe striatal damage in any animals
that were randomized to this treatment time point (total n = 7). The dataset for the chronic
treatment delay cohort is composed of the following treatment groups: Stroke/Anti-NogoA Ab (n = 3), Stroke/Control Ab (n = 2), Stroke Only (n = 2). The two control groups,
animals treated with control antibody and stroke only animals, were combined in order to
perform statistical calculations given the small number of animals in this dataset.

108

RESULTS
Body weight of adult rats at baseline, post-stroke, and post-treatment.
At the beginning of the experiments, rats were approximately 2 months of age and
weighed approximately 250 grams. There was no difference in overall weight between
the stroke groups in either the subchronic treatment cohort or the chronic treatment
cohort at: arrival prior to food restriction, after skilled reaching training/food deprivation
prior to the stroke procedure, prior to treatment initiation, or at the conclusion of the
study (p > 0.05).

Morbidity and mortality associated with experimental procedures
Following stroke surgery (n = 75), a total of 9 rats (12%) died either during or
within 24 hours of the stroke procedure.
Stroke lesion size did not differ across stroke groups in animals treated with antiNogo-A immunotherapy at 9 weeks post-stroke.
Total stroke lesion volume was measured for all animals and expressed as a % of
the intact contralateral hemisphere. In the cohort of animals treated with anti-Nogo-A
immunotherapy at 9 weeks post-stroke, there were no significant difference between the
stroke sizes between stroke groups within the ITT dataset (p = 0.775, one-way ANOVA),
Figure 5.1A. ITT stroke lesion volumes were found to be 27.7 % ± 1.9 in the Stroke/AntiNogo-A Ab group, 29.6 % ± 1.9 in the Stroke/Control Ab group, and 28.4 % ± 2.3 in the
Stroke only group, Figure 5.1A.
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In the PP dataset, there was also no significant difference between the stroke sizes
between stroke groups (p = 0.809, one-way ANOVA), Figure 5.1B. PP stroke lesion
volumes were found to be 27.2 % ± 3.0 in the Stroke/Anti-Nogo-A Ab group, 29.2 % ±
2.2 in the Stroke/Control Ab group, and 27.1 % ± 2.7 in the Stroke only group, Figure
5.1B.
The overall stroke size in both the ITT and PP datasets was similar and therefore
post-randomization exclusions did not affect the average stroke size (p = 0.957, one-way
ANOVA).
Topological location of the stroke lesion included major damage to the caudal
forelimb motor area, varying levels of damage to the rostral forelimb motor area, and
minimal to moderate damage to the striatum, Figure 5.2.

Stroke lesion size did not differ across stroke groups in animals treated with antiNogo-A immunotherapy at 25 weeks post-stroke.
There was no significant difference between the stroke sizes across the anti-NogoA antibody treated or control stroke groups (p = 0.279), Figure 5.3. Stroke lesion
volumes were found to be 23.7 % ±4.0 in the Stroke/Anti-Nogo-A Ab group and 35.2 %
± 8.2 in the combined control group (Control Ab + Stroke Only), Figure 5.3. Topological
location of the stroke lesion included major damage to the caudal forelimb motor area,
varying levels of damage to the rostral forelimb motor area, and minimal to moderate
damage to the striatum, Figure 5.2.
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Improved skilled reaching performance in animals treated with anti-Nogo-A
immunotherapy at 9 weeks post-stroke (ITT and PP analyses).
ITT Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A
antibody at 9 weeks post-stroke with a General Linear Model Repeated Measures
ANOVA
To test whether treatment with anti-Nogo-A immunotherapy at 9 weeks poststroke can improve sensorimotor function in rats with moderate to very severe stroke
deficits, skilled reaching performance was assessed across 12 weeks post-treatment
initiation (20 weeks post-stroke). Figure 5.4 shows the individual reaching recovery
scores of each animal in the ITT dataset across treatment type starting at post-stroke week
7 (two weeks prior to treatment) and ending with post-stroke week 20 (the final testing
week following treatment initiation).
Skilled reaching was first analyzed using a general linear model repeated
measures ANOVA. Repeated measures analysis of animals treated at 9 weeks post-stroke
(ITT) showed no statistically significant effect of treatment group upon reaching score
across time (p = 0.235), Figure 5.5A. However, inspection of the recovery profiles
indicated that the anti-Nogo-A Ab group had a trend towards a small improvement in
final reaching performance. Figure 5.5B shows a linear regression applied to the recovery
profiles of each treatment group showing that the two control groups, Stroke/Control Ab
and Stroke Only, have a nearly horizontal recovery slope while the Stroke/Anti-Nogo-A
Ab group shows a larger recovery slope, though modest. We therefore decided to
evaluate whether there existed a significantly different mean linear rate of recovery
across the different treatment groups. The mean linear recovery rate was quantified
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starting from post-stroke week 7 and ending with post-stroke week 20. We decided to use
both post-stroke weeks 7 and 8 as the pre-treatment stroke impairment baseline to
account for skilled reaching practice effects caused by the change in testing frequency
from post-stroke week 7 to post-stroke week 8 and beyond.1 The mean linear rate of
recovery (Figure 5.5C) was found to be significantly different between the different
treatment groups (p = 0.039), one-way ANOVA. Bonferroni post-hoc testing showed that
the mean linear rate of recovery in the anti-Nogo-A antibody treated group was
significantly greater than the recovery rate in animals treated with control antibody (p =
0.045) but not significantly different from stroke only animals that received no treatment
(p = 0.234).

ITT Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A
antibody at 9 weeks post-stroke with a Non-Linear Mixed Effects Logistic Regression
Model
A non-linear mixed effects logistic regression model was used to fit a 3 parameter
binomial logistic exponential function to the ITT recovery profiles in each treatment
group. The exponential function is represented by P(t) = Ɵ1 + (Ɵ2 – Ɵ1)*e(‐Ɵ3*(t‐7)),
where P = probability of success, t = time, Ɵ1 = recovery asymptote, Ɵ2 = initial
deficit (y‐intercept), and Ɵ3 = exponential recovery rate. This statistical method was

Rats were tested once a week during post-stroke weeks 1-7 in order to maintain skilled reaching ability
without introducing motor rehabilitation. During post-stroke week 8 it was decided to test the rats 3 days in
a row in order to re-establish an accurate post-stroke impairment baseline. However, this change in testing
frequency introduced practice effects and we observed a significant improvement in skilled reaching score
across all groups from post-stroke week 7 to week 8.
1
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chosen to further analyze the recovery of animals treated with anti-Nogo-A
immunotherapy at 9 weeks post-stroke (ITT dataset) due to the increased ability of nonlinear modeling methods to handle longitudinal data with its inherent complexity without
violating statistical assumptions. For a discussion of linear versus non-linear handling of
the longitudinal data in this dissertation please refer to chapter 3.
Figure 5.6A shows the fitted group-level logistic recovery functions for each
treatment group based on the non-linear model. The initial deficit severity (post-stroke
week 7), modeled by the parameter 2 (Figure 5.6B), was shown to be the same across all
three treatment groups (p = 0.317). Fitted functions including all parameter estimates
were found to be statistically identical for the two control groups, Stroke/Control Ab and
Stroke Only. Specifically, the exponential recovery rate and final skilled reaching
recovery asymptote was found to be statistically the same across both control groups.
Analysis of the exponential recovery rate between the two control groups and the antiNogo-A antibody treated group shows that the control animals improve faster than the
anti-Nogo-A antibody group. However, the control groups reach their maximal recovery
by post-stroke week 9 and show very little improvement beyond that time point. In
contrast, the anti-Nogo-A antibody treated animals improve slowly but continue to
improve over time and reach their maximal recovery asymptote at approximately poststroke week 20 and beyond (theoretically), as modeled by the function. The anti-Nogo-A
antibody treated animals reach a statistically greater final recovery magnitude of 33.31%
success than the final recovery magnitude of approximately 20% success reached by
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either the control antibody treated animals or the stroke only animals (p < 0.001 and p <
0.01 respectively). Parameter estimates and associated significance level contrasts are
shown in Table 5.1 and 5.2 respectively for the non-linear modeling of animals treated
with anti-Nogo-A immunotherapy at 9 weeks post-stroke (ITT).

PP Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A antibody
at 9 weeks post-stroke with a General Linear Model Repeated Measures ANOVA
Post-randomization exclusions were applied to the ITT dataset and the PP dataset
was created. Figure 5.7 shows the individual reaching recovery scores of each animal in
the PP dataset across treatment type starting at post-stroke week 7 and ending with poststroke week 20.
Mirroring the statistical handling of the ITT data, we analyzed the PP skilled
reaching recovery response to anti-Nogo-A immunotherapy initiated at 9 weeks poststroke by using a general linear model repeated measures ANOVA. Repeated measures
analysis of animals treated 9 weeks post-stroke (PP) showed a statistically significant
interaction between time and treatment group for reaching success score attained (p =
0.004), Figure 5.8A. However, Bonferroni post-hoc testing did not show any statistically
significant pairwise comparisons (p > 0.05). Figure 5.8B shows a linear regression
applied to the recovery profiles of each treatment group showing that the two control
groups, Stroke/Control Ab and Stroke Only, have a nearly horizontal recovery slope
while the Stroke/Anti-Nogo-A Ab group shows a larger recovery slope and final
magnitude. We therefore decided to evaluate whether there existed a significantly
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different mean linear rate of recovery across the different treatment groups. The mean
linear recovery rate was quantified starting from post-stroke week 7 and ending with
post-stroke week 20. The mean linear rate of recovery (Figure 5.8C) was found to be
significantly different between the different treatment groups (p < 0.01), one-way
ANOVA. Bonferroni post-hoc testing showed that the mean linear rate of recovery in the
anti-Nogo-A antibody treated group was significantly greater than the recovery rate in
animals treated with control antibody (p < 0.01) and significantly greater from stroke
only animals that received no treatment (p < 0.01).

PP Analysis of Skilled Reaching Recovery following treatment with anti-Nogo-A antibody
at 9 weeks post-stroke with a Non-Linear Mixed Effects Logistic Regression Model
The same non-linear mixed effects logistic regression model that was used for the
ITT dataset was fit to the PP dataset to evaluate the efficacy of anti-Nogo-A
immunotherapy in animals treated 9 weeks post-stroke. Figure 5.9A shows the fitted
group-level logistic recovery functions for each treatment group based on the non-linear
model. The initial deficit severity (post-stroke week 7), modeled by the parameter 2
(Figure 5.9B), was shown to be the same across all three treatment groups (p = 0.317).
Fitted functions including all parameter estimates were found to be statistically identical
for the two control groups, Stroke/Control Ab and Stroke Only. Specifically, the
exponential recovery rate and final skilled reaching recovery asymptote was found to be
statistically the same across both control groups. Analysis of the exponential recovery
rate between the two control groups and the anti-Nogo-A antibody treated group shows
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that the control animals improve faster than the anti-Nogo-A antibody group. However,
the control groups reach their maximal recovery by post-stroke week 9 and show very
little improvement beyond that time point. In contrast, the anti-Nogo-A antibody treated
animals improve slowly but do not approach their maximal recovery asymptote until
post-stroke week 20 and beyond (modeled projection). The anti-Nogo-A antibody treated
animals reach a statistically greater final recovery magnitude of 55.75% than the final
recovery magnitude of approximately 25% reached by either the control antibody treated
animals or the stroke only animals (p < 0.001). Parameter estimates and associated
significance level contrasts are shown in Table 5.3 and 5.4 respectively for the PP nonlinear modeling of animals treated with anti-Nogo-A immunotherapy at 9 weeks poststroke.

Correlation of Total Stroke Lesion Volume and Final Skilled Reaching Recovery in
animals treated with anti-Nogo-A immunotherapy at 9 weeks post-stroke (ITT and
PP datasets)
Due to the variability in stroke lesion size among animals treated with anti-NogoA immunotherapy we evaluated whether stroke size was correlated with final skilled
reaching recovery success score (post-stroke week 20). Figure 5.10B shows a scatterplot
of the correlation between stroke lesion volume % and final success score for both the
ITT and PP datasets across treatment groups. A negative although insignificant
correlation was found between total stroke volume and final skilled reaching recovery
score in both the ITT and PP datasets (p > 0.05). When the same data was expressed as
the stroke volume lesion % versus the final pellet difference (post-stroke week 20 – post-
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stroke week 8) virtually no association was seen between stroke size and improvement
across all treatment groups in both the ITT and PP dataset (p > 0.05), Figure 5.10C.

Correlation of % damage based on lesion location and the Final Skilled Reaching
Recovery in animals treated with anti-Nogo-A immunotherapy at 9 weeks poststroke.
Percent damage was measured for the rostral forelimb motor cortex, the caudal
forelimb motor cortex, and the striatum based on coordinates found in Paxinos and
Watson (2005) as well as Neafsey et al. (1986). A small subset of the ITT animal dataset
was used for this preliminary analysis: 4 animals treated with anti-Nogo-A antibody, 3
animals treated with control antibody, and 3 animals that received no treatment. First we
evaluated the correlation between the success score at post-stroke week 20 and % damage
in the three brain areas outlined above. In the animals treated with anti-Nogo-A
immunotherapy, there was a negative correlation between all three brain areas and final
reaching recovery score, however only the correlation between damage in the rostral
forelimb motor cortex was found to be significantly correlated with final reaching score
at post-stroke week 20 (r = -0.997, n = 4, p = 0.003). In animals treated with either
control antibody or no treatment (combined control group), there was a negative
correlation between all three brain areas and final reaching recovery score, however only
the correlation between damage in the rostral and caudal forelimb motor cortex was
found to be significantly correlated with final reaching score at post-stroke week 20 ((r =
-0.873, n = 6, p = 0.023)(r = -0.817, n = 6, p = 0.047) respectively). Next we evaluated
how the strength of the correlations change between the % damage of the three brain
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areas and the final pellet difference. In animals treated with anti-Nogo-A immunotherapy,
the relationship between % damage in the rostral forelimb area and final pellet
improvement showed an insignificant though negative correlation (r = -0.785, n = 4, p =
0.215), Figure 5.11B. In animals treated with control antibody or no treatment, there was
virtually no association seen between damage in the rostral forelimb motor cortex, the
caudal forelimb motor cortex, or the striatum and the final pellet difference, Figure
5.11B.

No sensory recovery in animals treated with anti-Nogo-A immunotherapy at 9 weeks
post-stroke (ITT and PP datasets)
Recovery of somatosensory function was evaluated using the bilateral adhesive
removal task. The time necessary to contact the sticker on the impaired forelimb and the
time to remove the sticker from the impaired forelimb was measured. There was no
difference between treatment groups in the time necessary for animals to contact and
remove the sticker on the impaired forelimb (p = > 0.05, Figure 5.12).

No skilled walking improvement in animals treated with anti-Nogo-A
immunotherapy at 9 weeks post-stroke (ITT and PP datasets)
Recovery of skilled walking ability was evaluated using the horizontal ladder
skilled walking task. There were no significant difference between treatment groups in
the mean skilled walking movement score (p = >0.05, Figure 5.13A) or in the number of
slips per ten steps while traversing the horizontal ladder (p = >0.05, Figure 5.13B).
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Improved skilled reaching performance in animals treated with anti-Nogo-A
immunotherapy at 25 weeks post-stroke (“PP”).
Animals were treated at 25 weeks post-stroke with either anti-Nogo-A antibody,
control antibody, or no treatment. Skilled reaching performance was assessed for this
dataset for 9 weeks post-treatment initiation (post-stroke weeks 25 through 32).
A general linear model repeated measures ANOVA was used to analyze the
skilled reaching recovery response to anti-Nogo-A immunotherapy initiated at 25 weeks
post-stroke. Repeated measures analysis of animals showed a statistically significant
interaction between time and treatment group for reaching success score attained (p =
0.004), Figure 5.14A. However, Bonferroni post-hoc testing did not show any statistically
signification pairwise comparisons (p > 0.05). Figure 5.14B shows a linear regression
applied to the recovery profiles of each treatment group showing that the combined
control group, Stroke/Control Ab and Stroke Only, has a nearly horizontal recovery slope
while the Stroke/Anti-Nogo-A Ab group shows a larger recovery slope and final
magnitude. We therefore decided to evaluate whether there existed a significantly
different mean linear rate of recovery across the different treatment groups. The mean
linear recovery rate was quantified starting from post-stroke week 23 and ending with
post-stroke week 32. The mean linear rate of recovery (Figure 5.14C) was found to be
significantly different between the different treatment groups (p < 0.01), one-way
ANOVA. Due to the small number of animals in this dataset, non-linear analysis was not
applied.
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No Change in Dendritic Complexity of Layer V Pyramidal Neurons within the
Perilesional Caudal Forelimb Motor Cortex
Following the completion of sensorimotor testing of animals treated with antiNogo-A immunotherapy at 9 weeks, animals were perfused and processed for analysis of
neuronal morphology using the Golgi-Cox method. The animals included for the analysis
of neuroanatomical plasticity were not distinguished based on the behavioral ITT or PP
datasets. Intact, non-ischemic Layer V pyramidal neurons in the medial perilesional
cortex within the rostrocaudal coordinates of the caudal forelimb motor cortex were
chosen for analysis. Neurons were selected within 2 mm of the ischemic border. The
number of branches in different branch orders and the dendritic length in different branch
orders was analyzed separately for each layer V neuron’s apical and basilar dendritic tree.
Inhibition of protein Nogo-A resulted in no discernable effect on the complexity of the
apical arbors of perilesional layer V neurons as evidenced by no significant differences
across treatment groups in terms of the number of apical branches across branch order,
total number of apical branches, dendritic length across branch order, or total dendritic
length (p > 0.05, Figures 5.15). Inhibition of the protein Nogo-A also resulted in no
discernable effect on the complexity of the basilar arbors of perilesional layer V neurons
as evidenced by no significant differences across treatment groups in terms of the number
of basilar branches across branch order, total number of basilar branches, dendritic length
across branch order, or total dendritic length (p >0.05, Figures 5.16).

No Change in Dendritic Complexity in Layer II/III or Layer V Pyramidal Neurons
within the Contralesional Caudal Forelimb Motor Cortex
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The brains of animals treated at 9 weeks post-stroke with anti-Nogo-A antibody,
control antibody, or no treatment were also analyzed for dendritic complexity changes in
the contralesional caudal forelimb motor cortex. Pyramidal neurons in layers II/III and V
were selected for analysis. Inhibition of protein Nogo-A resulted in no discernable effect
on the complexity of the apical arbors of contralesional layer II/III or layer V pyramidal
neurons located in the caudal forelimb motor cortex as evidenced by no significant
differences across treatment groups in terms of the number of apical branches across
branch order, total number of apical branches, dendritic length across branch order, or
total dendritic length, Figures 5.17 and 5.19. Inhibition of protein Nogo-A also resulted in
no discernable effect on the complexity of the basilar arbors of contralesional layer II/III
or layer V pyramidal neurons located in the caudal forelimb motor cortex as evidenced by
no significant differences across treatment groups in terms of the number of basilar
branches across branch order, total number of basilar branches, dendritic length across
branch order, or total dendritic length, Figures 5.18 and 5.20.
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Stroke Lesion Size in animals treated with anti-Nogo-A immunotherapy at
9 Weeks Post-Stroke
A
Stroke Lesion Volume %
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Figure 5.1. Stroke lesion size did not differ across stroke groups in animals treated
with anti-Nogo-A immunotherapy at 9 weeks post-stroke. Total stroke lesion volume
was measured for all animals and expressed as a % of the intact contralateral hemisphere.
(A) No significant difference in the stroke size was found across stroke groups in the ITT
dataset (p = 0.775, one-way ANOVA). ITT stroke lesion volumes were found to be 27.7
% ± 1.9 in the Stroke/Anti-Nogo-A Ab group, 29.6 % ± 1.9 in the Stroke/Control Ab
group, and 28.4 % ± 2.3 in the Stroke only group. (B) No significant difference was
found in stroke size across stroke groups in the PP dataset (p = 0.809, one-way ANOVA).
PP stroke lesion volumes (PP) were found to be 27.2 % ± 3.0 in the Stroke/Anti-Nogo-A
Ab group, 29.2 % ± 2.2 in the Stroke/Control Ab group, and 27.1 % ± 2.7 in the Stroke
only group.
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Representative Stroke Lesion Topology

Figure 5.2. Diagram of stroke lesion topology. Diagram displays the differences in
lesion territory between a large and small stroke size. The large lesion (approximately
40% stroke size) damages most the rostral-caudal hemispheric axis including damage to
the rostral forelimb motor area, caudal forelimb motor area, and the dorso-lateral
striatum. The small stroke lesion (approximately 15% stroke size) damages a more
limited portion of the hemisphere including primarily the caudal forelimb motor cortex
with minimal damage to the rostral forelimb motor cortex and dorso-lateral striatum.
Topologies of small and large lesions are similar in both the treatment delayed cohort
(treatment at 9 weeks post-stroke) and the prolonged treatment delay cohort (treatment at
25 weeks post-stroke).

123

Stroke Lesion Size in animals treated with anti-Nogo-A immunotherapy at
25 Weeks Post-Stroke Stroke Lesion Size
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Figure 5.3. Stroke lesion size did not differ across stroke groups in animals treated
with anti-Nogo-A immunotherapy at 25 weeks post-stroke. In the cohort of animals
treated with anti-Nogo-A immunotherapy at 25 weeks post-stroke (prolonged treatment
delay), there was no significant difference between the stroke sizes across the two stroke
groups (p = 0.279, t-test). Stroke lesion volumes were found to be 23.7 % ±4.0 in the
Stroke/Anti-Nogo-A Ab group and 35.2 % ± 8.2 in the combined control group (Control
Ab + Stroke Only).
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Individual Animal Skilled Reaching Recovery following treatment administered at
9 Weeks Post-Stroke (Intention-To-Treat [ITT] Dataset)
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Figure 5.4. shows the reaching recovery scores of each animal in the ITT dataset across
time based on (A) treatment with anti-Nogo-A antibody (B) treatment with control
antibody and (C) no treatment. Each plot shows the individual mean recovery score at
each week as well as the group mean recovery score at each week.
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Mean Skilled Reaching Recovery following Anti-Nogo-A Immunotherapy, Control
Antibody, or no treatment Administered at 9 Weeks post-Stroke (ITT Dataset)

Mean Success Score
(# pellets out of 20)
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Figure 5.5. Treatment analysis with anti-Nogo-A immunotherapy, control Ab, or no
treatment analyzed using a general linear model repeated measures ANOVA. (A)
Skilled reaching performance was analyzed at baseline, post-stroke, and post-treatment
using a repeated measures ANOVA. There were no differences in rats across stroke
groups in pre-stroke success scores. Following stroke surgery, rats across all stroke
groups develop a large impairment in skilled reaching that persists across time. Following
treatment initiation, there was no significant effect of treatment between groups on
skilled reaching performance. (B) shows the linear recovery rate following treatment. The
linear regression is shown using post-stroke scores at week 7 and 8 as the initial scores
prior to treatment initiation. The Stroke/Anti-Nogo-A Ab group shows a statistically
significant linear rate of recovery as compared to the Stroke/Control Ab group (p =0.045)
but not as compared to the Stroke Only Group (p = 0.234), one-way ANOVA). (*p <
0.05)
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Non-linear Modeling of Skilled Reaching Recovery in animals treated with antiNogo-A immunotherapy at 9 weeks post-stroke (ITT Dataset)
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Figure 5.6. Improved skilled reaching performance (ITT) following anti-Nogo-A
immunotherapy in adult rats with chronic severe stroke deficits using nonlinear
modeling. (A) shows the fitted group-level logistic recovery profiles for each treatment
group based on the non-linear model. Animals in the Stroke/Anti-Nogo-A Ab group
showed an improved recovery profile as compared to the Stroke/Control Ab and Stroke
Only groups (B) Initial deficit severity at post-stroke week 7 was the same across all
groups, as shown by the Ɵ2 parameter (p > 0.05). (C) The Stroke/Anti-Nogo-A Ab group
showed a greater final recovery than either the Stroke/Control Ab or Stroke Only group,
as given by the Ɵ1 parameter (p < 0.001 and 0.01 respectively). (D) Analysis of the
exponential recovery rate shows that the Stroke/Anti-Nogo-A Ab group had a slower rate
of recovery over a longer timeframe, while the Stroke/Control Ab and Stroke Only
groups had a faster recovery rate over a shorter timeframe. Error bars denote ± standard
error of the estimate (** p < 0.01, *** p < 0.001).
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Parameter Estimates from Non-linear Model of Skilled Reaching Recovery at 9
weeks post-stroke (ITT Dataset)
A. Parameter estimates for recovery asymptote
Group
Anti-Nogo-A
Ab
Control Ab
Stroke Only

1 Estimate

Standard
Error

Upper
Confidence
Level

0.3331

0.01573

0.3022

0.3640

0.2064
0.2109

0.005209
0.006904

0.1962
0.1973

0.2166
0.2245

B. Parameter estimates for initial deficit severity
Group
Standard
2 Estimate
Error
Anti-Nogo-A
Ab
Control Ab
Stroke Only

Lower
Confidence
Level

Lower
Confidence
Level

Upper
Confidence
Level

0.1142

0.01402

0.08662

0.1417

0.1370
0.08982

0.02242
0.02111

0.09293
0.04836

0.1810
0.1313

C. Parameter estimates for recovery rate
Group
Anti-Nogo-A
Ab
Control Ab
Stroke Only

3 Estimate

Standard
Error

Lower
Confidence
Level

Upper
Confidence
Level

0.1142

0.01402

0.08662

0.1417

0.1370
0.08982

0.02242
0.02111

0.09293
0.04836

0.1810
0.1313

Table 5.1. The estimates, standard error, and lower/upper confidence level intervals for
the parameters (1, 2, 3) of the non-linear functions fitted to the Stroke/Anti-Nogo-A
Ab, Control Ab, and Stroke Only groups are listed above in A, B and C respectively.
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Parameter Estimate Contrasts (ITT Dataset treated at 9 weeks post-stroke)
A. Contrast comparisons for recovery asymptote
1 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.3331
0.000001*
0.005517*
Anti-Nogo-A Ab -0.2064

Control Ab

0.000001*

--

0.637628

0.2109

Stroke Only

0.005517*

0.637628

--

B. Contrast comparisons for initial deficit severity
2 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.1142
-0.316637
0.316637
Anti-Nogo-A Ab
0.1370

Control Ab

0.316637

--

0.316637

0.08982

Stroke Only

0.316637

0.316637

--

C. Contrast comparisons for recovery rate
3 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.2116

Anti-Nogo-A Ab

--

0.000335*

0.008230*

0.7627

Control Ab

0.000335*

--

0.192050

0.5699

Stroke Only

0.008230*

0.192050

--

Table 5. 2. Significance levels for parameter estimate contrasts between treatment
groups. Hypothesis testing was performed by comparing the full non-linear model with
all 9 parameters to reduced versions of the original model with certain parameters held
constant. The skilled reaching outcome variable is binomial (success or no success) and
therefore the dataset is modeled by a χ2 distribution. Fitted models are contrasted by
using χ2 likelihood based ratio tests.
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Individual Animal Skilled Reaching Recovery following Anti-Nogo-A Ab, Control
Ab, or no treatment Administered at 9 Weeks Post- Stroke (PP Dataset)

Mean Success Score
(# pellets out of 20)

A

20
18
16
14
12
10
8
6
4
2
0
7

Mean Success Score
(# pellets out of 20)

B

Stroke/Anti-Nogo-A Ab Individual Animal Mean
Stroke/Anti-Nogo-A Ab Group Mean

Antibody
Infusion (two weeks)

8

9

10

11

12

13

14

15

16

17

18

19

20

Weeks Post-Stroke

20
18
16
14
12
10
8
6
4
2
0

Stroke/Control Ab Individual Animal Mean
Stroke/Control Ab Group Mean

Antibody
Infusion (two weeks)

7

8

9

10

11

12

13

14

15

16

17

18

19

20

Weeks Post-Stroke
Mean Success Score
(# pellets out of 20)

C

20
18
16
14
12
10
8
6
4
2
0

Stroke Only Individual Animal Mean
Antibody
Infusion (two weeks)

7

8

9

10

Stroke Only Group Mean

11

12

13

14

15

16

17

18

19

20

Weeks Post-Stroke

Figure 5.7. shows the reaching recovery scores of each animal in the PP dataset across
time based on (A) treatment with anti-Nogo-A antibody (B) treatment with control
antibody and (C) no treatment. Each plot shows the individual mean recovery score at
each week as well as the group mean recovery score at each week.
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Improved Skilled Reaching Performance following Anti-Nogo-A Immunotherapy
Administered at 9 Weeks Post-Stroke (PP Dataset)
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Figure 5.8. Analysis of improved skilled reaching recovery (PP) following treatment
with anti-Nogo-A immunotherapy using a general linear model repeated measures
ANOVA. (A) Following treatment initiation, a significant time x treatment group
interaction (weeks post-stroke) was found for skilled reaching recovery (p = 0.004),
however Bonferroni post hoc testing revealed no statistically significant pairwise
comparisons. Repeated measures ANOVA analysis of percent change from post-stroke
week 24 (B) also showed a significant time x treatment interaction, with statistically
significant improved recovery for animals treated with anti-Nogo-A immunotherapy
starting at post-stroke week 26 and lasting until the end of treatment (error bars omitted
for clarity). The Stroke/Anti-Nogo-A Ab group showed a significantly larger mean linear
rate of recovery (C) as compared to the Stroke/Control Ab and Stroke Only Groups (p <
0.001) (F(2,24) = 24.789, p < 0.001, one-way ANOVA).

131

Non-linear Modeling of Skilled Reaching Recovery in animals treated with antiNogo-A immunotherapy at 9 weeks post-stroke (PP Dataset)
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Figure 5.9. Improved recovery in skilled reaching performance (PP) following antiNogo-A immunotherapy. (A) shows the fitted group-level logistic recovery profiles for
each treatment group based on the non-linear model. Animals in the Stroke/Anti-Nogo-A
Ab group showed an improved recovery profile as compared to the Stroke/Control Ab
and Stroke Only groups. Initial deficit severity at post-stroke week 7 (B) was the same for
all groups (p > 0.05). The Stroke/Anti-Nogo-A Ab group showed a greater recovery
asymptote (C) than either the Stroke/Control Ab or Stroke Only group (p < 0.001).
Analysis of the exponential recovery rate (D) revealed that the Stroke/Anti-Nogo-A Ab
group had a slower rate of recovery over a longer timeframe, ultimately resulting in a
higher recovery asymptote, while the Stroke/Control Ab and Stroke Only groups had a
faster recovery rate over a shorter timeframe, but ultimately a lower recovery asymptote.
Error bars denote ± standard error of the estimate. *** p < 0.001, comparison of
Stroke/Anti-Nogo-A Ab group against both Stroke/Control Ab and Stroke Only groups.
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Parameter Estimates from Non-linear Model of Skilled Reaching Recovery (PP
Dataset treated at 9 weeks post-stroke)
A. Parameter estimates for recovery asymptote
Group
Anti-Nogo-A
Ab
Control Ab
Stroke Only

1 Estimate

Standard
Error

Lower
Confidence
Level

Upper
Confidence
Level

0.5575

0.03445

0.4898

0.6253

0.2445
0.2610

0.005621
0.008147

0.2334
0.2449

0.2555
0.2770

B. Parameter estimates for initial deficit severity
Group
Anti-Nogo-A
Ab
Control Ab
Stroke Only

2 Estimate

Standard
Error

Lower
Confidence
Level

Upper
Confidence
Level

0.08720

0.02028

0.04731

0.1271

0.1594
0.1135

0.02482
0.02599

0.1105
0.06234

0.2082
0.1646

C. Parameter estimates for recovery rate
Group
Anti-Nogo-A
Ab
Control Ab
Stroke Only

3
Estimate

Standard
Error

Lower
Confidence
Level

Upper Confidence
Level

0.1753

0.03309

0.1103

0.2404

0.8423
0.5754

0.4159
0.2152

0.02434
0.1520

1.6602
0.9987

Table 5.3. The estimates, standard error, and lower/upper confidence level intervals for
the parameters (1, 2, 3) of the non-linear functions fitted to the Stroke/Anti-Nogo-A
Ab, Control Ab, and Stroke Only groups are listed above in A, B and C respectively (PP
Analysis).
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Parameter Estimate Contrasts (PP treated at 9 weeks post-stroke)
A. Contrast comparisons for recovery asymptote
1 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.3331
-< 0.000001* 0.000004*
Anti-Nogo-A Ab
0.2064

Control Ab

< 0.000001*

--

0.157234

0.2109

Stroke Only

0.000004*

0.157234

--

B. Contrast comparisons for initial deficit severity
2 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.1142
-0.070651
0.070651
Anti-Nogo-A Ab
0.1370

Control Ab

0.070651

--

0.070651

0.08982

Stroke Only

0.070651

0.070651

--

C. Contrast comparisons for recovery rate
3 Estimate Group\Group Anti-Nogo-A Ab Control Ab Stroke Only
0.2116
-< 0.000001* < 0.000001*
Anti-Nogo-A Ab
0.7627

Control Ab

< 0.000001*

--

0.116484

0.5699

Stroke Only

< 0.000001*

0.116484

--

Table 5. 4. Significance levels for parameter estimate contrasts between treatment
groups (PP Dataset). Hypothesis testing was performed by comparing the full non-linear
model with all 9 parameters to reduced versions of the original model with certain
parameters held constant. The skilled reaching outcome variable is binomial (success or
no success) and therefore the dataset is modeled by a χ2 distribution. Fitted models are
contrasted by using χ2 likelihood based ratio tests.
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Figure 5.10. Correlation between total stroke volume and reaching recovery in the
ITT and PP datasets. (A) shows the total stroke lesion volume. (B) shows a negative
correlation although insignificant between the final reaching score and the total stroke
lesion volume in both ITT and PP datasets. (C) shows the lack of an association between
reaching recovery and stroke lesion volume when the final reaching score is expressed as
the percent improvement from pre-treatment (post-stroke week 8).
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Correlation of Lesion Location and Final Reaching Recovery
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Figure 5.11. Correlation between lesion location and final reaching recovery. (A)
shows the negative correlation between final reaching success score post-treatment (poststroke week 20) and damage in the caudal forelimb motor cortex, rostral forelimb motor
cortex, and the striatum in both the Stroke/Anti-Nogo-A Ab group and the control group.
When controlling for initial pre-treatment severity by using percent change from pretreatment, only the correlation between rostral forelimb motor cortex and final
improvement percent was found to be correlated in animals treated with anti-Nogo-A
immunotherapy.
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Somatosensory Recovery following treatment with anti-Nogo-A immunotherapy at
9 weeks post-stroke.
35

Stroke Only (ITT)
Stroke/Control Ab (ITT)
Stroke/Anti-Nogo-A Ab (ITT)

30
25
20
15
10
5

A’ 35
Time to contact sticker (s)

Time to contact sticker (s)

A

0

Stroke Only (PP)
Stroke/Control Ab (PP)
Stroke/Anti-Nogo-A Ab (PP)

30
25
20
15
10
5
0

0

8

16

20

0

Weeks Post-Stroke
Stroke Only (ITT)
Stroke/Control Ab (ITT)
Stroke/Anti-Nogo-A Ab (ITT)

60
50
40
30
20
10
0
0

8

16

Weeks Post-Stroke

20

B’ 60
Sticker Removal Time (s)

Sticker removal time (s)

B

8

16

20

Weeks Post-Stroke
Stroke Only (PP)
Stroke/Control Ab (PP)
Stroke/Anti-Nogo-A Ab (PP)

50
40
30
20
10
0
0

8

16

20

Weeks Post-Stroke

Figure 5.12. No somatosensory recovery following treatment with anti-Nogo-A
immunotherapy at 9 weeks post-stroke (ITT + PP Dataset). (A and A’) There was no
difference across groups for the time it took the rats to contact the sticker on the impaired
forelimb in either the ITT or PP dataset respectively (p > 0.05). (B and B’) There was no
difference across groups for the time it took the rats to remove the sticker on the impaired
forelimb in either the ITT or PP dataset respectively (p > 0.05).
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Recovery of Skilled Walking in animals treated with anti-Nogo-A immunotherapy
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Figure 5.13. No skilled walking recovery following treatment with anti-Nogo-A
immunotherapy at 9 weeks post-stroke (ITT + PP Dataset). (A and A’) There was no
difference across groups for the movement score across time in either the ITT or PP
dataset respectively (p > 0.05). (B and B’) There was no difference across groups in the
number of foot slips across time in either the ITT or PP dataset respectively (p > 0.05).
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Mean Skilled Reaching Recovery following treatment Administered at 25 Weeks
Post-Stroke (“PP” Dataset)
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Figure 5.14. Analysis of improved skilled reaching recovery (“PP”) following
treatment using Generalized Linear Model statistics. (A) Following treatment
initiation, there was a significant interaction between time x treatment across groups on
skilled reaching performance but individual time point analysis did not show significantly
different means. Percent change from post-stroke week 24 (B) also showed a significant
time x treatment interaction with improved recovery for animals treated with anti-NogoA immunotherapy starting at post-stroke week 26 and lasting until the end of treatment
(error bars omitted for clarity). The Stroke/Anti-Nogo-A Ab group shows a statistically
significant linear rate of recovery (C) as compared to the Stroke/Control Ab group (p
=0.016), one-way ANOVA).*p< 0.05, **p < 0.001
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Apical Dendritic Complexity of Layer V Pyramidal Neurons Located in the
Perilesional Caudal Forelimb Motor Cortex
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Figure 5.15. Apical dendritic tree morphology. Apical tree morphology was quantified
for number of branch points by branch order and branch length by branch order. (A)
Treatment with anti-Nogo-A immunotherapy had no effect on the number of dendritic
branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment with
anti-Nogo-A immunotherapy had no effect on the total number of branches in the apical
dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A
immunotherapy had no effect on the apical branch length across branch orders (p > 0.05,
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on
the total apical dendritic length (p > 0.05, one-way ANOVA).
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Basilar Dendritic Complexity of Layer V Pyramidal Neurons Located in the
Perilesional Caudal Forelimb Motor Cortex
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Figure 5.16. Basilar dendritic tree morphology. Basilar tree morphology was
quantified for number of branch points by branch order and branch length by branch
order. (A) Treatment with anti-Nogo-A immunotherapy had no effect on the number of
dendritic branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment
with anti-Nogo-A immunotherapy had no effect on the total number of branches in the
basilar dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A
immunotherapy had no effect on the basilar branch length across branch orders (p > 0.05,
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on
the total basilar dendritic length (p > 0.05, one-way ANOVA).
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Figure 5.17. Apical dendritic tree morphology. Apical tree morphology was quantified
for number of branch points by branch order and branch length by branch order. (A)
Treatment with anti-Nogo-A immunotherapy had no effect on the number of dendritic
branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment with
anti-Nogo-A immunotherapy had no effect on the total number of branches in the apical
dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A
immunotherapy had no effect on the apical branch length across branch orders (p > 0.05,
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on
the total apical dendritic length (p > 0.05, one-way ANOVA).
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Basilar Dendritic Complexity of Layer II/III Pyramidal Neurons Located in the
Contralesional Caudal Forelimb Motor Cortex
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Figure 5.18. Basilar dendritic tree morphology. Basilar tree morphology was
quantified for number of branch points by branch order and branch length by branch
order. (A) Treatment with anti-Nogo-A immunotherapy had no effect on the number of
dendritic branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment
with anti-Nogo-A immunotherapy had no effect on the total number of branches in the
basilar dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A
immunotherapy had no effect on the basilar branch length across branch orders (p > 0.05,
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on
the total basilar dendritic length (p > 0.05, one-way ANOVA).
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Apical Dendritic Complexity of Layer V Pyramidal Neurons Located in the
Contralesional Caudal Forelimb Motor Cortex
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Figure 5.19. Apical dendritic tree morphology. Apical tree morphology was quantified
for number of branch points by branch order and branch length by branch order. (A)
Treatment with anti-Nogo-A immunotherapy had no effect on the number of dendritic
branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment with
anti-Nogo-A immunotherapy had no effect on the total number of branches in the apical
dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A
immunotherapy had no effect on the apical branch length across branch orders (p > 0.05,
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on
the total apical dendritic length (p > 0.05, one-way ANOVA).
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Figure 5.20. Basilar dendritic tree morphology. Basilar tree morphology was
quantified for number of branch points by branch order and branch length by branch
order. (A) Treatment with anti-Nogo-A immunotherapy had no effect on the number of
dendritic branch points across branch order (p > 0.05, one-way ANOVA). (A’) Treatment
with anti-Nogo-A immunotherapy had no effect on the total number of branches in the
basilar dendritic tree (p > 0.05, one-way ANOVA). (B) Treatment with anti-Nogo-A
immunotherapy had no effect on the basilar branch length across branch orders (p > 0.05,
one-way ANOVA). (B’) Treatment with anti-Nogo-A immunotherapy had no effect on
the total basilar dendritic length (p > 0.05, one-way ANOVA).
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Comparison of anti-Nogo-A immunotherapy efficacy across different treatment
initiation time points and ages of animals
Treatment
Initiation

Age

Data
Type

Stroke
Lesion
Volume
(SEM)

% Improv.
at 8
Weeks
Post‐
Treatment

% Improv.
at 12
Weeks
Post‐
Treatment

% Improv.
at 14
Weeks
Post‐
Treatment

Author

Immediate.
after stroke

Adult

?

8%

30%

‐‐

‐‐

Papadopoulos

1 week post‐
stroke

Adult

?

10%

35%

‐‐

‐‐

Seymour

1 week post‐
stroke

Aged

?

?

20%

20%

45%

Markus

9 weeks
post‐stroke

Adult

PP

30%

‐‐

‐‐

Tsai

9 weeks
post‐stroke

Adult

ITT

27%

10.5%

13%

‐‐

Podraza

9 weeks
post‐stroke

Adult

PP

27%

20%

Nearing
35%

‐‐

Podraza

25 weeks
post‐stroke

Adult

PP

20%

35%

‐‐

‐‐

Podraza

16%

Table 5.5. Comparison of anti-Nogo-A immunotherapy efficacy across different
treatment initiation time points and ages of animals.
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DISCUSSION
This present study demonstrates that there exists an extended treatment window
for the use of anti-Nogo-A immunotherapy to improve sensorimotor function in adult rats
with chronic moderate to very severe stroke deficits. Adult rats that were treated with
anti-Nogo-A antibodies at either 9 (~ 2 months) or 25 (~ 6 months) weeks post-stroke
displayed an improvement in skilled forelimb reaching performance but exhibited no
change in skilled walking or sensory function. Furthermore, the improvement in skilled
forelimb reaching performance was not associated with changes in dendritic tree
complexity in layer V pyramidal neurons located in the perilesional caudal forelimb
motor cortex or in layers II/III and V pyramidal neurons located in the contralesional
caudal forelimb motor cortex.
In order to determine an unbiased efficacy rate for anti-Nogo-A immunotherapy
in animals with moderate to very severe stroke deficits treated at 9 weeks post-stroke, the
data was first evaluated using an intention-to-treat analysis and then using a per-protocol
analysis. An intention-to-treat (ITT) procedure was used whereby all randomized
animals, regardless of experimental protocol deviations, were used in the final analysis.
Although, this approach may lead to conservative estimates of efficacy, it provides the
most valid assessment of meaningful differences across groups and is considered the gold
standard approach to data analysis in human clinical trials (Day et al., 2008; FDA, 1988).
The ITT dataset included all animals that scored 10 out of 20 pellets or less on the skilled
forelimb reaching task, and could be stratified by deficit severity. Our ITT population
included a range of animals with moderate stroke deficits (36%), severe deficits (42%),
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and very severe deficits (22%). We found that this population when treated with antiNogo-A immunotherapy at 9 weeks post-stroke had a statistically significant
improvement in the final recovery asymptote (probability of success out of 20 trials) as
compared to both of the control groups. Animals treated with anti-Nogo-A antibody had a
final recovery asymptote of 33.31%  2.0, compared to animals treated with control
antibody (20.64%  1.0), and stroke only animals (21.09%  1.0). When adjusting the
recovery percent by initial deficit pre-treatment (post-stroke week 8), anti-Nogo-A
antibody treated animals displayed an improvement in skilled forelimb reaching
performance by 21.89%, while animals treated with control antibody improved by only
6.94% and stroke only animals improved by only 12.11%. However, of note, only
animals with moderate to severe deficits improved after anti-Nogo-A immunotherapy.
Animals in the very severe category, i.e. those that never grasped a pellet in the
timeframe between their stroke and prior to treatment, showed no improvement on the
skilled reaching task after treatment. Therefore, these results show the effectiveness of
anti-Nogo-A immunotherapy in the early chronic stage after stroke (9 weeks post-stroke)
in adult rats with moderate to very severe stroke deficits, but also highlight the inability
of anti-Nogo-A immunotherapy to result in recovery of skilled forelimb reaching when
there is no residual ability to move the forelimb prior to treatment. To our knowledge, the
present study is the first report of using anti-Nogo-A immunotherapy to improve
sensorimotor function after stroke at a clinically relevant chronic time point and in a
population that includes rats with severe and very severe stroke deficits and

148

corresponding large stroke sizes. The positive results from the present study support the
perspective that the brain can respond to treatment interventions in the chronic phase
after stroke and also in the context of severe stroke damage.
However, given the fact that the ITT treatment efficacy estimates were based on a
dataset that included animals that deviated from the experimental protocol, we set out to
see how the efficacy of anti-Nogo-A immunotherapy is affected by post-randomization
exclusions. Animals were excluded for various reasons. Firstly, animals were excluded if
the antibody intracerebroventricular pump was found to be disconnected upon removal,
thereby potentially supplying a suboptimal therapeutic dose of antibody to the animal.
Secondly, animals were excluded when displaying very severe reliance on using the
unimpaired forelimb during the skilled reaching task. These animals primarily used their
“good” forelimb for reaching for pellets leading to very inaccurate success score
estimations for the impaired forelimb. Thirdly, animals were excluded if they displayed
an “absolute deficit” phenotype where post-stroke, no pellets were ever successfully
grasped and brought to the mouth. Fourthly, rats were excluded with very severe
subcortical damage (complete damage of dorso-lateral striatum). Our PP results showed
that once these animals were excluded from the study, the efficacy rate of anti-Nogo-A
immunotherapy in animals treated at 9 weeks post-stroke improved. Although the mean
total stroke size per treatment group did not change between the ITT and PP datasets, the
distribution of stroke deficit severity at time of treatment in the population was affected.
Our PP population on average included animals with moderate stroke deficits (43.5%),
and severe deficits (56.5%), with no animals displaying very severe deficits (0%).
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Animals treated with anti-Nogo-A antibody had a final recovery asymptote of 55.75% 
3.0, compared to animals treated with control antibody (24.45%  1.0), and stroke only
animals (26.10%  1.0). When adjusting the recovery percent by initial deficit pretreatment, anti-Nogo-A antibody treated animals displayed an improvement in skilled
forelimb reaching performance by 47.03%, while animals treated with control antibody
improved by only 8.51% and stroke only animals improved by only 14.75%. Therefore,
the results from the PP analysis show that when animals with chronic moderate to severe
stroke deficits are treated at 9 weeks post-stroke with anti-Nogo-A immunotherapy,
recovery from initial impairment will be 35% greater than that of controls. These PP
results suggest that in a population of rats that received the entire dose of anti-Nogo-A
antibody, had no behavioral abnormalities during testing procedures, did not have very
severe deficits or severe subcortical damage, we can expect a greater improvement of
sensorimotor function after treatment with anti-Nogo-A immunotherapy at 9 weeks after
stroke than suggested by the ITT efficacy rates.
As mentioned above, comparison of the ITT and PP datasets shows that among
moderate to very severe stroke deficits, and correspondingly moderate to very large
stroke sizes, not all animals will recover and not all will recover the same amount with
anti-Nogo-A antibody treatment. Based on the ITT and PP results, the mean efficacy rate
for anti-Nogo-A immunotherapy above controls when administered at 9 weeks poststroke may vary anywhere from 12% to 35%. The efficacy rates of anti-Nogo-A
immunotherapy in this present study may be related to an animal’s individual total stroke
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size, total damage to particular areas important for skilled reaching (rostral forelimb area,
caudal forelimb area, striatum), specified and unspecified behavioral characteristics,
experimental error, and unknown factors. Therefore we evaluated the correlation between
total stroke size and recovery in both the ITT and PP datasets. Although we found a
significant correlation between the total stroke lesion size and final reaching success
score (out of 20), we found no correlation between the total stroke size and the final
absolute increase in pellets obtained in the skilled reaching task. Hence the relationship
between the total stroke lesion size and treatment induced improvement is complex. This
complex relationship has been seen in human stroke studies as well. Studies have shown
conflicting results, with some showing significant correlations between total stroke lesion
size and upper extremity recovery (Beloosesky et al. 1995; Van Everdingen et al., 1998),
while others have shown little to no correlation between total stroke lesion size and upper
extremity recovery (Pantano et al., 1996; Miyai et al., 1997). Interestingly, using both
total stroke lesion size and lesion size based on location seems to be more strongly
correlated with recovery potential (Chen et al., 2000). Therefore we decided to perform a
preliminary location specific stroke lesion analysis to gain a greater understanding
between anti-Nogo-A immunotherapy induced improvements and lesion size and
location. We evaluated, in a small subset of the animals (n=4), the correlation between
the final absolute increase in pellets obtained after treatment and the % damage in the
rostral forelimb motor cortex, caudal forelimb motor cortex, and striatum. Although not
statistically significant, we found a strong inverse correlation between the damage in the
rostral forelimb motor cortex and the final improvement in the number of pellets obtained
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at the end of the study in animals treated with anti-Nogo-A immunotherapy at 9 weeks
post-stroke. Based on these preliminary results, this might suggest that the residual
ipsilesional rostral forelimb motor cortex may also play a role in the recovery seen after
anti-Nogo-A immunotherapy and underscore the importance of detailed lesion location
analysis. Future analyses will complete detailed lesion based analysis on all animals in
the ITT and PP datasets.
In addition to evaluating skilled reaching recovery after anti-Nogo-A
immunotherapy at 9 weeks post-stroke, we evaluated recovery in sensory function and
skilled walking. Results from these two tasks showed that the improved skilled forelimb
reaching recovery did not translate to improvements seen in sensory function and skilled
walking. Sensory function, tested by the use of the bilateral adhesive removal task, has
been tested after anti-Nogo-A immunotherapy after a corticospinal tract (CST) lesion and
after a traumatic brain injury. In the first study, adult rats were given unilateral CST
lesions at the medulla oblongata and sensory function was tested using the bilateral
adhesive removal task. Animals treated with anti-Nogo-A antibodies (IN-1) showed a
profound recovery of sensory function (Thalmair et al., 1998). In contrast, another study
showed no improvement in sensory function, as measured by the bilateral adhesive
removal task, in animals treated with anti-Nogo-A antibodies (11C7) after traumatic brain
injury (Lenzlinger et al., 2005). Therefore, sensory recovery after anti-Nogo-A
immunotherapy may be related to lesion type and location. Additionally, the task used to
test sensory function, the bilateral adhesive removal task, has been shown to be highly
variable and requires a large number of subjects to show significant differences
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(Whishaw & Kolb., 2005). The task sensitivity can also be affected by the type of stickers
used since different levels of adhesiveness can affect the difficulty of the task. It is
possible the sensitivity of our task was low and our sample size was too small to pick up
any meaningful differences across groups. Regarding skilled walking, at the chronic time
points assessed, there were very mild deficits seen after stroke on this task at pretreatment and therefore there was little room for improvement after treatment. The lack of
large deficits on this task may be related to the spinal cord’s ability to mediate
locomotion with little input from the sensorimotor cortex (Dietz et al., 2003; Forssberg et
al., 1975). The discrepancy between improved recovery seen in the skilled forelimb
reaching task and the little improvement seen in both the bilateral adhesive removal task
and the skilled horizontal ladder walking task also underscore the complex relationship
mediating the transfer of task related improved skills. The topic of whether trained skills
can be translated to an untrained task is controversial, with both supporting evidence
(Multon et al., 2003; Engessser-Cesar et al., 2007) and conflicting evidence (Edgerton et
al., 1997; De Leon et al., 1998; Grasso et al., 2004). In the case of this study, rats were
trained on the skilled forelimb reaching task prior to stroke injury and then during the
treatment phase, were tested on the task almost daily. In contrast, the bilateral adhesive
removal task and the skilled ladder horizontal ladder walking task do not require training,
and simply require habituation to the testing environment. Furthermore, the rats in this
present study were tested on these two tasks only four times during the study (baseline,
pre-treatment, post-treatment time 1, post-treatment time 2), therefore negating any
training effects that could have helped stimulate recovery. Finally, since the neural

153

strategy used for the movements in our three tasks differ, it might be less likely for the
recovery of function on one task to be converted to the recovery of function in another
task (Singh et al., 2010).
Next we evaluated skilled reaching recovery after treatment with anti-Nogo-A
immunotherapy at 25 weeks post-stroke. These results are based on a small dataset (n =
7). All animals in this dataset were analyzed as randomized, however since the animals
selected for this time point did not have any protocol deviations as seen in the 9 week
treated group, the results could be considered as a PP analysis, in order to compare the
results to the 9 week time point. Nonlinear modeling was not possible with this dataset
due to the small number of animals. Repeated measures ANOVA showed anti-Nogo-A
antibody treated animals had a significant interaction between time and treatment as
compared to the control treated animals. However, the study was not properly powered
for post-hoc tesing to show a significant difference between control treated and antiNogo-A antibody treated animals at any given time point. However, we did find that the
linear mean rate of improvement was significantly greater in the animals treated with
anti-Nogo-A antibodies. Additionally, rats treated with anti-Nogo-A immunotherapy at
25 weeks post-stroke showed a similar final magnitude of improvement as the animals
treated with anti-Nogo-A immunotherapy at 9 weeks (PP analysis). Although the final
magnitude of recovery was similar, the animals treated at 25 weeks had a faster rate of
recovery than the animals treated at 9 weeks post-stroke. This difference in recovery rates
may be due to the smaller lesion size in the animals treated with anti-Nogo-A
immunotherapy at 25 weeks versus the lesion size in animals treated at 9 weeks.
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Numerous reports from our laboratory have investigated whether treatment with
anti-Nogo-A immunotherapy at various time points post-stroke is efficacious for
improving sensorimotor recovery in skilled reaching function (for a summary refer to
Table 5.5). Treatment with anti-Nogo-A immunotherapy immediately and up to 1 week
post-stroke in adult rats with mild to moderate stroke deficits (~10% stroke size) has been
found to improve recovery beyond control therapy by 30-35% within 8 weeks of
treatment initiation (Papadopolous et al., 2002; Seymour et al., 2005). A similar final
recovery magnitude was also found in aged animals treated with anti-Nogo-A
immunotherapy however, it took longer for the animals to reach this final recovery, up to
post-stroke week 14 (Markus et al., 2005). A recent study by Tsai et al. (2010) treated
adult rats with mild to moderate stroke deficits (~16% stroke size) at 9 weeks post-stroke
and also found a similar rate and final magnitude of recovery as adult rats treated one
week post-stroke, implying that recovery from anti-Nogo-A immunotherapy is
independent from the differences between the post-ischemic brain at one week versus 9
weeks post-stroke. Our study set out to further analyze the efficacy of anti-Nogo-A
immunotherapy in the chronic phases after stroke. As discussed previously, the animals
treated at 9 weeks and 25 weeks post-stroke used in our study were considered to have
moderate to very severe chronic stroke deficits and had an average stroke size of 27%
and 19% respectively. In the animals treated with anti-Nogo-A immunotherapy at 9
weeks post-stroke, the final improvement in the recovery asymptote according to the nonlinear modeling in the PP analysis, was determined to be ~ 35%, similar to the Tsai study.
However, it is important to note that the animals did not near this final recovery
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magnitude until 12 weeks post-stroke. Given that the experimental parameters of the
study were identical to the Tsai et al. (2010) study, it is likely that the stroke lesion size
and/or location played a role in the delayed recovery rate seen in this study. The recovery
results from the animals treated at 25 weeks post-stroke support the relationship between
stroke lesion size/location and recovery since these animals had a nearly identical
magnitude and rate of improvement as the animals treated at 9 weeks post-stroke in Dr.
Tsai’s study. Not surprisingly, the stroke lesion size in the animals treated at 25 weeks
post-stroke was smaller (~ 19% ) than the lesion size of animals treated at 9 weeks poststroke in this study (~27%). Since overall we do not see a decrease in potency of antiNogo-A immunotherapy chronically after stroke, it is likely that other factors such as
lesion size and location are playing some role in the different recovery rates seen after
treatment.
Following cortical lesions, various areas directly and remotely connected to the
damaged cortex are thought to undergo spontaneous neuroanatomical structural plasticity
(Murphy et al., 2009). Additional supporting evidence for this idea comes from previous
work in our laboratory showing an increase in dendritic complexity in layer V pyramidal
neurons in the contralesional sensorimotor cortex following treatment with anti-Nogo-A
immunotherapy one week post-stroke (Papadopoulos et al., 2006). Therefore, we decided
to investigate whether the improved skilled reaching recovery seen after administration of
anti-Nogo-A immunotherapy at 9 weeks post-stroke in the adult rat was correlated with
structural changes in neurons located within the contralesional caudal forelimb motor
cortex.
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We found no evidence of increased dendritic complexity in either layer II/III or
layer V pyramidal neurons in the contralesional caudal forelimb motor cortex. This lack
of apparent dendritic structural plasticity following anti-Nogo-A immunotherapy may be
due to several reasons. Following large-scale damage to the motor cortex, rats often
display a change in preferred forelimb use in the skilled reaching task (Castro-Alamancos
et al., 2003). Given this change in preference, rats will try to use the unimpaired forelimb
to obtain sugar pellets during skilled reaching. Without directly inhibiting the use of the
unimpaired forelimb through the application of some sort of constraint, it is likely that the
rat will over time acquire improved skill training in this forelimb, even with the best
attempts at disallowing reaching attempts with this forelimb. Therefore, it is likely that
this inadvertent skilled reach training may lead to increased dendritic complexity in the
contralateral sensorimotor cortex innervating this forelimb, as has been shown with
skilled reaching training (Kolb et al., 2008). However, since this is the same sensorimotor
cortex being evaluated for treatment-induced changes in plasticity, any treatment effects
may be obscured. In the previous study by Papadopoulos et al. (2006) that found
increased dendritic plasticity in the contralesional sensorimotor cortex, the adult rats were
not trained on the skilled reaching task and therefore forelimb switching was not a
confounding factor in that study. It is possible that in our study, one reason for the lack of
apparent changes in dendritic complexity in the contralesional caudal forelimb motor
cortex may be due to the potential increase in basal level plasticity seen in this area due to
the widespread use of the unimpaired forelimb among most rats post-stroke. Furthermore,
the total number of apical and basilar branches and the total apical and basilar dendritic
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length in layer V pyramidal neurons in the contralesional sensorimotor cortex in stroke
only animals in this present study are much higher than the averages seen in stroke only
animals seen in the study by Papadopoulos (Papadopoulos et al., 2006). The
neuroanatomical data also supports the possibility that skilled use of the unimpaired
forelimb in the animals in our study increased the basal complexity of layer V pyramidal
neurons in the contralesional sensorimotor cortex. Additionally, the larger stroke size
seen in our study as compared to the Papadopoulos study could have also increased the
basal level of dendritic complexity as there is a direct relationship between increasing
stroke size and increased dendritic complexity in the contralesional caudal forelimb
motor cortex (Biernkaske et al., 2004). Furthermore, the treatment antibody used in the
two studies was different. In the present study, the monoclonal antibody used was 11C7,
a specific antibody raised against an 18-amino Nogo-A peptide to the rat sequence of
amino acids 623-640. However in the Papadopolous study, hybridoma cells secreting IN1 antibody were used. The use of hybridoma cells could have had the additional effect of
secreting growth factors that may have enhanced the plasticity response in the animals
treated with IN-1 in the Papadopoulous study. Another difference between the two
studies is that the animals were treated at different times post-stroke, either one week
post-stroke or 9 weeks post-stroke. Finally, dendrites were also evaluated much later
post-treatment in this present study than in the Papadopolous study. The dendrites were
evaluated for plasticity more than 12 weeks post-treatment initiation in our study while in
the Papadopolous study, dendrites were evaluated 6 weeks post-treatment. It is possible
that an increase in dendritic plasticity early after treatment could have undergone
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pruning, such as seen in mammalian neurological development (Rakic & Bourgeouis,
1986) so that by 12 weeks post-treatment, dendritic changes may not have been
detectible. In summary, a plasticity response in the neurons within the contralesional
caudal forelimb motor cortex may have been masked due to a potential higher level of
dendritic complexity due to forelimb switching, coupled with the a pruning response and
therefore not detectible by our evaluation. Conversely, it is possible that anti-Nogo-A
immunotherapy at 9 weeks post-stroke does not enhance plasticity in pyramidal neurons
found within layers II/III and V of the contralesional caudal forelimb motor cortex and
dendritic changes in other brain areas related to sensorimotor function, such as the
contralesional rostral forelimb motor cortex or contralesional striatum, may account for
the improved sensorimotor function seen in our study.
There have been conflicting reports of increased plasticity in the perilesional area
after stroke. Brown and colleagues found an increased number of spines on layer V
pyramidal neurons that were located within 200 microns of the infarct border in adult rats
after photothrombotic stroke (Brown et al., 2008). In direct conflict with this study are
the results from Mostany and colleagues that used in vivo two-photon imaging in adult
mice and found no large scale dendritic plasticity of layer V pyramidal neurons located in
the peri-infarct cortex (Mostany et al., 2011). However, functional imaging studies in
humans have also supported the role of the perilesional cortex in stroke recovery (Dong
et al., 2007). Therefore, we decided to investigate the effect of anti-Nogo-A
immunotherapy administered at 9 weeks post-stroke on dendritic plasticity in the
perilesional caudal forelimb motor cortex. We found no change in dendritic complexity
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in layer V pyramidal neurons located within the perilesional caudal forelimb motor
cortex. The lack of dendritic plasticity in the perilesional area may to due to various
reasons. Since we did not analyze dendritic spine number and morphology it is possible
that spine dynamics could have played a role in the improved sensorimotor function seen
after anti-Nogo-A immunotherapy in our experiments. Additionally, dendritic
rearrangements may be related to the distance of the neuron from the ischemic border
(Brown et al., 2008). Since in our study we included neurons within 2 millimeters from
the ischemic border, it is possible that only neurons close to the ischemic border (200
microns) could have undergone reorganization. Additionally, dendritic pruning could
have also played a role in the perilesional cortex and hence our evaluation time point
could have missed the dendritic rearrangements. Finally, dendritic changes could have
occurred in other brain areas such as the ipsilesional rostral forelimb area and the
ipsilesional striatum.
Due to the lack of dendritic plasticity in either perilesional or contralesional areas
of the caudal forelimb motor cortex in animals treated with anti-Nogo-A immunotherapy
at 9 weeks post-stroke, it is possible that behavioral improvement is occurring due to
other mechanisms that do not involve the dendritic arbors. In the study by Tsai and
colleagues (2010), animals with mild to moderate stroke deficits treated with anti-NogoA immunotherapy at 9 weeks post-stroke displayed skilled reaching recovery that was
correlated with enhanced corticorubral axonal sprouting from the contralesional forelimb
motor cortex to the deafferented red nucleus. Therefore, it is likely that axonal sprouting
from the undamaged corticospinal tract is also the source of the improvements seen in our
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study. Other areas that may be undergoing axonal sprouting and may be playing a role in
the improvements seen in our study include axonal sprouting from callosal fibers of the
undamaged hemisphere to the rostral forelimb motor cortex, callosal fibers in the
undamaged hemisphere to the ipsilesional dorso-lateral striatum, undamaged
corticospinal tract axonal sprouting to the basilar pontine nuclei, and undamaged
corticospinal tract axonal sprouting in the spinal cord. Additionally, it is possible that
anti-Nogo-A immunotherapy could have enhanced the electrophysiological
characteristics or biochemical functioning of neurons in neural circuits important for
sensorimotor function.
In conclusion, in this study we have found that anti-Nogo-A immunotherapy
is efficacious up to 25 weeks post-stroke for improving sensorimotor recovery on the
skilled forelimb reaching task and is a promising therapeutic strategy for improving
disability after stroke, even long after the ischemic injury has taken place, although the
exact mechanism by which this improvement occurs is still not known.

CHAPTER SIX
GENERAL DISCUSSION

Summation of Results
In animals with spinal cord injury, anti-Nogo-A immunotherapy has been found
to be efficacious when administered up until one-week post-lesion, with treatment
potency dropping if administered after two weeks post-lesion (Gozenbach et al., 2011).
Given this short treatment window for the use of anti-Nogo-A immunotherapy in spinal
cord injury, a previous study from our laboratory set out to determine whether anti-NogoA immunotherapy was efficacious over a similar or longer time frame when applied in
the chronic phase after ischemic stroke. We found that in animals with mild to moderate
stroke deficits (15% stroke size), treatment with anti-Nogo-A immunotherapy up to 9
weeks post-stroke was able to induce functional sensorimotor functional recovery in adult
rats after stroke (Tsai et al., 2010). Interestingly, the effect size and time course of
treatment-induced recovery was similar to that of animals treated immediately or up to 1
week post-stroke, implying no loss in treatment effect potency. We therefore set out to
further examine the critical time window for the application of anti-Nogo-A
immunotherapy in the chronic phases after stroke. In addition to the critical time window
for applying such a neuro-restorative therapy, we were also interested in studying
whether the initial severity of stroke deficit mitigates the efficacy of anti-Nogo-A
161

162

immunotherapy. Therefore, we investigated the efficacy of anti-Nogo-A immunotherapy
for improving moderate to very severe stroke deficits when applied either at 9 weeks (~ 2
months) and 25 weeks (~ 6 months) post-stroke in adult rats.
Previous studies have shown that a limited amount of spontaneous recovery
occurs in rats as well as humans post-stroke. Therefore, we evaluated the time-course of
spontaneous recovery of skilled forelimb performance after stroke for the first 8 and 24
weeks prior to the application of anti-Nogo-A immunotherapy. Interestingly we found
two important parallels in motor recovery post-stroke in adult rats that correspond very
well to human post-stroke recovery. Firstly, limited but statistically significant poststroke recovery in skilled reaching performance was seen overall in animals during the
first month post-stroke. Statistically significant recovery post stroke was seen until poststroke week 2, however minimal improvement was seen up to 4 weeks post-stroke with a
stable plateau in recovery seen thereafter. The timeframe in recovery seen in adult rats
post-stroke is similar to the timeframe seen in humans. Typically, the majority of
spontaneous recovery seen in humans post-stroke is seen within three months post-stroke.
However, some estimates show that the majority (80%) of significant motor recovery
takes place within 4.5 week post-stroke (Jorgensen et al., 1995a; Jorgensen et al., 1995b)
and corresponds well to the time-frame of spontaneous recovery we see in adult rats poststroke in this study. Secondly, we found that initial deficit severity after stroke modulates
the rate and magnitude of spontaneous recovery seen after stroke in adult rats. This
relationship between initial deficit severity after stroke and recovery potential has also
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been well demonstrated in human stroke recovery (Jorgensen et al., 1995a; 1995b; 1995c)
and underscores the similarity between rat and human post-stroke recovery profiles.
Animals with initial mild to moderate deficits at 1 week post-stroke generally showed
both little deficit and little improvement over time. Effectively, animals in these two
deficit categories show very mild deficits and the need for treatment or rehabilitation is
low. Conversely, animals with severe deficits at 1 week post-stroke, show statistically
significant recovery over time up to post-stroke week 3, however the magnitude of
recovery is quite low. This population of animals has the greatest need for a neurorestorative therapy and most likely will show the greatest benefit. Animals with very
severe deficits at post-stroke week 1 show no improvement over time and may be very
difficult to rehabilitate with any form of treatment.
Based on the spontaneous recovery profiles seen after stroke in adult rats, we
decided to treat animals with anti-Nogo-A immunotherapy at two delayed chronic time
points, 9 (subchronic) and 25 (chronic) weeks post-stroke. The stroke deficits seen at
post-stroke week 9 and 25 are thought to be stable and the potential for spontaneous
recovery of function minimal. The cohort of animals treated with anti-Nogo-A
immunotherapy at 9 or 25 weeks post-stroke included animals with moderate, severe, and
very severe deficits. Two separate approaches to analyze the recovery data were used for
these results. An intention-to-treat analysis was performed that included all deficit
severity animals (moderate, severe, very severe) as well as any protocol deviations. A
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per-protocol analysis was performed including only animals with moderate and severe
deficits as well as no protocol deviations.
The experimental data from these experiments supports the existence of an
extended therapeutic time window for the use of anti-Nogo-A immunotherapy to improve
sensorimotor functional recovery after stroke in the chronic phase. We demonstrate the
effectiveness of anti-Nogo-A immunotherapy when initiated 9 and 25 weeks post-stroke
in the adult rat to significantly improve sensorimotor performance on the skilled reaching
task using both an intention-to-treat and per-protocol paradigm. Based on these results, it
is likely that anti-Nogo-A immunotherapy is effective chronically after stroke and long
after the lesion-induced neuroplasticity-promoting environment in the brain has
diminished (Biernaske et al., 2004). However, given the fact that animals with very
severe deficits prior to treatment do not improve with anti-Nogo-A immunotherapy and
that the recovery rates and recovery plateau (based on PP analysis) are slower and lower
than that seen in previous studies at similar time points, it is likely that anti-Nogo-A
immunotherapy may have differential efficacy rates based on initial stroke deficit
severity prior to treatment.
Multiple research studies show that inhibiting protein Nogo-A leads to axonal and
dendritic reorganization that is associated with functional recovery (Seymour et al., 2005;
Papadopoulos et al., 2006; Tsai et al., 2011). Therefore, we evaluated dendritic plasticity
in the perilesional and contralesional forelimb motor cortex. We did not find any changes
in complexity across layer V pyramidal neurons in either the perilesional or
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contralesional caudal forelimb motor cortex or layer II/III neurons in the contralesional
caudal forelimb motor cortex. These results underscore the difficulty relating
neuroanatomical structural plasticity with recovery in function and potentially imply
other mechanisms or brain areas are responsible for the functional recovery seen in these
experiments.
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Translation of Anti-Nogo-A Immunotherapy to the Clinic
Over the last two decades, there has been a paradigm shift regarding the ability of
the adult CNS to undergo spontaneous cortical reorganization as well as the ability to
induce substantial neuronal plasticity through neuro-restorative therapies. With the
discovery and cloning of the neurite outgrowth inhibitory myelin associated protein,
Nogo-A (Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 2000), a new era of
investigation geared towards improving function following various CNS lesions has
taken place. Since then, the inhibition of Nogo-A has been shown to promote functional
recovery following various brain injuries such as stroke, spinal cord injury and traumatic
brain injury in animal studies.
Proof of concept experiments using anti-Nogo-A immunotherapy to improve
functional recovery after stroke has been extensively studied in pre-clinical studies and
been shown to be effective. Studies primarily from the Kartje laboratory have shown that
inhibiting protein Nogo-A using function inhibiting monoclonal antibodies after ischemic
middle cerebral artery occlusion leads to substantial sensorimotor functional recovery
when applied immediately (Papadopoulos et al., 2002), 24 hours (Weissner et al., 2003),
1 week (Seymoure et al., 2005), 9 weeks (Tsai et al., 2011; this dissertation), and 25
weeks post-stroke (this dissertation). Furthermore, significant improvement using this
therapy was seen in the Weissner study that used a rat model that is spontaneously
hypertensive, showing the efficiacy of this thereapy in a model with hypertension as a
comorbid factor. Additionally, we have shown that this therapy is efficacious in the aged
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rat, showing only a slowing of recovery, but ultimately the same magnitude of recovery
(Markus et al., 2005). Finally, other methods of inhibiting the protein Nogo-A signaling
pathway have also been shown to be significant at inducing sensorimotor recovery after
stroke, i.e. targeting the Nogo-A related receptor, NgR (Lee et al., 2004) as well as using
NEP1-40 to competitively antagonize the NgR receptor (Fang et al., 2010). All these
findings support the use of blocking protein Nogo-A in order to improve functional
recovery after stroke.
General limitations to the translation of this therapy to the clinic is the necessity
of either intrathecal or intracerebroventircular infusion of the antibody. Although an
intravenous route of application would improve the feasibility of this therapy, intrathecal
and intracerebroventricuar drug application routes are already in possible in clinical
practice and therefore can be used. Examples of drugs delivered intracerebroventircularly
include the anti-spasmodic drug baclofen used for dystonia (Rocque et al., 2012),
chemotherapeutic agents such as methotrexate for brain neoplasms (Gabay et al., 2012),
and anti-fungals such as amphotericin B for fungal brain infections (Tsung et al., 2010).
However, development of a less invasive route of delivery would be of great clinical
importance, especially if clinical trials for the use of this therapy show positive results for
spinal cord injury and pave the way for this therapy to be tested in clinical trials for other
central nervous system injures and disorders.
Currently, anti-Nogo-A immunotherapy is being evaluated in a phase I human
clinical trial in patients with spinal cord injury and a phase II trial is currently being
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planned (Abel al., 2011). A phase I clinical trial is meant to evaluate the safety of a new
treatment and identify side effects. In the case of anti-Nogo-A immunotherapy, since
Nogo-a plays a role in stabilizing mature neuronal circuits in the human adult brain, it is
possible that increasing neuroplasticity in the brain could have other effects than to
restore impaired functions. There is a potential risk of destabilizing important circuits
involved in long term memory and a potential risk of psychiatric symptoms (Mirnova et
al., 2013). Although, no side effects of the treatment have been reported in animal or the
phase I clinical trial (Abel et al., 2011), it will be important to monitor cognitive function
during anti-Nogo-A immunotherapy in humans. Other potential side effects of too much
neuroplasticity in the brain could include the development of seizures and pain
syndromes.
The results from our laboratory over the years and specifically this project can be
used to better design a human clinical trial for the evaluation of anti-Nogo-A
immunotherapy in human stroke. Firstly, our studies have shown that anti-Nogo-A
immunotherapy can be used in chronic stroke, and therefore many more stroke survivors
could be enrolled in a clinical trial. Secondly, we have shown that anti-Nogo-A
immunotherapy is effective in chronic stroke in adult rats with moderate and severe
deficits after stroke. Therefore, it is possible that this therapy could be efficacious in
moderate and severe human stroke, thereby also providing a larger group of patients
eligible for testing. Finally, an important caveat regarding patient enrollment in an antiNogo-A immunotherapy study is the fact that patients will need to have some residual
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function in their upper extremity since we have shown that adult rats with very severe
deficits where no forelimb grasping is possible do not improve after anti-Nogo-A
immunotherapy.
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Future Directions
It is of interest to further characterize the efficacy of anti-Nogo-A immunotherapy
across acute and chronic time points of administration and how treatment effects are
modulated by initial deficit severity, stroke size, and stroke location. Results from this
type of analysis would have the ability to further inform clinical trial design for testing
anti-Nogo-A immunotherapy in humans after ischemic stroke. Therefore, future analyses
will incorporate data from all experiments from the Kartje laboratory utilizing anti-NogoA immunotherapy, including those from this dissertation, in a non-linear regression
model using stroke lesion size and location as co-variate parameters. This way,
differences in recovery rate and magnitude can be evaluated directly to see what factors
modulate anti-Nogo-A immunotherapy efficacy (age, lesion size, lesion location, initial
deficit severity, treatment delay time).
Furthermore, additional experiments can be conducted to evaluate which other
neural correlates of recovery may be playing a role in the improved recovery seen in the
experiments in this dissertation. Additional brain areas associated with spontaneous
recovery after stroke in humans and non-human primates involve the premotor and
supplementary areas (Benowitz et al., 2010). An area in the rat brain that is important for
forelimb reaching and corresponds to either a premotor or supplementary motor function
is called the rostral forelimb area (also known as the forelimb area of Neafsey; Neafsey et
al. 1986). Therefore, dendritic plasticity could be evaluated in the
ipsilesional/contralesional rostral forelimb area. Furthermore, other brain areas involved
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in motor function could be evaluated such as the ipsilesional/contralesional dorsolateral
striatum and ipsilesional/contralesional cerebellum. Additionally, axonal sprouting into
the denervated red nucleus was already shown to be correlated with sensorimotor
recovery displayed by rats with mild to moderate stroke deficits treated at 9 weeks poststroke with anti-Nogo-A immunotherapy (Tsai et al., 2010). It is possible that axonal
plasticity is playing a larger role than dendritic plasticity in recovery after anti-Nogo-A
immunotherapy and axonal sprouting from the undamaged corticospinal tract could be
evaluated at the level of the red nucleus, basal pontine nuclei and spinal cord.
Additionally, axonal sprouting within the ipsilesional dorsolateral striatum, or callosal
sprouting in the perilesional cortex or ipsilesional rostral forelimb motor cortex could be
evaluated.
Further experiments could look to see how to rehabilitate the animals that did not
respond to therapy, the very severe deficit animals. It is possible that additional methods
to improve functional recovery need to be used in addition to anti-Nogo-A
immunotherapy. Methods such as intensive skilled reaching rehabilitation or
environmental enrichment have been shown to improve functional recovery after stroke
in adult rats. Therefore, a combinatorial approach could be taken with these very severe
animals to see if a regimen of anti-Nogo-A immunotherapy, intensive skilled reach
training, and environmental enrichment could lead to improved skilled forelimb reaching
performance. Additionally, increased dosage and length of treatment using anti-Nogo-A
antibodies could also be effective.
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